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Levothyroxine (LT4) is celebrating its 70th birthday, since its introduction to the 
management of hypothyroidism or primary thyroid failure.
This is a good opportunity to explore the history and the current state of the art 
with regard to the therapeutic use of LT4, now one of the most-prescribed treat-
ments worldwide. In our book, we explore the early research that led to an under-
standing of the role of thyroid gland that led to the initial therapeutic use of LT4. We 
also describe the pharmacokinetics, pharmacodynamics and mechanism of action of 
LT4, its actions on key target organs (heart and bone), and its use and effects in 
important special populations (children, older persons, pregnancy, and survivors of 
thyroid cancer). A concluding chapter summarizes pragmatic recommendations for 
the practicing physician on the optimal clinical application of LT4 substitution.
As the Editor of this book, I am extremely grateful to the nine internationally 
respected physicians and clinical researchers in the field of thyroid research, based 
in three continents (Asia, Europe, and the Americas), who agreed to join me to make 
up our expert Faculty. They were Drs. Takashi Akamizu (Japan), Tomasz Bednarczuk 
(Poland), Bernadette Biondi (Italy), Gabriela Brenta (Argentina), James Hennessey 
(USA), Hans-Peter Lipp (Germany), Kris Poppe (Belgium), Salman Razvi (United 
Kingdom), and Weiping Teng (China). Their expertise, knowledge, and active par-
ticipation greatly facilitated my task as book Editor. Their important contributions, 
well-taken points, constructive comments, and excellent proposals made this book 
possible. This book also benefited from independent peer review by two experts in 
the field of thyroidology, in addition to the experience and knowledge of our faculty.
I also thank our medical writer, Dr. Mike Gwilt. Mike provided effective editorial 
support to our Faculty, from the building of the first draft through successive revi-
sions, to the final book you see here. His engagement with the authors—including 
myself—helped greatly in bringing their knowledge and experience to the page. His 
engagement with me as Editor helped me to oversee the production of a book of ten 
coherent chapters that not only stand individually as expert reviews in our authors’ 
fields of expertise, but also work together tell us the full story of seven decades of 
therapeutic use of LT4.
vi
The idea for this anniversary book, and logistical support, came from Merck 
Healthcare KGaA, Darmstadt, Germany. I am most grateful to Dr. Bogumila Urgatz 
(Medical Director) and Dr. Ulrike Hostalek (Executive Medical Director, GMA, 
GM & Endocrinology) from this company, for this productive and successful 
collaboration.
Enjoy the reading!
With all best wishes,




 Therapeutic Use of Levothyroxine: A Historical Perspective . . . . . . . . . . .    1
George J. Kahaly
 Administration and Pharmacokinetics of Levothyroxine . . . . . . . . . . . . . .   13
Hans-Peter Lipp
 Pharmacodynamic and Therapeutic Actions of Levothyroxine . . . . . . . . .   23
James V. Hennessey
 Levothyroxine in Pregnancy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   47
Kris Gustave Poppe
 Levothyroxine in Children . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   61
Gabriela Brenta
 Levothyroxine in the Older Patient . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   75
Salman Razvi
 Levothyroxine and the Heart . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   85
Bernadette Biondi
 Levothyroxine and Bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   97
Weiping Teng
 Levothyroxine and Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  109
Tomasz Bednarczuk
 Practical Application of Levothyroxine- Based Therapy . . . . . . . . . . . . . . .  121
Takashi Akamizu
ix
About the Editor and Contributors
Editor
George J. Kahaly, MD, PhD Professor of Medicine 
and Endocrinology/Metabolism and Director of the 
Molecular Thyroid Research Laboratory, at the 
Johannes Gutenberg University (JGU) Medical Center, 
Mainz, Germany.  Dr. Kahaly directs the endocrine and 
thyroid autoimmunity program at the JGU endocrine 
outpatient clinic and chairs the ORPHAN referral expert 
center for Graves’ orbitopathy and autoimmune 
polyendocrinopathy.
He has authored 281 original papers and reviews, 
covering clinical, experimental, and immune genetic 
aspects of endocrine autoimmunity, as well as cardio-
vascular involvement of metabolic disorders, in leading 
journals, including the New England Journal of 
Medicine, The Lancet, JAMA, Annals of Internal 
Medicine, Clinical Chemistry, the Journal of 
Autoimmunity, the Journal of Clinical Endocrinology 
and Metabolism (JCEM), the Journal of Nuclear 
Medicine, Endocrinology, Thyroid, Endocrine Reviews, 
Nature Reviews, and Autoimmunity Reviews (current 
citation H index 48, 8768 citations).
Dr. Kahaly is the 2019 recipient of the American 
Association of Clinical Endocrinologists/American 
College of Endocrinology (AACE/ACE) Endocrinology 
Award and is the 2019 recipient of the British Thyroid 
Association “George Murray Award” medal.  Further 
awards: include Research Program of the German 
Endocrine Society (2006, 2008); Poster prize, German 
x
Society of Internal Medicine (2006, 2008); Poster prize, 
German Endocrine Society (2009); Investigator Award 
of the European Thyroid Association (2009); 
Investigator Award of the German Ophthalmic Society 
(2011); Best Reviewer Award, European Thyroid 
Journal (2018); and British Medical Association 
Medical Book Award (2018).
Dr. Kahaly is Treasurer and Principal Officer of the 
European Group on Graves’ orbitopathy, and a member 
of the Editorial Board of the European Thyroid Journal, 
and the Publication Core Committee of the American 
Endocrine Society (2020–2023).  Other recent posts 
include Editor of the Journal of Clinical Endocrinology 
and Metabolism (2015–2019), Associate Editor of 
Thyroid (2009–2012), Treasurer and Principal Officer 
of the Executive Committee of the European Thyroid 
Association (2007–2016), membership of the scientific 
program organizing committees of the 2020 International 
Thyroid Congress, Xian, China, and the 2020 spring 
meeting of the American Thyroid Association (ATA), 
and the Executive Committee of the German Thyroid 
Board (2005–2011), as well as numerous ATA 
Committees (Laboratory Services Committee 
[2018–2022], Public Health [2015–2018], Research 
[2012–2015], Finance and Audit [2007–2011], and 
Membership and Publication Committees [2000–2006]).
Disclosures: The JGU Medical Center has received 
research-associated funding from, and GJK consults 
for, Merck Healthcare KGaA.
Department of Medicine I, Johannes Gutenberg University 
(JGU) Medical Center, Mainz, Rheinland-Pfalz, Germany
Contributors
Hans-Peter  Lipp, PharmD, PhD Professor for 
Pharmacoeconomics and Pharmacoepidemiology at the 
Pharmaceutical Institute of the University of Tübingen. 
There, I participate in the education of students as a 
teaching practitioner, with a focus on judgment analy-
ses for accurate selection of therapies.
My research has focused on the clinical pharmacoki-
netic behavior (including drug–drug interactions) of a 
broad spectrum of available drugs, based on more than 
200 publications in diverse fields, including hemostasis, 
About the Editor and Contributors
xi
hemato-oncology, mycology, ophthalmology, endocri-
nology, and many others.  As a director of a large hospi-
tal pharmacy within the University Clinic of Tübingen, 
Germany, I am co-responsible for the dynamic revision 
of the established drug formulary, especially when 
drugs and formulations are added, switched, or removed. 
I am also responsible for continuous negotiations of 
purchasing conditions, which are very associated 
closely with the drugs’ pharmacology and quality, espe-
cially for novel therapeutics.
Disclosures: Professor Lipp has no relationships with 
or financial interests in any commercial companies 
related to this book.
University Hospital Tübingen, Tübingen, Germany
James  V.  Hennessey, MD Director of Clinical 
Endocrinology at Beth Israel Deaconess Medical 
Center and Associate Professor of Medicine at the 
Harvard Medical School.  He graduated from the 
Medical Faculty of the Karl Franzens University of 
Graz, Austria. He completed a Medical Residency at 
the New Britain Hospital in Connecticut.  He served 
with the US Air Force (USAF) as an Internist/Flight 
Surgeon and later subspecialty training in endocrinol-
ogy and metabolism at the Walter Reed Army Medical 
Center in Washington, DC, where he conducted 
research in thyroxine bioequivalence.
Dr. Hennessey served as the Chief of Endocrinology 
at USAF Medical Center Wright-Patterson in Ohio and 
later joined the faculty at Wright State University 
School of Medicine as the Director of Clinical 
Clerkships, maintaining a clinical- teaching practice at 
Wright State and in thyroidology at Wright-Patterson 
Medical Center.  Upon arrival at Brown Medical School 
in Providence, RI, he transferred to the Air National 
Guard as a flight surgeon and finally as Rhode Island 
State Surgeon, retiring after a 25-year USAF career in 
2006.  While at Brown, he was Associate Director for 
Clinical Education in the Division of Endocrinology at 
Rhode Island Hospital and directed the Medical School 
Endocrine Pathophysiology course.
His career has focused on the clinical education of 
medical students, resident physicians in internal medi-
cine, and fellows in endocrinology and metabolism.  In 
About the Editor and Contributors
xii
this capacity, he has conducted lectures, precepted clini-
cal care, and carried out original and sponsored clinical 
research with his trainees.  Currently, he is pursuing his 
clinical interest in thyroid disease and osteoporosis with 
both expanding clinical programs.
Disclosures: Dr. Hennessey has consulted for AbbVie, 
Allergan, and Spetrix for clinical trial design and as an 
invited speaker on bioequivalence for Merck 
Healthcare KGaA.
Harvard Medical School, Division of Endocrinology, 
Beth Israel Deaconess Medical Center, Boston, 
MA, USA
Kris  Gustave  Poppe, MD, PhD Head of the endo-
crine unit and coordinator of the thyroid outpatient 
clinic and research unit at the University Hospital CHU 
St-Pierre, a teaching hospital from the Université Libre 
de Bruxelles (ULB), in downtown Brussels.
For more than 20 years, my research is focused on 
the relationship between thyroid disorders and preg-
nancy, in particular on the impact of thyroid disorders 
on female infertility and subsequent treatment with 
assisted reproductive technology.
I have published more than 70 original and review 
papers, gave plenary lectures at many European 
Thyroid and Endocrine meetings, and “meet the 
Professor” sessions at Endocrine Society meetings.  In 
addition, I have served as a member of the Executive 
Board of the European Thyroid Association (2008–2012) 
and coordinator of the Belgian Thyroid Club 
(2009–2015), and currently serve as a member of the 
Editorial Board of the European Thyroid Journal.
Disclosures: I received lecture fees from the IBSA 
Institut Biochimique SA (satellite meeting of the 
European Thyroid Association) in 2016 and the Berlin- 
Chemie AG company (ETA educational thyroid meet-
ing) in 2017–2018 and 2020.  I have no direct conflict of 
interest in relation to this book.
Endocrine Unit, Centre Hospitalier Universitaire Saint 
Pierre, Brussels, Belgium
Université Libre de Bruxelles (ULB), Brussels, Belgium
About the Editor and Contributors
xiii
Gabriela  Brenta, MD, PhD Staff member of the 
Department of Endocrinology and Metabolism at Dr. 
Cesar Milstein Care Unit in Buenos Aires, where she 
coordinates the Thyroid Unit and holds the rank of 
Assistant Professor at the Medical School of the 
University of Buenos Aires. Her areas of interest in 
clinical research include the cardiovascular and meta-
bolic effects of thyroid hormones, the field of thyroid 
nodular disease and, in particular, the study of thyroid 
diseases in the elderly.  Original papers and reviews 
have been published in peer-reviewed journals, includ-
ing Thyroid, Endocrine, Nature and the Journal of 
Clinical Endocrinology and Metabolism.  She is a 
member of the Argentine Society of Endocrinology and 
Metabolism (SAEM) with an active participation at its 
Thyroid Department.
She is also member of the editorial board of the peer-
reviewed journals, Thyroid and Journal of Endocrinology 
Investigation.  In June 2019, Dr. Brenta completed her 
term as President of the Latin American Thyroid Society 
(LATS) and is now engaged on behalf of LATS in the 
Scientific Committee of the 16th International Thyroid 
Congress and also in the 19th International Congress of 
Endocrinology.
Disclosures: Professor Brenta declared no conflict of 
interest with regard to this book.
Dr. Cesar Milstein Hospital, Buenos Aires, Argentina
Salman  Razvi, MD, FRCP Senior Lecturer in 
Endocrinology at Newcastle University and a 
Consultant Endocrinologist at Queen Elizabeth 
Hospital.  He completed his higher medical degrees 
and specialist training in the North East of England. 
His doctoral thesis was based on assessing cardiovas-
cular risk in subclinical hypothyroidism. Subsequent to 
this, he has continued to pursue research evaluating the 
action of thyroid hormones particularly on the cardio-
vascular system. The focus of his research has been on 
investigating the association of thyroid function with 
cardiovascular events in various populations.
He is the chief investigator of several projects funded 
by various statutory funding bodies as well as charities. 
About the Editor and Contributors
xiv
His main research programs include investigating treat-
ment of subclinical hypothyroidism with thyroid hor-
mones in acute myocardial infarction and 
age-appropriate treatment of hypothyroidism in the 
elderly.  He has authored more than 75 peer-reviewed 
publications, relating mainly to thyroid dysfunction.
Dr. Razvi is a member of the editorial board of 
Thyroid, Frontiers in Endocrinology and the Journal of 
Endocrinological Investigations.  He is also the Director 
of Research and Development at Gateshead Hospitals 
and the Speciality Group Lead for Metabolic and 
Endocrine Research at the North East and North 
Cumbria Local Clinical Research Network.
Disclosures: Dr. Razvi has received speaker fees from 
Merck Healthcare KGaA, Abbott India Pharmaceuticals 
(Pvt) Ltd., and Berlin-Chemie Ltd., manufacturers of 
levothyroxine.
Translational and Clinical Research Institute, University 
of Newcastle, Newcastle-upon-Tyne, UK
Bernadette  Biondi, MD Full professor of internal 
medicine at the University of Naples “Federico II,” 
where she researches cardiovascular endocrinology 
and clinical thyroidology, with a special focus on sub-
clinical thyroid dysfunction.
Professor Biondi is author and co-author of numer-
ous papers in leading peer- reviewed journals, includ-
ing the Journal of Clinical Endocrinology and 
Metabolism, European Journal of Endocrinology, 
Annals of Internal Medicine, Circulation, Nature 
Clinical Practice in Endocrinology and Metabolism, 
the New England Journal of Medicine, Endocrine 
Reviews, JAMA, The Lancet, and the Journal of the 
American College of Cardiology.  She also authors the 
chapter “Endocrine Disorders and Cardiovascular 
Disease” in the book, Braunwald’s Heart Disease.
Professor Biondi serves as Associate Editor of 
Clinical Thyroidology.  She is also a member of the 
Awards Committee Roster of the American Thyroid 
Association and chaired the task force of the European 
Thyroid Association for the development of clinical 
practice guidelines on the diagnosis and treatment of 
subclinical hyperthyroidism.
About the Editor and Contributors
xv
Disclosures: This research was not supported by exter-
nal funding and did not receive any specific grant from 
any funding agency in the public, commercial, or not-
for-profit sector.
Professor of Endocrinology and Internal Medicine, 
University of Naples Federico II, Naples, Italy
Weiping Teng, MD Professor of Medicine at The First 
Hospital of China Medical University, Shenyang, and 
also the Chief of the Institute of Endocrinology of China 
Medical University and the Chief of State Key 
Laboratory (Cultivation Base) for Endocrine diseases. 
Dr. Teng was graduated from China Medical University 
in 1976.  He completed his postdoctoral fellowship 
training in endocrinology at the University of 
Cambridge, UK (1988–1990) and at the University of 
Toronto, Canada (1994–1995).
His key research orientation is thyroid diseases, 
especially in the fields of epidemiology, the relationship 
between iodine excess and thyroid diseases, genetics of 
Graves’ disease, autoimmune thyroid diseases, the rela-
tionship between pregnancy and thyroid diseases, and 
the effects of thyroid hormone on brain development. 
He has published more than 300 articles including in 
peer-reviewed journals.  He considers that the article, 
“Effect of iodine intake on thyroid diseases in China,” 
published in the New England Journal of Medicine (doi: 
https://doi.org/10.1056/NEJMoa054022) is especially 
representative of his work.
Currently, Dr. Teng is the Predecessor President of 
Chinese Endocrine Society (CES). He is also Vice 
President of AOTA (Asia and Oceania Thyroid 
Association), the member of ATA (American Thyroid 
Association) and TES (The Endocrine Society), and the 
member of editorial board of Thyroid.
Disclosures: Dr. Teng declared no conflict of interest 
with regard to this book.
First Hospital of China Medical University, 
Shenyang, China
About the Editor and Contributors
xvi
Tomasz  Bednarczuk, MD, PhD Professor of 
Medicine and head of the Department of Internal 
Medicine and Endocrinology at the Medical University 
of Warsaw.  The department is one of the referral cen-
ters in Poland for treatment of patients with various 
endocrine disorders, including thyroid, parathyroid, 
adrenal and neuroendocrine tumors.
Dr. Bednarczuk completed his internal medicine 
and endocrinology training in Warsaw and spent 3 
years at the Thyroid Eye Disease Laboratory, 
Allegheny-Singer Research Institute, Pittsburgh, USA 
(supervisor Prof. Jack Wall) and Division of 
Endocrinology and Metabolism, University School of 
Medicine, Kurume, Japan (supervisor Prof. Yuji 
Hiromatsu).  He  received his Ph.D. in 1998 and his 
habilitation degree in 2004 from the Medical Research 
Center, Polish Academy of Science.
Dr. Bednarczuk is a clinical scientist with a special 
research focus on the pathogenesis of Graves’ orbitopa-
thy and the genetics of Graves’ disease (GD). His 
research on the genetics of GD involved collaborations 
with various centers in Europe and Japan.  He has pub-
lished more than 100 papers in peer-reviewed journals.
Dr. Bednarczuk serves as Treasurer of the European 
Thyroid Association.  Moreover, he is a member of the 
executive committees of the Polish Society of 
Endocrinology and the Polish Thyroid Association.
Disclosures: Dr. Bednarczuk declared no conflict of 
interest with regard to this book.
Department of Internal Diseases and Endocrinology, 
Medical University of Warsaw, Warsaw, Poland
Takashi  Akamizu, MD, PhD Professor Emeritus of 
Wakayama Medical University and Vice President of 
Kuma Hospital. He obtained his MD and PhD from 
Kyoto University School of Medicine and completed 
3-year postgraduate training at the National Institute of 
Diabetes and Digestive and Kidney Disorders at the US 
National Institutes of Health.
He is currently the President of Japan Endocrine 
Society (JES), the President of Asia-Oceania Thyroid 
Association (AOTA), and the former President of Japan 
Thyroid Association (JTA). He received several awards 
from all these associations including the JES Award of 
About the Editor and Contributors
xvii
the Japan Endocrine Society, Nagataki-Fujifilm Prize of 
AOTA and Shichijo/Miyake Awards (JTA), etc.  He is 
an Associate Editor of JCEM and an Editorial member 
of the Thyroid. His major research interests include 
pathogenesis and pathophysiology of autoimmune thy-
roid disease, management of thyroid storm, transla-
tional research on ghrelin and IgG4-related disease.
Disclosures: Professor Akamizu declared no conflict of 
interest with regard to this book.
Wakayama Medical University, Wakayama, Japan
Kuma Hospital, Kobe, Japan
About the Editor and Contributors
1© The Author(s) 2021
G. J. Kahaly (ed.), 70 Years of Levothyroxine, 
https://doi.org/10.1007/978-3-030-63277-9_1
Therapeutic Use of Levothyroxine: 
A Historical Perspective
George J. Kahaly
The therapeutic use of levothyroxine (LT4) arose from observations made in 
the second half of the nineteenth century that linked the severe physical and 
cognitive defects of cretinism with an under-developed, or absent, thyroid 
gland. Improved outcomes for these subjects following empirical treatment 
with crude thyroid extracts spurred further research, and isolation, 
characterisation, and chemical synthesis of LT4 and triiodothyronine (T3) 
followed in the first half of the twentieth century. Treatment with LT4 + T3 
combinations superseded the use of thyroid extracts from the 1960s onwards. 
The development of reliable and specific assays for thyroid hormones 
contributed greatly to understanding the importance and function of the 
thyroid and facilitated individualised treatment. Monotherapy with LT4 has 
been the mainstay of management of hypothyroidism from about 1970. Thyroid 
research is far from complete, however, and further research into several 
outstanding clinical issues will continue to shape LT4-based therapy in 
the future.
1  Introduction
In the opening chapter of this book, we consider the history of the therapeutic use 
of levothyroxine (LT4). Recognition of the therapeutic value of LT4 emerged from 
experience gained from, essentially, empirical administration by physicians of crude 
thyroid extracts to people with advanced sequelae of hypothyroidism [1–4]. These 
clinical experiments arose from early studies of people we would today describe 
as having severe congenital hypothyroidism. Accordingly, our story begins in the 
G. J. Kahaly (*) 




latter half of the nineteenth century, when these pioneering observations were being 
made, continues to the current management of hypothyroidism with LT4 and con-
cludes with a brief review of outstanding research issues in this fast-moving field. 
Fig.  1 provides a timeline of key events along this journey, and these important 
advances are described below.
2  Early Beginnings: Growing Understanding of the Thyroid
2.1  Cretinism, Goitre, and the Recognition of the Importance 
of the Thyroid Gland
An appreciation of thyroid disease as a clinical entity began during the second half 
of the nineteenth century [1–4]. Briefly, sporadic, and widely spaced, reports in 
medical journals during this period described young, short-lived individuals pre-
senting with growth retardation and “sporadic cretinism”, which were found to be 
associated with minimal or absent thyroid tissue [5–7]. Such cases today would be 
described as congenital hypothyroidism, with the term “sporadic” used to differ-
entiate them from “endemic cretinism”, associated with goitre in iodine-deficient 
regions, which had been described centuries before. Later work during this period 
introduced the term, “myxoedema”, to describe the anatomic appearance of the thy-
roid in these patients [1].
Surgery to remove goitre was being performed at this time, for example, to relieve 
symptoms of compression in the neck, despite a continuing lack of understand-
ing of the function of the thyroid gland [8]. One contemporary study showed that 
removal of the entire thyroid led to the development of symptoms resembling those 
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Fig. 1 Overview of key events relevant to the history of therapeutic use of levothyroxine for hypo-
thyroidism. LT4 levothyroxine, Na sodium. Times are approximate
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of “sporadic cretinism”, and this observation led the author to restrict future surger-
ies to partial resection of the thyroid, with better outcomes [9]. Elsewhere, thyroid-
ectomy in animals was shown to produce symptoms reminiscent of myxoedema, 
providing further strength to the association of athyroid status with “sporadic cre-
tinism” [10]. These extreme cases were the first demonstrations of the pathophysi-
ological importance of the thyroid gland to healthy development although not based 
on any understanding of the function of the thyroid. Other experiments conducted 
at this time noted that thyroidectomy was lethal to dogs, but that the health of the 
animals could be preserved temporarily by grafting the thyroid elsewhere in the 
animals’ bodies [11]. Even so, it was assumed that the function of the thyroid was 
allied to detoxification of the blood, rather than to an independent and specific endo-
crine function [3].
2.2  An Endocrine Function for the Thyroid Gland
It had been suggested in about 1820 (soon after the characterisation of iodine as a 
chemical element) that the limited efficacy of dietary ingestion of foodstuffs such as 
sponges or seaweed in the diet (an ancient, traditional remedy for goitre) was con-
nected to the presence of iodine in these items [12]. The first attempts at iodine supple-
mentation, either using a tincture of iodine, or with iodised salt, followed during the 
following decade [4]. A correlation between scarcity of iodine in the environment and 
an increased prevalence of goitre was published some 30 years later [13]. This was 
followed by further trials of iodine supplementation in three Departments of France 
where problems with goitre were especially severe. These were largely successful, 
and it was reported in 1869 that about 80% of cases of goitre responded favourably 
to treatment [14]. Several problems with the conduct of these trials led to their early 
cessation; these included an excessively high dose of iodine (which commonly caused 
hyperthyroidism in adult recipients), continuing scepticism among the medical pro-
fession, and reluctance to participate by citizens who feared that curing their sons’ 
goitres would remove an obstacle to their being conscripted for military service [4].
From about 1890 onwards, physicians were experimenting with the administra-
tion of thyroid extracts (orally or subcutaneously) to people with myxoedema [3]. 
These early clinical studies were generally successful; one patient with advanced 
myxoedema that developed in middle age was treated with subcutaneous injec-
tions of sheep thyroid extract and lived for 28 years before dying of heart failure 
at age 74 years [15]. The author, the British physician, George Murray, concluded 
that the thyroid is “purely an internal secretory gland”, that the “functions of this 
gland in man can be fully and permanently carried on by the continued supply of 
thyroidal hormones”, and, crucially, that “duration of life need not be shortened 
by atrophy of the thyroid gland provided this substitution treatment is fully main-
tained” [15]. These concepts underpin the management of hypothyroidism to this 
day. Interestingly, this represents an early example of the seeking of informed con-
sent for a trial of a therapeutic agent: the physician had explained the experimental 
nature of the treatment and had sought and obtained the patient’s consent. A review 
of 100 cases of patients with myxoedema and cretinism, published in 1893 attests to 
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the remarkable success attributed to this treatment, using phrases such as “complete 
transformation” and “the patient has ceased to be a patient” [16].
The discovery in 1895 of a substance containing high concentrations of iodine 
within the thyroid gland (“thyroiodine”) was therefore of considerable interest in 
unifying concepts relating to hypothyroidism and iodine, and the role of the thy-
roid as an endocrine organ [17]. The substance that would come to be known as 
thyroxine (T4) was isolated in the USA in 1915 and fully chemically characterised 
in 1926 (and published the following year [18]). It was also established that LT4 
had greater biological activity than a racemic mixture. The discovery of triiodothy-
ronine (T3) as a “normal constituent of the organic iodine fraction of the plasma” 
of subjects with normal thyroid function or hyperthyroidism followed in 1952 [19]. 
Fig. 2 shows the chemical structures of these hormones.
3  Towards the Modern Era in the Management 
of Hypothyroidism
3.1  Introduction of Chemically Synthesised Thyroid Hormones
The early attempts at thyroid replacement via “organ therapy” (as the practice of 
administration of extracts of animal organs became known), described briefly in 





















widespread in the management of other conditions [20]. For example, a report by 
a leading physician in France on the allegedly rejuvenating effects of self-injection 
with animal testicular extracts led to great enthusiasm for this practice among other 
physicians. Eventually, a growing association with widespread quackery in the 
hands of other practitioners led to a general discrediting of the principle of “organo-
therapy” [20, 21].
Nevertheless, although early practitioners such as Murray switched from injected 
to oral preparations of thyroid extracts, mainly to prevent serious systemic adverse 
reactions and abscesses and other problems at the local injection site, it was some 
time before chemically synthesised LT4 entered into clinical practice. This was 
partly due to limitations of chemically synthesised LT4, which was produced as an 
acid and had limited bioavailability before the synthesis of a sodium salt of in 1949 
[21]. This preparation entered clinical use in that year in the USA, and entered clini-
cal use in Europe some years later.
It took considerable time for synthesised LT4 to become the mainstay of treat-
ment for hypothyroidism, however. Indeed, the use of products based on thyroid 
extracts did not decline markedly until the latter part of the 1960s, due to difficul-
ties with reproducibility of their biological action and limited storage life [2, 22]. 
Desiccated thyroid products are available for therapeutic use to this day, despite the 
currently high regulatory standards for manufacture of LT4 tablets, which ensure 
reproducibility of day-to-day dosing (see below). Such preparations have persisted, 
despite lack of convincing objective evidence of superior efficacy in controlling 
hypothyroid symptoms [23]. There is an enduring perception that these products 
are a more “natural” treatment than the pharmaceutical preparation [24] although 
the balance of T4 and T3 levels in animals is not the same as that in humans, and 
preparations contain excipients and other non-natural substances, as does any phar-
maceutical [22].
3.2  Monotherapy or Combination Therapy?
In the 1960s, the use of oral combinations of LT4 and T3 became widely used in 
the management of hypothyroidism, due to an assumption that delivery of both 
thyroid hormones would mimic the natural function of the thyroid gland [25]. In 
addition, as thyroid extracts were essentially the reference product for clinical tri-
als at this time, studies comparing thyroid extracts and LT4 + combinations gave 
broadly similar clinical results. However, the pharmacokinetic half-life of T3 is 
much shorter than that of T4 [26]. In addition, it was discovered in the 1970s that 
about 80% of T3 in peripheral tissues is derived from local conversion from T4 by 
local deiodinases, rather than from the thyroid [27]. Moreover, too high a dose of 
T3 results in symptoms of hyperthyroidism, complicating the delivery of combina-
tion therapy [26]. A series of clinical trials from 1970 onwards compared T4 + T3 
combination therapy with monotherapy with LT4 in hypothyroid patients, and these 
studies have established monotherapy with LT4 as the standard of care for manag-
ing hypothyroidism for the vast majority of patients [28, 29]. Today, LT4 is the most 
commonly prescribed medication in the USA [30]. A fuller account of the current 
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status of and prospects for LT4 + T3 combination therapy is given in the chapter, 
“Pharmacodynamic and Therapeutic Actions of Levothyroxine” of this book.
3.3  Technological Advances: Better Assays 
of Thyroid Function
The introduction of pharmaceutical preparations of synthetic thyroid hormones and 
establishment of monotherapy with LT4 as the standard of care for hypothyroid-
ism opened up a prospect of delivery of stable, reproducible therapy tailored to the 
needs of the individual patient. To achieve this, it was necessary to measure circulat-
ing levels of thyroid hormones accurately and reproducibly. In the 1950s, the only 
thyroid hormone test available (the protein bound iodine assay) provided an indirect 
measurement of serum total T4; today, sensitive and specific assays exist for free 
and bound T4 or T3, thyrotropin (thyroid-stimulating hormone; TSH), thyroglobu-
lin (a precursor of thyroid hormones), and a range of proteins that bind thyroid 
hormones in the circulation, based on radioimmunoassay or liquid chromatography- 
tandem mass spectrometry (LC-MS/MS) technology [31]. These assays made it 
possible to accurately determine the thyroid status of patients with all degrees of 
severity of thyroid dysfunction and facilitated a leap in our understanding of the 
physiology of the thyroid gland.
The discovery of a workable TSH test in the mid 1970s was a key development 
in the diagnosis and management of hypothyroidism. Levels of T4 and T3 are low in 
the setting of hypothyroidism, and the pituitary responds by increasing the secretion 
of TSH in an attempt to correct this, leading to an abnormally high TSH level [25]. 
The relationship between levels of T4 and TSH is not linear, however, as decreasing 
the level of T4 by half results in an increase in the TSH level of as much as 100-fold 
[32]. Large changes in TSH are clearly more amenable to accurate measurement 
than the accompanying relatively much smaller changes in T4. Accordingly, the 
management of hypothyroidism is now based on normalisation of the circulating 
TSH level to within a reference range for this parameter derived from a healthy 
population [33–35].
3.4  Recent Developments in Levothyroxine Therapy
LT4 was introduced into the therapeutic armamentarium in the USA in the 1950s 
without a requirement for regulatory oversight. This situation is very different 
today, with increasingly close regulatory attention paid to the standards of manu-
facture of LT4 products. This has led to the development of new formulations of 
LT4, with more accurate and reproducible dosing, designed to improve the accuracy 
and reproducibility of exposure to LT4 for a patient taking this medication. A full 
account of this new formulation is given in the following chapter [36].
G. J. Kahaly
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4  Where We Stand Today
4.1  A Fuller (But Incomplete) Understanding of Thyroid 
Hormone Homeostasis
Our understanding of the complex homeostatic mechanisms underlying the regula-
tion of thyroid hormones and their actions continues to increase. Fig. 3 provides 
an overview of the principal systems involved [37–40]. Briefly, inputs from phys-
iological processes all around the body are integrated within the hypothalamus. 
Neurones within the periventricular nucleus of the hypothalamus secrete higher 
or lower amounts of thyrotropin-releasing hormone (TRH), depending on current 
physiological needs, which acts on the nearby anterior pituitary gland to promote 
secretion of TSH, the principal regulator of thyroid hormone secretion. Most (about 
80%) of the thyroid hormone secreted by the thyroid in response to TSH is T4, with 
T3 making up the remainder. T3 and T4 feedback to the hypothalamus and pituitary 
to inhibit further production of TSH: thus, hypothyroidism is characterised by high 
levels of TSH, due to lack of inhibition of TSH secretion by thyroid-derived T4.
In the peripheral tissues, thyroid hormone-sensitive target cells of the body take up 
































Fig. 3 Simplified schematic overview of the principal physiological systems involved in thyroid 
hormone homeostasis. D1/2/3 deiodinase 1/2/3, T2 diiodothyronine, rT3 reverse triiodothyronine 
(inactive), RXR retinoic acid receptor, TRE thyroid hormone response element, T3 triiodothyro-
nine, T4 thyroxine, THR thyroid hormone receptor, TRH thyrotropin-releasing hormone, TSH thy-
rotropin (thyroid-stimulating hormone), PVN periventricular nucleus (of the hypothalamus)
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deiodinases, which also deactivate thyroid hormones, by converting T4 into reverse 
T3, and T3 into diiodothyronine. A complex of T3, its intracellular thyroid hormone 
receptor, and the thyroid hormone-responsive element alters the transcription of a large 
number of genes to mediate the pleiotropic physiological actions of thyroid hormones.
It is clear that the regulation of thyroid hormone function takes place on a num-
ber of distinct levels, including during integration of signal inputs in the hypothala-
mus and secretion of TRH, feedback inhibition of TSH release by T4, and, locally, 
by control of the deiodinases that determine the prevailing level of functionally 
active T3. Other chapters of this book, especially chapters, “Administration and 
Pharmacokinetics of Levothyroxine”, and “Pharmacodynamic and Therapeutic 
Actions of Levothyroxine” will touch on specific aspects of thyroid hormone 
homeostasis relevant to their subjects of interest.
4.2  Unresolved Issues and Current Research Questions
Research continues into the management of hypothyroidism, and Table 1 highlights 
several important issues that remain unresolved [28, 32, 41–47]. Resolution of these 
Table 1 Outstanding research questions concerning the management of hypothyroidism and 
therapeutic use of LT4
Clinical issue Outstanding research questions
Subclinical 
hypothyroidism
This term describes a mild elevation of TSH where the thyroid-derived 
hormones are within their normal reference ranges. The current consensus is 
that most people with subclinical hypothyroidism, and a baseline serum 
TSH below 10 mU/L, should not receive treatment with LT4 [41]. However, 
a trial of LT4 may be given to non-elderly patients with symptoms, risk 
factors for atherosclerosis and coronary heart disease, e.g. hyperlipidaemia, 




Debate continues as to whether the upper reference limit for serum TSH 
should be reduced [32].
Cardiovascular 
disease
People with foremost acute cardiovascular disease have reduced levels of 
thyroid hormones, particularly T3, on average, and this has been associated 
with increased risk of adverse clinical outcomes in observational studies 
[45].  Experts in the field have called for clinical evaluations of thyroid 
hormone treatment (with LT4 and/or T3) in this population [46].  More data 
are required on the association between subclinical hypothyroidism and the 




Some patients report symptoms reminiscent of thyroid dysfunction despite 
well-controlled thyroid hormones [47].  Many of these symptoms will be 
found to relate to a non-thyroid cause, and can be eliminated through careful 
patient workup [47].  However, patients may have their own individual set 
point for thyroid hormone levels, and the delivery of individualised therapy 
for this population requires further study [32].
LT4 monotherapy, 
or LT4 + T3?
Current guidance does not support the use of combinations of LT4 and T3 to 
correct hypothyroidism (see text). However, some experts support the use of 
a trial of LT4 + T3 where patients’ symptoms have not been controlled by 
TSH-optimised LT4 monotherapy and cannot be explained by other 
conditions [28].  Combination therapy with thyroid hormones remains 
within the research domain, for now.
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clinical issues will influence the future management of hypothyroidism, including 
the therapeutic use of LT4.
5  Conclusions
The history of hypothyroidism and its management spans the golden age of clini-
cal research, from empirical medical and surgical treatments unencumbered by 
understanding of thyroid physiology in the nineteenth century to individualised, 
TSH- guided treatment with LT4 today. Along the way, many clinical and experi-
mental studies, enhancements in technology, and improved LT4 preparations have 
increased greatly our ability to deliver optimal care for hypothyroidism, based on 
the therapeutic administration of LT4.
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Lifelong treatment with LT4, guided by levels of thyrotropin, is the mainstay of 
management of hypothyroidism. The bioavailability of LT4 is about 70% following 
an oral dose, with absorption occurring mainly in the ileum and jejunum. 
Maximum plasma concentrations of LT4 are achieved about 3 h after an oral dose 
in patients with hypothyroidism. The long terminal half-life of orally administered 
LT4, about 7.5  days, is consistent with once-daily dosing. Pregnancy, several 
medical conditions (especially) those affecting the gut, and a number of drugs, 
supplements, or foodstuffs can reduce the absorption and absolute bioavailability 
of LT4, or can alter the secretion of TSH, with detrimental consequences for long-
term control of thyroid function. Poor adherence to LT4 therapy is also a common 
challenge. The introduction of novel formulations of LT4, with more precise 
delivery of the active ingredient and higher levels of bioequivalence with existing 
products will facilitate accurate titration of LT4 for patients with hypothyroidism.
1  Introduction
Oral administration of levothyroxine (LT4), which targets the circulating level of 
thyrotropin (thyroid-stimulating hormone, TSH) to within a predefined reference 
range, is the mainstay of treatment of hypothyroidism [1–3]. This chapter sum-
marises the administration, absorption, distribution, metabolism, and elimination 
of LT4. In addition, it addresses the therapeutic significance of pharmacologic and 
other factors that can alter exposure to LT4, and of changing regulatory require-
ments concerning the manufacture of LT4 tablets.
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2  Absorption, Distribution, Metabolism, and Elimination 
of Levothyroxine
2.1  Absorption and Distribution
In general, about 70–80% of an oral dose of LT4 is absorbed from the intestine [4], 
which may involve transport of the LT4 molecule on the Organic Acid Transporting 
Polypeptide 2B1 (OATP2B1) transporter [5]. One study did not find significant dif-
ferences in absorption of LT4 between subjects with and without hypothyroidism, 
whereas another study demonstrated higher bioavailability of LT4 in subjects with 
hypothyroidism or hyperthyroidism, compared with euthyroid subjects [6]. It has 
been shown that about half of an oral dose of the hormone was absorbed in the 
jejunum and ileum following administration of radiolabelled LT4 [7]. A modest 
reduction in LT4 absorption was noted in elderly subjects (>70 years), compared 
with younger adults [8]. In routine clinical practice, titration of the LT4 dose in an 
elderly patient to an appropriate age-specific reference range would account for this 
effect of age on LT4 absorption (see chapter, “Levothyroxine in the Older Patient”, 
of this book) [9]. Unlike T4, T3 is essentially completely absorbed (100%) from the 
intestine following an oral dose [10].
Fig. 1 shows the plasma concentration-time curve from a pharmacokinetic evalu-
ation of two formulations of LT4  in healthy subjects [11]. The time to maximal 
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Fig. 1 Plasma concentration-time curves from a comparison of an existing LT4 tablet formulation 
with a new LT4 tablet formulation designed to meet new regulatory requirements for the manufac-
ture of such products. (Reproduced with permission from Ref. [11])
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hypothyroidism and 2 h in euthyroid controls [12]. Concomitant food intake reduces the 
bioavailability of LT4, hence the labelling requirement to take LT4 tablets on an empty 
stomach, e.g. 30 min before breakfast, or 3 h after the evening meal [12, 13]. In plasma, 
LT4 is highly bound to plasma proteins (>99.9%) and distributes within a volume equal 
approximately to the human body’s total extracellular space (about 11–15 L) [14, 15].
2.2  Metabolism and Elimination
The main route of metabolism of LT4, and the route most relevant to its physi-
ological actions, is conversion to T3 and deactivation, mediated by three peripheral 
deiodinases (Table 1) [16, 17]. Briefly, deiodinases D1 and D2 can mediate the con-
version of T4 to T3, enhancing the availability of T3 to local tissues. Accordingly, 
LT4 may be considered to act largely as a prodrug for delivery of T3 to peripheral 
tissues. D2 is more important than D1 for generating T3; D1 is especially important 
for clearing the inactive thyroid hormone metabolite, reverse T3 (rT3), from the 
system via conversion to a further inactive deiodinated thyroid hormone metabo-
lite. The main function of deiodinase D3 is the degradation of thyroid hormones. 
Polymorphisms of deiodinases may inhibit the conversion of LT4 to T3  in the 
periphery and have been proposed to explain an incomplete effect of exogenous 
LT4 treatment in resolving symptoms of hypothyroidism in some patients [18].
Multiple metabolites of thyroid hormones exist, and some of these may have 
intriguing biological actions that are the focus of current research [19–21]. Pathways 
for biotransformation of LT4 include decarboxylation and oxidative deamination, 
which results in, e.g. 3-iodothyroacetic acid. The biological activity of metabolites 
of LT4 remains to be established; 3-iodothyroacetic acid, for example, has been 
shown to induce antidepressant effects, and to promote itching and discomfort, in 
animal models [21].
Table 1 Metabolism of levothyroxine by peripheral deiodinases
Deiodinase D1 Deiodinase D2 Deiodinase D3
Mainly 
expressed in














•  Important source of 
plasma T3




•  Regulation of local 
cellular T3 levels
•  Maintaining pituitary/
hypothalamic feedback 
for thyroid hormone 
production
•  Regulation of local 
cellular D3 levels, 
independent of local T3 
or T4 levels
•  Degradation of thyroid 
hormones
T4 thyroxine, T3 triiodothyronine, rT3 reverse triiodothyronine, T2 3,3′-diiodothyronine. Compiled 
from information presented in Refs. [16, 17]
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The elimination half-life of LT4 after oral dosing averages 7.5 days in patients 
with hypothyroidism, consistent with once-daily dosing [14]. A slightly lower 
elimination half-life was reported in euthyroid subjects (average 6.2  days) [14]. 
Interestingly, the elimination half-life of T3 is much lower (1–1.4 days, on aver-
age) [14], which may complicate future attempts to deliver LT4–T3 combination 
therapies [22].
3  Factors That May Alter Exposure to an Oral Dose 
of Levothyroxine
3.1  Factors That May Reduce Exposure to Levothyroxine
3.1.1  Diurnal Variation
Taking LT4 at bedtime (e.g. 3 h after the evening meal) rather than in the morning 
modestly but significantly increased LT4 levels and reduced TSH levels in the blood 
[23]. Consequently, it has been proposed to move the routine administration of LT4 
from morning to evening, especially as a range of secondary measures (creatinine, 
lipids, body mass index, heart rate, quality of life) were unchanged between morn-
ing and bedtime administration. However, the usually recommended time of intake 
of LT4 remains in the morning (but at least 30 min before consumption of tea, cof-
fee, or breakfast).
3.1.2  Malabsorption of, and Suboptimal Adherence to, Levothyroxine
Numerous factors may inhibit the absorption of LT4 into the bloodstream, includ-
ing pre-existing intestinal disorders (e.g. celiac disease, prior gut resection or some 
forms of bariatric surgery), or concomitant intakes of certain supplements that con-
tain metal ions (e.g. antacids, calcium, iron), drugs (e.g. laxatives, sevelamer, proton 
pump inhibitors), or soya protein [24–29]. The solubility of LT4 increases as pH 
decreases [30]. Proton pump inhibitors reduce the acidity (and increase the pH) of 
the stomach, and thus may reduce the bioavailability of LT4 by about 40% [29]; 
conversely, co-administration of ascorbic acid (vitamin C) reduces gastric pH and 
increases the absorption of LT4 [29, 30].
Malabsorption of LT4 results in lower than expected blood levels of LT4 and 
higher than expected levels of TSH, sometimes even in the setting of high doses of 
exogenous LT4. Alternative formulations to the usual tablet may be considered for 
patients with documented LT4 malabsorption [27, 31]. In cases where suboptimal 
adherence to LT4 therapy is suspected [32], the LT4 absorption test, where thyroid 
hormone levels are measured after a supervised dose of LT4, can be useful in distin-
guishing non-adherence of LT4 from genuine cases of malabsorption of LT4 [33]. 
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Intramuscular LT4 treatment has been proposed for patients with severe intestinal 
malabsorption of LT4 though this approach remains within the research domain at 
present [34].
3.2  Factors That May Alter the Measured Level of Thyrotropin
A series of other factors influences the TSH test result, and therefore have clinical 
implications for the administration of LT4. This has been reviewed elsewhere [27], 
and is summarised briefly as follows:
Pregnancy The requirement for, and production of, thyroid hormones increase markedly 
during pregnancy, with a consequent fall in TSH levels. Current guidelines 
recommend use of locally derived, trimester-specific reference ranges for 
testing thyroid function in pregnant women [35].
Drugs Substances that alter the level of TSH will impact on the required dosage of 
LT4, as the TSH level is used to guide therapy. Several medications have the 
potential to decrease the TSH result, including dopamine antagonists, 
glucocorticoids, alemtuzumab, proton pump inhibitors, interferon-alpha, and 
metformin. Other drugs may increase or decrease the TSH test result, 
including lithium or amiodarone [27, 36–40].
Biorhythms TSH secretion follows a diurnal variation, with the lowest value recorded 
around the middle of the day [41]. A circannual variation in TSH has also 
been observed in a large database study, with lower values during the 
summer [42], although the functional significance of this observation remains 
uncertain [43].
Demographics TSH levels increase with age and are higher in women vs. men [43, 44]. 
Ethnicity also influences thyroid hormone levels [43, 44], which adds weight 
to the importance of using relevant reference populations for determining 
“normal” TSH results.
Smoking TSH levels may be lower in smokers vs. non-smokers [45].
Obesity Obesity is often considered to be a consequence (or a symptom) of 
hypothyroidism [1]. However, TSH levels correlate positively with BMI, 
consistent with a mechanism in which increased leptin secretion in obese 
subjects may drive increased secretion of TSH [46, 47]. The relationships 





Different commercial TSH assays may have different ability to recognise 
“macro-TSH”, which is TSH attached to IgG autoantibodies [48]. Macro- 
TSH is secreted variably between individuals with hypothyroidism.
Other substances in the patient’s circulation may interfere directly with the 
operation of the TSH test, such as autoantibodies to LT4, rheumatoid factors 
(IgM antibodies directed against human IgG), and heterophilic antibodies 




4  Levothyroxine Tablets in a Changing 
Regulatory Environment
The manufacture of pharmaceutical products is subject to regulatory supervision to 
ensure maintained, high quality and consistency of successive batches; in particular, 
new formulations of currently available LT4 products must be bioequivalent to the 
existing formulation [50]. A small change in the level of T4 in the bloodstream will 
result in a much larger relative change in TSH secretion [28]. Accordingly, LT4 is 
regarded as a “narrow therapeutic index” drug in Europe (similar terms are used in 
other countries). According to the standard criteria for bioequivalence between an 
equivalent oral dose of two pharmaceutical preparations, the 90% confidence inter-
vals (90%CI) for the geometric mean ratio of the area under the concentration-time 
curve (AUC) and the peak plasma concentration (Cmax) must be contained between 
80% and 125% [51, 52]. For most narrow therapeutic index drugs, including LT4, 
current specifications now require that the 90% CI for the geometric mean ratio 
of the AUC and Cmax values must lie between 90% and 111%, for the products to 
be considered to be bioequivalent [51, 52]. Updated regulations in several coun-
tries now also require the actual LT4 content of LT4 tablets to lie between 90% or 
95% (depending on the country) and 105% of the amount declared on the package, 
throughout the shelf life of the product [53–55].
A randomised clinical trial compared the clinical pharmacokinetics of a new 
formulation of LT4 that meets these updated, narrowed requirements for bioequiva-
lence with the previous formulation, in 216 healthy subjects [11, 56]. Fig. 1 showed 
that the plasma concentration-time curves and Cmax values of the two formulations 
were essentially identical [11]. A formal evaluation of bioequivalence showed that 
the new formulation with improved specifications met the updated, stricter crite-
ria for bioequivalence for a new formulation of a narrow therapeutic index drug 
(Fig. 2).
85 90 95 100 105 110 115
Geometric mean ratio (90% CI)
AUC(0–72 h, adj) 
Cmax, adj
90 111.11
Fig. 2 Formal demonstration of bioequivalence according to updated regulatory criteria between 





LT4 is absorbed well and quickly from the gastrointestinal tract after oral adminis-
tration. Once-daily dosing is feasible, based on its long half-life. Several medical 
conditions, particularly those affecting the gut, a number of drugs, pregnancy, and 
ingestion of supplements or food can interfere with the absorption of LT4 or the cor-
responding TSH test. As a consequence, care must be taken to identify and exclude 
these factors, as well as suboptimal adherence to therapy, when a patient presents 
with symptoms of hypothyroidism in spite of LT4 prescriptions. The introduction 
of novel formulations of LT4, with improved drug stability over time, more precise 
delivery of the active ingredient, and higher levels of bioequivalence compared with 
existing products promises to simplify accurate titration of LT4 for patients with 
hypothyroidism.
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The regulation of thyroid hormones within the hypothalamic-pituitary-thyroid 
axis is complex, consisting of multiple feedback and feed-forward loops. In 
addition, this system contributes to and likely reflects the regulation of 
sensitivity to thyroid hormones at the level of other target tissues. The effects of 
levothyroxine (LT4) replacement therapy for people with hypothyroidism must 
be considered within this context, as many patients will have residual thyroid 
activity. LT4 replacement reverses many metabolic disturbances associated 
with hypothyroidism including resetting of reduced energy expenditure and 
metabolic rate, correction of dyslipidaemia, improvement in insulin sensitivity 
and glycaemic control, and reversal of a pro-inflammatory and procoagulant 
state, and the eventual correction of mood disturbances (although on the 
surface these appear more refractory to LT4 treatment than other consequences 
of hypothyroidism). Monotherapy with LT4 remains the mainstay of treatment 
for hypothyroidism, due to a lack of clinical evidence for superior treatment 
outcomes with combinations of LT4 and triiodothyronine.
1  Introduction
The opening chapters of this book outlined the historical development of levothy-
roxine (LT4) as a treatment for hypothyroidism and described the pharmacokinetic 
properties of exogenously applied levothyroxine. The purpose of this chapter is to 
summarise the therapeutic actions of LT4  in key organs of the body. Exogenous 
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LT4 is indistinguishable from endogenous T4, and so I have sought to summarise 
the biological actions of T4 per se, in terms of the regulation of secretion and action 
of thyroid hormones and the therapeutic effects of LT4 supplementation in people 
with hypothyroidism in key areas of the body (Fig. 1). This chapter will not include 
detailed descriptions of the effects of LT4 on the heart or the skeleton: these aspects 
are covered in chapters, “Levothyroxine and the Heart” and “Levothyroxine and 
Bone” of this book, respectively. Finally, I have considered the evolution and cur-
rent status of guidelines for the management of hypothyroidism, and the current 
evidence base for the therapeutic use of LT4 monotherapy, the current mainstay of 
treatment for hypothyroidism.
2  Thyroid Hormone Homeostasis
A simplistic view of the hypothalomo-pituitary-thyroid (HPT) axis entails secre-
tion of thyrotropin-releasing hormone (TRH) from the hypothalamus acting on the 
pituitary to enhance secretion of thyrotropin (thyroid-stimulating hormone, TSH) 
[1–3]. Increased circulating concentrations of TSH then stimulate release of thyroid 
hormones from the thyroid gland, with a negative feedback loop causing secretion 
of TSH to fall as the concentration of thyroid hormones in the blood and tissues 
increases. In practice, the operation of the HPT axis is extraordinarily complex. Key 





























Fig. 1 Overview of key sites of thyroid hormone action. a,bNot described in this chapter: see chap-
ters, “Levothyroxine and the Hearta” and “Levothyroxine and Boneb”
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2.1  Conversion of T4 to T3
T4 is the primary secretory product of the thyroid and accounts for about 60–80% of 
circulating thyroid hormones. Triiodothyronine (T3) accounts for most of the remain-
der (other molecular species such as diiothyronine, or reverse T3 may have biological 
activity [4], but are beyond the scope of this review). Eighty percent of the T3 found 
in the circulation is derived through peripheral activation of T4 while the remaining 
20% of circulating T3 is produced in the thyroid. T4 (or exogenous LT4) is converted 
to T3 locally in target tissues, via the actions of three deiodinase enzymes, particularly 
Deiodinase 2 (see chapter, “Administration and Pharmacokinetics of Levothyroxine” 
for a fuller account of the functions of different deiodinases) [5].
2.2  Regulation of Deiodinases and Individual “Set Points” 
for Thyroid Function
The activity of intrathyroidal deiodinase is regulated by TSH in a feed- forward man-
ner, providing a means of adjustment of local T3 levels as needed [3]. In addition, 
ubiquitination of Deiodinase 2 in some tissues reduces its activity; this occurs to a 
lesser extent in the hypothalamus than in some other tissues, which may increase 
sensitivity to feedback inhibition of TRH release by (L)T4 [6].
The relationship between TSH levels, free T3 and free T4 (FT3 and FT4) is not the 
same in a euthyroid healthy individual and a patient with thyroid disease treated with 
LT4 [7, 8]. In general, T4 levels (especially when measured in the post- absorptive 
state) tend to be higher once TSH is controlled to its reference range, compared with 
euthyroid individuals [9–11]. However, studies in hypothyroid patients rendered 
surgically athyroid who were titrated to a normal TSH with LT4 have also reported 
normalised T3 levels; in fact, 49% of those titrated to a normal TSH had higher T3 
levels on LT4 than in their native preoperative state in one study [12]. A retrospective 
study of hypothyroid subjects on LT4 monotherapy reported lower FT3 levels than 
in healthy individuals [13]. Finally, in one retrospective study, serum T3 levels in 
subjects with an elevated or normal-range TSH were lower than the same individuals’ 
preoperative values but surprisingly all were still within the normal reference range. In 
those with modest TSH suppression, T3 levels were no different from their native state 
while several of those with more complete suppression of TSH demonstrated frankly 
elevated T3 values [8]. Accordingly, each patient with thyroid dysfunction has an indi-
vidual “set point” for optimum functioning of the HPT axis, whether levels of TSH, 
FT3, and FT4 are precisely within their formally defined reference ranges or not [14].
2.3  Thyroid Hormone Receptors (THRs)
THRs are nuclear receptors that bind T3 after uptake into cells via active transporters. 
The most important THRs for mediating the actions of thyroid hormones are [13, 15, 16]:
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• THRα1: expressed most strongly in bone, the gut, the central nervous system, 
and cardiac and skeletal muscle
• THRβ1: expressed most strongly in the liver, kidney, and the inner ear
• THRβ2: expressed most strongly in the hypothalamus, pituitary, cochlea, 
and retina
THRβ2 appears to be about ten-fold more sensitive than THRβ1 [13]. Loss-of- 
function mutations in THRs have been shown to produce elevated circulating T4 
and T3 levels simultaneously with signs of a functional peripheral hypothyroid-
ism [17].
2.4  Regulation of TSH Release
Production of TRH by the hypothalamus is an absolute requirement for the produc-
tion of TSH, and thus thyroidal T4 [18]. TRH modulates the bioactivity of TSH, 
with more bioactive forms produced in the setting of thyroid deficiency [19]. TSH 
itself exerts an autocrine function in the pituitary and a paracrine function in the 
hypothalamus to inhibit further TSH release [20].
Importantly, TSH release is highly sensitive to the prevailing level of T4 in the circu-
lation, such that reducing FT4 by half would typically increase the TSH level by up to 
100-fold; conversely, a five-fold increase in the TSH level might be seen when FT4 is 
reduced by only about 10% [21]. The relationship of TSH levels to FT4 levels has been 
described as inverse log-linear although more complex non-linear associations have 
been described [22–25]. This relationship is the main reason why the TSH level is used 
to guide treatment of hypothyroidism with LT4, as the large changes in TSH are far 
easier to measure than small changes in T4 or FT4 (within the traditional 95% normal 
range) in the routine setting [21, 26]. Multiple factors, such as age, gender, smoking, 
the presence of antithyroid antibodies, and the difference between prevailing thyroid 
hormone levels and an individual’s “set point” for HPT axis function (see above), influ-
ence the shape of the relationship between TSH and FT4 levels [22, 23, 25].
3  Clinical Pharmacodynamics of (Levo)Thyroxine
3.1  Which Thyroid Hormones Are Important?
LT4 acts essentially as a prodrug of T3 in target tissues, via the actions of the deiodin-
ase enzymes, described above [5]. Accordingly, this section will include information 
on the effects of hypothyroidism on key organs of the body, as well as the restorative 
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Influence of  
hypothyroidism
Principal effects of LT4 replacement in a 
patient with hypothyroidism
Energy expenditure Reduced Reverses reductions in resting energy 
expenditure and metabolic rate
Lipid profiles Promotes dyslipidaemia 
mainly via ↓ hepatic LDL 
receptors
Reduces total and LDL-cholesterol, and other 
markers of dyslipidaemia







increases insulin resistance 
and risk of diabetes
Corrects changes of IGT in thyrotoxicosis
Improves insulin sensitivity
Improves glucose tolerance
Inflammation Increased systemic 
inflammation
Reduced markers of systemic inflammation
Coagulationa Overt hypocoagulant state 
often induces coagulopathy 
similar to aVWS
Subclinical hypothyroidism 
induces a procoagulant 
state
LT4 corrects deficiencies
Improved markers of fibrinolysis and 
coagulation
Brain Altered mood/affect Evidence for improved mood/affect (e.g. 
reduced depression questionnaire scores)
Adipose tissue Modest ↑ weight
↓ Brown fat activation
Reverses weight gain in hypothyroidism (but 
little effect on body composition)





Reverses abnormalities in cardiac structure 
and function
Bonea Thyroid hormones reduce 
bone density
Over treatment and hyperthyroidism may 
cause excessive bone loss
Thyroid function must be assessed especially 
carefully in people at risk of fractures
Kidney Hypothyroidism can 
reduce renal function
Reverses hypothyroidism-induced reduction 
in GFR
Some evidence of benefit (reduced decline in 
GFR, reduced uric acid and albumin 
excretion)
QoL Decreased health-related 
QoL
Fatigue is common
Inconsistent effects of LT4 on relatively 
non-specific symptoms (importance of 
ensuring an accurate diagnosis of 
hypothyroidism)
aDealt with only briefly here, see chapters, “Levothyroxine and the Heart” and “Levothyroxine and 
Bone” of this book for a fuller account of the effects of hypothyroidism and LT4 on these organs, 
including discussion of the effects on cardiac outcomes. aVWS acquired Von Willebrand Syndrome, 
GFR glomerular filtration rate, IGT impaired glucose tolerance, QoL quality of life. See text for 
references
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effects of treatment with LT4. Table 1 summarises these effects of LT4 replacement 
on important physiologic and metabolic processes in patients with hypothyroidism. 
3.2  Actions on Skeletal Muscle
3.2.1  Mechanisms
Skeletal muscle is a major site of action of thyroid hormones. Active membrane 
transporters regulate the uptake of T4 and T3 from the extracellular space; once 
inside the cell, the T3 level is adjusted via deiodination of T4 and inactivation of 
T3, by Deiodinases 2 and 3, respectively [27–29]. Activation of the thyroid recep-
tor drives multiple processes, from the initiation of muscle formation during early 
embryogenesis, to the differentiation of the various fast and slow skeletal muscle 
fibre phenotypes in adult muscle (high T3 levels favour fast-twitch type muscle 
fibres [30]), to the repair or replacement of damaged muscle fibres [27, 28]. Defects 
in these mechanisms, associated with changes in levels of thyroid hormones, may 
be implicated in the progression of myopathy states, including Duchenne muscular 
dystrophy, among others [31]. High levels of thyroid hormones increase energy 
utilisation, and decrease the efficiency of skeletal muscle, with opposite effects in 
hypothyroidism. Skeletal muscle accounts for up to half of an individual’s body 
weight and changes in energy homeostasis in skeletal muscle exert an important 
influence on the overall metabolic rate [27, 28].
3.2.2  Clinical Studies of Interest
LT4 replacement therapy vs. no treatment has been shown to improve cardiopulmo-
nary performance (O2 uptake, minute ventilation, and heart rate) in subjects with 
subclinical hypothyroidism [32], although not all studies have shown this [33]. In 
another study, variation of LT4 doses to induce minor fluctuations of TSH around 
the reference range did not influence energy expenditure or body composition in 
patients with hypothyroidism [34]. Studies in euthyroid subjects showed variable 
effects of LT4 on muscle performance [35–37], consistent with the absence of indi-
cations for LT4 intervention in those without hypothyroidism.
3.3  Effects on Lipid Profiles
Thyroid hormones are metabolised in the liver, which influences their levels in the 
circulation [38]. T3  in the liver induces 3-hydroxy-3-methylglutaryl-coenzyme 
A (HMG-CoA, which initiates cholesterol synthesis), increases the synthesis and 
release of LDL receptors (enhancing LDL-cholesterol clearance), and stimulates 
the activity of lipoprotein lipase and apolipoprotein AV (which play a major role 
in triglyceride regulation) [39]. Thus, even mild hypothyroidism increases total 
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cholesterol, LDL-cholesterol and, sometimes, triglycerides [40]. The administration 
of LT4 reduces serum cholesterol and other markers of dyslipidaemia in patients 
with varying degrees of hypothyroidism [40–44]. LT4 also reduced intrahepatic 
lipid content in an uncontrolled study in euthyroid subjects with non-alcoholic fatty 
liver disease and type 2 diabetes, suggesting a possible future role for LT4 in this 
population [45]. At present, LT4 does not have a recognised role in dyslipidaemia 
management of euthyroid individuals, however [46].
3.4  Actions in Adipose Tissue
Thyroid hormones have a powerful effect in stimulating thermogenesis in brown 
adipose tissue, to a much greater extent than that observed in white adipose tissue 
[27, 47]. TSH correlates positively with body mass index, and overt hypothyroidism 
is associated with modest weight gain, which reverses with LT4 treatment; however, 
this weight loss may be associated more with loss of excess fluid than loss of fat 
mass [48]. A study in women with hypothyroidism showed that normalisation of 
TSH with LT4 did not affect body fat percentage significantly [49]. Changes in rest-
ing energy expenditure during LT4 treatment in humans are driven mainly by effects 
in skeletal muscle, as described above.
3.5  Effects on Glucose Metabolism
An association of autoimmune thyroid disease and type 1 diabetes mellitus has long 
been recognised [50, 51]. Thyrotoxicosis was long believed to be the prime thyroid 
function abnormality associated with glucose intolerance and two-thirds of those 
found to be glucose intolerant while thyrotoxic were normal when retested after 
adequate antithyroid treatment; on the other hand, glucose intolerance persisted in 
the remainder [52]. Increased intestinal hexose absorption, decreased responsive-
ness to insulin, and increased glucose production have been proposed to mediate 
hyperglycaemic effects of thyrotoxicosis [50]. Further observations of insulin secre-
tion/action defects in thyrotoxicosis were mainly accounted for by ageing [53, 54]. 
Normal insulin secretory function and adipocyte sensitivity in the face of a reduced 
number of adipocyte insulin receptors shifted the search for a mechanism toward 
the hepatocyte and resultant increased gluconeogenesis or changes in skeletal mus-
cle glucose metabolism as the basis of glucose intolerance in thyrotoxic patients 
[55–57]. In summary, an increase in T3 activity as seen in overt hyperthyroidism, 
seems to drive increased production of glucose by the liver and may be associated 
with reduced insulin secretion from the pancreas, increasing the risk of glucose 
intolerance and diabetes [27].
Ironically, more recent research indicates that overt thyrotoxicosis is not necessar-
ily the only influence on glucose intolerance and frank type 2 diabetes in genetically 
at-risk subjects. In fact, compared with euglycaemic, unrelated controls, those with 
new onset type 2 diabetes, impaired glucose intolerance (IGT) and relatives of type 2 
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diabetes patients had higher FT4 and FT3 though all were within the expected range 
[58]. Cross-sectional observations showed that impaired fasting glucose (IFG) was 
associated with higher free T3 and FT3/FT4 ratios but lower FT4 than IGT, indicat-
ing that thyroid hormone levels may play differing roles in the development of differ-
ent forms of dysglycaemia [59]. Further evidence of a direct influence of inadequate 
thyroid function on insulin resistance was reported in a group of athyrotic subjects, 
in the form of a negative correlation of FT4 and insulin during thyroid hormone 
withdrawal [60]. Another study showed that people with overt and subclinical hypo-
thyroidism had similar severity of insulin resistance, each higher than in euthyroid 
controls, providing further evidence that hypothyroidism is an insulin-resistant state 
[61]. A study of 2,399 euthyroid, non-diabetic subjects showed that FT4 levels in the 
lower part of the normal range were associated with an increased risk of prediabetes 
[62], and other clinical data indicated that higher TSH levels, as found in hypothy-
roidism, increase the risk of developing type 2 diabetes [63].
Correction of subclinical hypothyroidism with LT4 has been shown to improve 
insulin resistance and/or control of blood glucose [42, 64–66]. A recent study 
showed that malabsorption of LT4 associated with concomitant calcium carbonate 
supplementation was associated with a decline in the quality of glycaemic control, 
which was reversed when the interval between LT4 and calcium supplementation 
was increased [67]. Practically, and reassuringly, exogenous LT4 does not seem to 
be associated with glucose tolerance issues, even at TSH-suppressive doses that 
result in prolonged subclinical thyrotoxicosis [68].
These studies leave us with some unanswered questions in regard to the mecha-
nisms linking thyroid function and glucose intolerance. A recent review summarises 
six areas of mechanistic connections between the presence of thyrotoxicosis and 
abnormal glucose metabolism, and Fig. 2 summarises its main findings [51].
Direct or indirect effects on the pancreas
b-cell growtha 
Insulin secretion
Actions that tend to
increase plasma glucose 
Gut motility Hepatic gluconeogenesis glucose absorption
Actions that tend to
decrease plasma glucose 
Skeletal muscle glucose uptake
Lipolysis FFA
(glucotoxicity)
Fig. 2 Overview of some 
important effects of 
levothyroxine on 
glycaemia. aEffects 
mediated via decreased 
apoptosis and enhanced 
growth and differentiation. 
(Compiled from 




3.6  Actions on Mood and Affect
The hypothalamus is involved intimately in the complex relationships between 
thyroid hormone status and numerous aspects of metabolism and homeostasis, as 
described above. Changes in mood and affect are classically recognised symptoms 
of hypothyroidism [69]. LT4 administration to symptomatic hypothyroid subjects 
should improve mood and affect only if thyroid function provoked such symptoms. 
Unfortunately, recent observations in subclinical thyroid dysfunction alert us to 
the need to diagnose specific underlying thyroid abnormalities accurately, rather 
than empirically assuming a thyroid-deficient state. Subclinical hyperthyroidism 
has emerged as a more frequent underpinning of depression than mild thyroid 
failure [70–72], indicating that thyroid hormone replacement would not be univer-
sally appropriate for all situations where hypothyroidism is assumed to be present. 
Although some studies have reported very robust improvement in thyroid-specific 
symptoms when LT4 is used to titrate TSH into the normal range [73, 74], and other 
investigations seem to indicate that LT4 treated patients fare as well as appropriately 
selected controls [75], some investigators emphasise less than perfect resolution of 
symptoms with thyroid hormone replacement therapies [76–78].
Recently, a randomised, placebo-controlled trial in 60 patients with subclini-
cal hypothyroidism did demonstrate a significant improvement in Beck Depression 
Inventory (BDI) scores in those randomised to LT4 therapy, while improvement 
was not observed in the placebo group [79]. The effect in the LT4 group was driven 
strongly by improvements in the somatic subscale of the BDI, with no significant 
improvement in the affect scale. A case-control study indicated that a population 
of women with hypothyroidism continued to have a higher prevalence of anxi-
ety or depression than a control group of euthyroid women, even after correction 
of TSH using LT4 [80]. These findings have prompted some experts to propose 
individually derived cut-offs for TSH in the management of hypothyroidism with 
LT4, that is based on resolution of symptoms of depression [81]. These contradic-
tory findings emphasise the current difficulties encountered in identifying specific 
symptoms truly due to thyroid hormone deficiency rather than the other, common, 
non- thyroid- related, symptoms that result in a major obstacle in the clinical assess-
ment of self- reported complaints, especially in patients with chronic conditions 
[82]. Such symptoms would not be expected to respond to manipulation of the thy-
roid axis in those with normal thyroid function. Multiple alternative explanations 
for LT4- treated subjects’ occasional unhappiness with their clinical outcomes have 
been reported extensively and potentially include independent effects of autoim-
munity [83, 84], theoretical brain hypothyroidism with normal TSH [85], selection 
bias of subjects seeking health care [86], and awareness of having a chronic disease 
[87]. These and other explanations will be discussed in detail below.
Some have speculated that the documentation of biochemical hypothyroidism 
is less sensitive than clinical symptoms in identifying truly hypothyroid individu-
als who would benefit from LT4 replacement therapy. These anecdotal and testi-
monial reports seldom acknowledge the lack of effect of LT4 vs. placebo on the 
Hospital Anxiety/Depression Scale (HADS) and the Standard Form-36 (SF-36) in a 
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randomised trial [88]. It seems clear that symptoms consistent with hypothyroidism 
in euthyroid individuals do not respond to (nor should they be treated with) LT4.
The relationship between hypothyroidism and the response of neuropsychiatric 
function to LT4 therapy has continued to generate interest in the potential applica-
tion of LT4 treatment to correct these symptoms in euthyroid patients with psy-
chiatric disorders. One study did not find a significant effect of LT4 on a validated 
instrument for quantifying symptoms of depression in people with bipolar disorder 
[89], while randomised [90] or observational [91] trials have indicated improved 
mood in euthyroid patients with bipolar disorder given an LT4 300 μg/day. It is dif-
ficult to disassociate effects on mood of LT4 per se from the adverse psychological 
impact of having a chronic thyroid condition, however [92]. LT4 is not indicated for 
this purpose, and these studies remain in the realm of research.
3.7  Fatigue
Patients with fatigue (a classic symptom of hypothyroidism) are reported to receive a 
lifetime diagnosis of depression or anxiety disorder much more frequently than oth-
ers (45% vs. 28%) [93]. Similarly, tiredness, another non-specific “thyroid” symp-
tom common in primary care is associated as frequently with chronic diseases such 
as diabetes, or anaemia, as with hypothyroidism, and more strongly associated with 
depression [94]. The correlation of symptoms consistent with hypothyroidism and 
actual, documentable hypothyroidism is poor [95]. The predictive value of individual 
symptoms in identifying hypothyroidism is substantially overlapping with symptoms 
offered by euthyroid individuals [96], and this lack of specificity is diminished even 
further by female gender and older age [97]. Persistent symptoms encountered in 
those on thyroid hormone replacement with well-controlled TSH levels and normal 
serum T3 levels have been demonstrated to be correlated more closely with comor-
bidities than thyroid function [98, 99], again highlighting the importance of assessing 
the entire patient rather than to assume that all complaints are thyroid related.
3.8  Actions on Inflammation and Haemostasis
Circulating levels of inflammatory cytokines were increased in hypothyroidism and 
reduced after treatment with LT4  in a randomised, placebo-controlled trial [100] 
and in an observational study [101]. In general, low levels of circulating thyroid 
hormone shift the haemostatic system to a hypocoagulable hyper-fibrinolytic state, 
with reduced Factors VIII, IX, and XI and von Willebrand factor (VWF) that are 
normalised on LT4 [102, 103]. The coagulopathy of overt hypothyroidism has been 
referred to as an acquired von Willebrand syndrome (aVWS), seen in about one- 
third of these patients, with low VWF and FIII, with mucocutaneous bleeding that 
responds to desmopressin [104–106]. The incidence of aVWS may approach 33% 
of those with overt hypothyroidism, may play a role of the menorrhagia observed 
in hypothyroidism, and may diminish the risk of venous thromboembolism (VTE) 
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[105, 106]. Subclinical hypothyroidism is paradoxically associated with a shift to a 
procoagulant state, with higher FVII, PAI-1, and tissue plasminogen activator (t-PA), 
which seem to normalise with 6 months of LT4 [107]. Thrombin-activatable fibrino-
lysis inhibitor (TAFI) levels are elevated, and global fibrinolytic capacity is lower, vs. 
control subjects in subclinical hypothyroidism [108, 109]. Correction of TSH levels 
to normal using LT4 replacement correct these abnormalities [102, 110, 111].
Excess thyroid hormone activity results in a procoagulant state, with increased 
VWF, FVIII, fibrinogen, and D-dimer in subclinical hyperthyroidism and elevations 
in fibrinogen, fibronectin, VWF, thrombomodulin, and PAI-1, with decreased t-PA in 
overt, endogenous hyperthyroidism [103, 112–115]. The enhanced risk of VTE (deep 
vein thrombosis or pulmonary embolism) has been expertly summarised recently 
[103]. This underlying prothrombotic state interacts with the additional risk of atrial 
fibrillation/flutter to elevate the risk of ischaemic stroke [116]. Underlying mecha-
nisms may include the presence of autoimmune disease, but unique observations from 
subjects with thyroid hormone resistance at the TRβ infer that the hyper-coagulation 
seen in thyrotoxicosis is a direct consequence of T3 action on levels of the coagulation 
factors described above [117]. Thyrotoxicosis induced by administration of LT4 to 
healthy volunteers and those with thyroid nodules also induces a procoagulant state, 
associated with increased levels of FVIII, FIX, FX, VWF, fibrinogen D-dimer, and 
PAI-1 with delayed fibrin clot lysis and a shortening of the APTT, but with an incon-
sistent impact on clot structure parameters potentially based on subtle mechanistic 
differences between endogenous and iatrogenic hyperthyroidism [118–121].
3.9  Effects in the Kidney
The hypothyroid state itself reduces renal function [122]. Administration of LT4 
has been observed to improve renal function, in one study improving odds of pro-
gression and lowering the incidence of end-stage kidney disease by limiting the 
rate of decline in glomerular filtration rate [123]. In another randomised, placebo-
controlled study, LT4 treatment reduced serum uric acid and excretion of albumin 
in a trial in patients with diabetic nephropathy and subclinical hypothyroidism, an 
effect consistent with a renoprotective effect [41].
3.10  Effects on the Heart and in Bone
Chapters, “Levothyroxine and the Heart” and “Levothyroxine and Bone” provide 
a description of the effects of LT4 in heart and bone, and only a brief summary is 
provided here in Table 1.
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Table 2 Summary of “strong” recommendations relating to the management of overt hypothyroidism 
from a guideline proposed by the American Thyroid Association
Main therapy Monotherapy with LT4 adjusted using TSH; thyroid extracts are not 
recommended.
Key goals of 
therapy
Normalise TSH (and improve other thyroid hormones), abolish symptoms 
(including lipid abnormalities), avoid over treatment (iatrogenic 
thyrotoxicosis).
Starting dose Consider factors including weight, age, comorbidity, aetiology of thyroid 




Consider a mental health professional if psychosocial, behavioural, or 
mental health symptoms do not respond adequately to LT4, or if these 
issues impair management.
Elderly patients Start with low dose, increase slowly (NB: ideal TSH may be higher in 
older patients).
Pregnancy Use trimester-specific TSH reference ranges to guide therapy.a
Infants Treat as soon as hypothyroidism is confirmed; aim to move TSH to the 
mid-to-lower half of the paediatric TSH reference range within 2–4 weeks.
Subgroups/
comorbidities
There is no evidence to support targeting low- or high-normal TSH for 




Maintain the FT4 in the upper half of the reference range (may be lower in 
older patients or those with comorbidities).
Well-being and 
quality of life
Use general instruments + hypothyroidism-specific tools to evaluate 
general well-being and quality of life during treatment.
Euthyroid subjects Do not use LT4 in biochemically euthyroid people with hypothyroid-like 




Withdraw thyroid hormones from patients with factitious thyrotoxicosis 
and refer for education and/or psychological support
LT4 + T3 therapy Insufficient clinical evidence to support a routine-use recommendationb
Nutraceuticals and 
supplements
Not supported in hypothyroidism management (pharmacological doses of 
iodine may exacerbate underlying thyroid pathology)
Hospitalised/not 
critically ill patients
Consider starting or adjusting oral LT4 (consider temporary use of i.v. LT4 
if necessary), based on normalisation of TSH; exclude adrenal 
insufficiency
Myxoedema coma Start with i.v. LT4 (+standard management for coma including 
glucocorticoids), with starting dose depending on age and comorbidities, 
and switch to oral LT4 when possible. Improved mental status and 




LT4 is not recommended for hospitalised patients with this condition.
Recommendations are abstracted from Ref. [125]. They have been paraphrased for brevity, and 
combined in some cases. Only strong recommendations relating to the use of LT4 are included 
here: see the full guideline for details
aSee chapter, “Levothyroxine in Pregnancy” for a description of hypothyroidism management in 
pregnancy. GI gastrointestinal, LT4 levothyroxine, TSH thyrotropin, thyroid-stimulating hormone
bEvidence for LT4 + T3 combination therapy is discussed later in this chapter
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4  Evidence-Based Guidelines for the Management 
of Hypothyroidism
4.1  Current Status of Evidence-Based Guidelines
The American Thyroid Association (ATA) has been publishing regular guidance on 
the management of thyroid disease since its recommendations on nomenclature for 
goitre in 1931 [124]. The most recent ATA guideline for the management of hypo-
thyroidism (2014) considered 64 questions relating to the care of these patients, 
grouped under 24 topics [125]. An overview of its strong recommendations with 
regard to the management of overt hypothyroidism in adults is given in Table 2. 
These guidelines emphasise the key role of monotherapy with LT4 (the use of thy-
roid extracts is not supported) in the management of hypothyroidism, due mainly 
to its proven efficacy and safety profile, long half-life and low cost. The level of 
thyrotropin is used to guide therapy in almost all circumstances, rather than other 
thyroid hormones, or symptoms of hypothyroidism. The therapeutic use of LT4 for 
other conditions, such as obesity, psychiatric conditions, and dyslipidaemia, is not 
supported and such uses remain an area for research (see above). A guideline from 
the UK National Institute for Health and Care Excellence (2019) provided similar 
recommendations [126].
The 2014 ATA guidance did not address the issue of managing subclinical hypo-
thyroidism. Additional information is now available from the TRUST study, a large, 
prospective, randomised, controlled trial of LT4 in a population likely to be enriched 
with people with subclinical hypothyroidism (TSH >4.6 mIU/L with normal FT4) 
[127]. A total of 737 patients aged >65 years were recruited and the primary out-
come parameter was QoL (Thyroid-Related Quality of Life Patient Reported 
Outcome [ThyPro] subscales for hypothyroid symptoms score and tiredness score). 
Neither thyroid symptoms nor tiredness scores were changed significantly in the 
LT4 or placebo groups by 12 months [127]. Reassuringly, there were no adverse 
effects of LT4. Although the quality of this trial warranted publication in a premier 
medical journal, the use of non-age-adjusted TSH at entry likely led to the inclusion 
of many functionally euthyroid subjects, rendering demonstration of a therapeutic 
effect of LT4 very unlikely. Although the TSH levels in those on LT4 were reduced 
impressively, one-quarter of subjects were asymptomatic. The mean baseline TSH 
in both groups was below the age expected 97.5th percentile (normal) of euthyroid, 
antibody negative individuals observed for the US population [128]. Additionally, 
the TSH levels of the placebo group had also normalised in an unknown but signifi-
cant portion with no intervention, further reducing the potential for demonstrating 
a therapeutic impact of LT4.
A recent (2018), high quality meta-analysis of 21 randomised, placebo- 
controlled trials of LT4 (N = 2192 subclinically hypothyroid adults) focussed on 
QoL and thyroid-related symptoms and confirmed a lack of improvement with 
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LT4 in these subjective endpoints [129]. A guideline from the European Thyroid 
Association (ETA) based on this meta-analysis recommended that a trial of LT4 
should be considered in younger (<65 years) subjects with symptoms reminiscent 
of hypothyroidism with TSH that is elevated, but <10 mIU/L [130]. LT4 can be 
withdrawn if symptoms have not resolved after normalisation of the thyrotropin 
level. Younger subjects with thyrotropin >10 mIU/L should receive LT4 whether 
or not they have symptoms [130]. Another international expert group concluded 
that few patients with subclinical hypothyroidism would be likely to benefit from 
treatment with LT4 [131].
Another meta-analysis and independent review provided guidance on the 
need for confirmation of the diagnosis of mild thyroid failure/subclinical hypo-
thyroidism in non-pregnant adults [132]. TSH and FT4 should be re-measured 
in 1–3  months when TSH is 4.5–14.9 mIU/L, and in 1–2  weeks when TSH is 
≥15 mIU/L. Confirmation of the elevated TSH is considered essential in establish-
ing the diagnosis of subclinical hypothyroidism although this is not a guarantee 
of persistent thyroid failure [127, 133]. Additionally, LT4 may be considered for 
reduced risk of progression to overt hypothyroidism and adverse cardiovascular 
outcomes for patients aged >65 years with TSH >7 mIU/L, and offered when TSH 
is persistently over 10 mIU/L. Recommendations for individuals aged <65 years are 
more liberal and recommend measurement of anti-TPO antibodies when the TSH 
is 4.5–6.9 mIU/L, with annual follow-up. LT4 treatment would be considered when 
multiple symptoms are present, TPO antibodies are positive, TSH is increasing, 
pregnancy is anticipated, or goitre is present. LT4 therapy is recommended in this 
age group when TSH is persistently >7.0 mIU/L [132].
4.2  Levothyroxine Monotherapy, or Levothyroxine Plus 
Triiodothyronine, for Hypothyroidism
Loss-of-function polymorphisms in deiodinases have been proposed to contribute 
to failure of thyrotropin-guided LT4 therapy to completely abolish symptoms of 
hypothyroidism in some patients, due to insufficient provision of T3 [134, 135]. 
This has stimulated interest (and use to this day) in LT4-levotriiodothyronine (lio-
thyronine, LT3) combination therapy, or thyroid extracts (which are not supported 
by any guidelines), in these patients [135, 136]. The results of trials comparing 
LT4–LT3 combinations with LT4 monotherapy, or meta-analyses of these trials, 
have been inconsistent, without demonstrating convincing or consistent benefit 
for combination therapy [135, 137, 138]. In addition, the short plasma half-life of 
LT3 (hours), compared with that of LT4 (days) does not support straightforward 
once- daily administration of these combinations. Accordingly, there is currently 




It has been suggested that more trials are needed, in patients with reduced sensi-
tivity to thyroid hormones [137]. Alternatively, differences in initial residual thyroid 
function between patients may have introduced variability into the results of these 
trials [139]. Although there is support in a European guideline for a trial of LT4-LT3 
therapy in individuals with persistent hypothyroid-like symptoms on LT4 after 
exclusion of other possible causes [140], further research will be needed before this 
approach becomes part of the routine care of hypothyroidism.
4.3  Barriers to Optimal Care of Patients with Hypothyroidism
4.3.1  The Impact of the Diagnosis Itself
Diagnostic labelling influences individual patient’s self-reported health results as 
illustrated in a recent report derived from the HUNT study which asked subjects to 
rate their perception of their health [141]. Data on thyroid function at entry were 
available to researchers only. Most (at least 75%) of the general population and 
subjects unaware of their thyroid dysfunction reported their health as good; how-
ever, only half of those aware of a diagnosis of thyroid dysfunction reported good 
health. Increasing age, lower education, smoking, low self-esteem, underweight, 
overweight, or obese and long-term illness/injury—but not thyroid function—pre-
dicted lower self-reported health.
4.3.2  Avoiding over Diagnosis
Who would typically be evaluated with thyroid function testing in a primary care 
practice and potentially labelled as hypothyroid? According to a study in the pri-
mary care setting, those referred for thyroid function tests have high rates of psy-
chological stress and low (no) correlation of typical thyroid symptoms and thyroid 
test results [142]. The authors expressed concern that a mild TSH elevation might 
result in reflexive LT4 initiation. This of course assumes that the symptoms are 
truly due to hypothyroidism and a search for alternative explanations ends. I would 
point out that failure of LT4 intervention to cure these likely non-thyroid symp-
toms would not only disappoint our now-labelled patient, but might also distract the 
treating physician from the potential of psychiatric morbidity and initiate a quest 
for alternative thyroid solutions rather than providing the patient with the help they 
really need.
Once confidence in a diagnosis of hypothyroidism is established, further attempts 
to satisfy subjects treated with LT4 who continue to report symptoms consistent 
with hypothyroidism has led to the practice of finely titrating the TSH into spe-
cific tertiles of the expected range with small LT4 dose adjustments. Two excellent 
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prospective controlled studies have used validated measures of health-related qual-
ity of life (HR-QoL) and cognition to demonstrate little or no benefit from this 
approach [143, 144]. Most importantly, patients were unable to correctly identify 
whether they had received the lower, medium, or higher dose, but associated the 
higher dose with a perception of greater efficacy [144].
5  Conclusions
Thyroid hormones are tightly integrated within the development, homeostasis, and 
repair of numerous tissues in the body, including the regulation of the HPT axis 
itself. Accordingly, hypothyroidism disturbs multiple functions within the body. 
Hormone replacement with LT4 can reverse many symptoms of hypothyroidism, 
including reduced energy expenditure, dyslipidaemia, and disturbances of diverse 
functions, including haemostasis and mood. Not all patients feel completely well 
on optimised LT4 therapy, however, often for various non-thyroid-related reasons. 
Variations in sensitivity to thyroid hormones, arising for example, in variations in 
genes for the deiodinases that convert LT4 to T3 within target tissues or in thy-
roid hormone transporters, may contribute to this phenomenon, and this remains a 
subject for future research. Monotherapy with LT4, optimised according to a nor-
malised serum TSH level, remains the preferred treatment for hypothyroidism rec-
ommended by current major guidelines in this area.
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Thyroid hormone homeostasis changes markedly during pregnancy, and first 
trimester- specific reference ranges for thyrotropin (thyroid-stimulating 
hormone, TSH) are needed to diagnose hypothyroidism. Treatment consists in 
levothyroxine (LT4) in this setting (triiodothyronine or desiccated thyroid 
preparations have no role here). Severe hypothyroidism is associated with 
infertility, and levels of TSH above 4.0  IU/mL signal an increased risk of 
adverse pregnancy outcomes. All pregnant women (and women planning a 
pregnancy) with overt hypothyroidism must be managed effectively with oral 
LT4. Thyroid autoimmunity increases the risk of adverse pregnancy outcomes 
and is associated with certain causes of infertility. Current European and US 
guidelines recommend a role for patients with subclinical hypothyroidism and 
thyroid autoimmunity, not least to guard against progression to overt 
hypothyroidism during the pregnancy. Women with hypothyroidism 
undergoing assisted reproduction technology to become pregnant appear to be 
strong candidates for LT4-based therapy.
1  Introduction
About 1% of pregnant women have overt hypothyroidism (OH) and about 10% 
have subclinical hypothyroidism (SCH) during pregnancy [1]. This chapter will 
address the issue of hypothyroidism in women who are pregnant, planning a 
pregnancy (with or without assisted reproductive technology [ART]), or who 
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are in the immediate postpartum period. Topics to be discussed will include the 
impact of pregnancy on the management of hypothyroidism, the effects of hypo-
thyroidism and its management with levothyroxine (LT4) on maternal and neo-
natal outcomes, and the current status of guidelines for the management of these 
patients.
2  Changes in Thyroid Function During Pregnancy
A number of changes take place due to the presence of the placenta and the foe-
tus [2, 3]. During the first trimester of pregnancy, the foetus is dependent on thy-
roid hormones of the mother, and at the same time, placental deiodinase type 3 
protects it against an excess, by degrading them. Other changes necessitating an 
increased production of thyroid hormones in the mother are the increased urinary 
iodine clearance, and thyroxine-binding globulin (TBG) levels due to the higher 
oestradiol concentrations. This latter phenomenon takes place earlier and is more 
accentuated if an ovarian hyperstimulation (OS) takes place for a pregnancy con-
ceived using ART. On the other hand, increasing human chorionic gonadotrophin 
stimulates maternal thyroid to augment thyroid hormone production. Therefore, the 
thyrotropin level decreases during the first trimester, which partially reverses as the 
pregnancy progresses [2, 3].
All these changes can lead to the development of (subclinical) hypothyroidism 
during pregnancy especially where women have severe iodine deficiency, thyroid 
autoimmunity (TAI), or do not take enough LT4 after thyroid surgery.
Pregnancy markedly increases the dose of LT4 required to control TSH, with 
changes in LT4 requirement varying according to the aetiology of the hypothy-
roid state and thyroid status before pregnancy [2–5]. For example, longitudinal 
studies in pregnant women with hypothyroidism showed that the dose of LT4 
needed to control TSH adequately (<2.5 mIU/L) increased by about half dur-
ing the first trimester and remained relatively stable for the remainder of the 
pregnancy [6, 7]. This is not a universal finding during pregnancy, however, 
and a minority of patients in the larger of these studies required no increase in 
the LT4 dose, and a few even required a dose decrease [6]. Another study, in 19 
women, showed that the LT4 dose increased by 47% in the first trimester, and 
then remained at this level throughout the pregnancy. Current guidelines (see 
below) recommend an immediate increase in the dose of LT4 when pregnancy 
is discovered. Postpartum, thyroid function, and LT4 requirements return to pre-
pregnancy levels for most patients though some continue to require a higher dose 
than that received before the pregnancy [6, 8]. In women pregnant after ART, the 
increase in the LT4 dose is higher and takes place earlier in pregnancy [8]. The 
presence of TAI is the sole condition that predicts the fact that LT4 will have 




3  Maternal and Foetal Outcomes in Women 
with Hypothyroidism
3.1  Effects of Hypothyroidism on Fertility 
and Preterm Delivery
Severe overt hypothyroidism decreases fertility through its actions on the produc-
tion of sex hormone-binding globulin (decreased) and prolactin (increased), and 
via a direct impact on the ovaries [10]. In a meta-analysis of 19 cohort studies 
(involving a total of 47,045 pregnancies), SCH was associated with an increased 
risk of preterm delivery, with an odds ratio (OR) 1.04 (95%CI, 1.00–1.09) for each 
increase in TSH of one standard deviation [11]. The presence of antibodies to thy-
roid peroxidase also increased the risk of preterm delivery in this study (OR 1.33; 
95%CI, 1.15–1.56). In women with iodine deficiency (urinary iodine <100 μg/L) 
TSH ≥4.0 mIU/L was associated with a 2.5-fold (p = 0.024) increased risk of pre-
term delivery, compared with lower TSH levels, in the population-based Tehran 
Thyroid and Pregnancy Study [12]. In another study, inadequately controlled hypo-
thyroidism was associated with an increased risk of miscarriage, especially where 
TSH level exceeded 4.5 mIU/L [13].
3.2  LT4 Treatment and Pregnancy Outcomes: Importance 
of Thyroid Autoimmunity
A placebo- (or no treatment-) controlled evaluation of LT4 in pregnant women with 
overt hypothyroidism would be unethical, given the known association of mark-
edly elevated TSH with miscarriage [14]. Overt hypothyroidism should always be 
treated with LT4 during pregnancy, as in other settings [14].
Most evidence relating to the effects of LT4 on pregnancy outcomes has come 
from clinical studies in women with SCH. A randomised trial in 64 infertile women 
with SCH undergoing in vitro fertilisation (IVF) and intracellular sperm injection 
(ICSI) found a higher embryo implantation rate and live birth rate, associated with 
a lower miscarriage rate, in subjects randomised to LT4 vs. no LT4 [15]. The study 
population was not selected for the presence of TAI per se though higher anti-TPO 
and anti-Tg levels predicted a higher risk of miscarriage in the control group. The 
potential influence of TAI on pregnancy outcomes in LT4-treated women undergo-
ing ICSI is discussed in more detail later in this chapter.
A meta-analysis of 13 randomised and observational studies included more than 
11,000 women with SCH [16]. Treatment vs. no treatment with LT4 in this analysis 
affected different pregnancy outcomes in different ways, with fewer lost pregnan-
cies (OR 0.78; 95% CI 0.66–0.94) and more live birth rates (OR 2.72; 95% CI 
1.44–5.11), but a higher chance of premature labour (OR 1.82; 95% CI 1.14–2.91). 
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Increasing the dose of LT4 for women with TSH >2.5 mIU/L in the first trimester 
was also associated with a ~15-fold reduction in the frequency of preterm birth, 
compared with pregnant women whose LT4 dose remained stable, according to 
a retrospective analysis [17]. However, there appeared to be no upper limit for 
TSH in this study, and the median TSH level before the LT4 dose increase was 
5.0 mIU/L.
The appearance of TAI is also strongly associated with certain causes of infer-
tility, in particular polycystic ovary syndrome and idiopathic infertility [10]. 
Numerous studies have addressed the impact of TAI on pregnancy outcomes, 
following the initial finding of a two-fold increase in the risk of miscarriage 
associated with anti- TPO- Ab and/or anti-Tg-Ab three decades ago [18]. Meta-
analyses have confirmed these initial findings consistently, with odds for mis-
carriage ratios of 2.31 (cohort studies in women with vs. without TAI) [19], 
2.55 (case-control studies from the same meta-analysis) [19], 2.8 (women with 
vs. without SCH or TPO-Ab who had undergone ART [20], 3.9 (cohort studies 
of euthyroid women with vs. without TAI) [21], 1.8 (case-control studies from 
the same meta-analysis), 21 and 1.44 (women with vs. without TAI undergoing 
ART) [22]. Furthermore, a recent (retrospective) analysis demonstrated a 17-fold 
increase in the requirement for neonatal intensive care treatment associated with 
TAI [23].
Two recent meta-analyses in both spontaneous and assisted pregnancies have 
appeared recently, from the same group published one year apart (2018–2019), 
finding that treatment with LT4 was associated with less pregnancy loss and fewer 
preterm births in women with SCH and TAI [24, 25]. A further meta-analysis (14 
randomised or observational trials) focussed on women with SCH and/or TAI and 
found that LT4 vs. placebo or no treatment was associated with reduced risk of a 
range of adverse outcomes (higher fertilisation and delivery rates, lower rates of 
miscarriages, gestational diabetes, and gestational hypertension, preterm deliveries, 
and low birth weights) [26].
A prospective study compared the effects of LT4 vs. no treatment on pregnancy 
outcomes in 131 patients with SCH (TSH could be as high as 10 mIU/L) and 
TPO-Ab [27]. LT4 treatment was associated with fewer preterm deliveries vs. no 
treatment or a euthyroid, TPO-Ab–control group. Finally, a report from the Tehran 
Thyroid and Pregnancy Study described randomisation of 366 pregnant women 
with SCH (TSH cut-off 2.5 mIU/L), but no TPO-Ab, to LT4 or no treatment [28]. 
LT4 did not affect the risk of adverse pregnancy outcomes. Interestingly, there was a 
significant reduction for LT4 vs. no treatment for preterm delivery for patients with 
TSH >4.0 IU/L.
Accordingly, the results of clinical studies in women with SCH have been 
conflicting, with regard to the effects of LT4 on pregnancy outcomes. This might 
be due to the use of TSH >2.5 mIU/L as cut-off to define SCH during the period 
2005–2016. Most studies defining SCH as a TSH >4.0 mIU/L or above the upper 




3.3  LT4 Treatment of Euthyroid Women 
with Thyroid Autoimmunity
Two randomised trials have been conducted in euthyroid women with TAI.  The 
Thyroid Antibodies and Levothyroxine study (TABLET) randomised 952 women 
with TPO-Ab and a history of miscarriage or infertility to treatment with LT4 50 μg 
or placebo from before conception to the end of the pregnancy. There were no dif-
ferences between groups in the live birth rate (primary outcome) or the number of 
miscarriages [29]. In an earlier (2006), smaller, randomised trial in women with 
TPO-Ab not selected for the presence of thyroid dysfunction, treatment with LT4 
was associated with a lower miscarriage rate, compared with no LT4 treatment [30].
Other evidence in this area is from meta-analyses and observational studies. One 
meta-analyses demonstrated no marked effect of LT4 supplementation on pregnancy 
outcomes in euthyroid women with TAI [31]. Administration of LT4 of women with 
loss of at least two prior pregnancies and TSH 2.5–4.0 mIU/L did not influence the 
success of a subsequent pregnancy significantly, and TPO antibody status did not 
modify this finding, in an observational study [32]. On the contrary, in a recent large 
cohort of women with unexplained recurrent pregnancy loss, TPO-Ab positivity 
was predictive of a reduced live birth rate, and furthermore, LT4 improved odds of 
live birth [33]. More randomised controlled trials are needed to resolve this issue.
An additional case-control study found no dose-related effect of LT4 treatment 
on pregnancy outcomes, compared with an untreated control group, in euthyroid 
women without TAI, despite significant changes in placental function markers [34]. 
These data support the current recommendation that euthyroid women without 
TAI, including those with high-normal TSH levels, may not require intervention 
with LT4 treatment (see below). A single-centre, cross-sectional analysis of 1321 
women without thyroid disease showed that variation of the TSH level within nor-
mal range for non-pregnant women did not increase the risk of adverse pregnancy 
outcomes, including gestational diabetes, pre-eclampsia, postpartum haemorrhage, 
intra- uterine growth retardation, or low birth weight [35].
3.4  Thyroid Autoimmunity and Pregnancy Outcomes 
in Women Receiving Assisted Reproduction 
Technologies (ART)
Thyroid autoimmunity is common among women seeking treatment for infertility: 
one study of detected thyroid autoantibodies in 16% of an unselected cohort women 
attending specialist care for this reason [36]. The majority (12%) had anti-TPO-
Ab ± anti-thyroglobulin antibodies (anti-Tg-Ab), and 5% had only anti-Tg-Ab. 
However, most studies in this area have been based on detection of anti-TPO-Ab, 
which is more often measured routinely [14].
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Observations of increased miscarriage rates associated with TAI (see above) 
have prompted evaluations of LT4 in euthyroid women with anti-thyroid antibodies 
receiving ART. Another study found that randomisation of such a population to LT4 
(25 μg [TSH <2.5 mIU/L] or 50 μg [TSH ≥2.5 mIU/L]) vs. placebo had no signifi-
cant effect on miscarriage rates (primary outcome) or on clinical pregnancy rates or 
live birth rates (secondary outcomes) [37]. An accompanying editorial welcomed 
the study, but noted its relatively low miscarriage rate, compared with other, similar 
populations, and the relatively low proportion of pregnancies achieved using ICSI 
about half [38]. Moreover, previous neutral evaluations of LT4 in similar popula-
tions were underpowered and/or non-randomised [30, 39].
A recent meta-analysis of 765 pregnancies achieved using ICSI showed that the 
rate of miscarriage in these women was unaffected by TAI [40]. This is an opposite 
result compared with previous meta-analyses on the impact of TAI on pregnancy 
outcomes, as described above. More studies are needed to find out whether this is 
due to the use of ICSI or because studies were included that used a cut-off for TSH 
of 3.0 mIU/L (or lower) to define SCH. An argument in favour of the latter hypoth-
esis is a meta-analysis from Velkeniers et  al. (published in 2013), in which LT4 
treatment vs. no additional treatment decreased the miscarriage rate and increased 
the live birth rate in women with SCH (defined by TSH levels >4.0 mIU/L) achiev-
ing pregnancy through ART (Fig. 1) [20]. However, no beneficial impact of LT4 was 
noted in women with TAI undergoing ART in a more recent meta-analysis in which 
SCH was defined in the majority of included studies by TSH <4.0 mIU/L [24].
ICSI and LT4 may work together to improve outcomes especially when ICSI is 
used to assist conception: ICSI may bypass inhibitory effects of thyroid antibodies 
in the follicular fluid that surrounds the ovum, while LT4 preserves a more normal 
hypothalamic-pituitary-thyroid axis after implantation [38].
A cross-sectional study in 279 women undergoing ART found that either TSH 
above vs. below 2.5 mIU/L in women without TAI, or the presence vs. absence of 
TPO-Ab, did not affect the quality of oocytes retrieved, the fertilisation rate or the 










Fig. 1 Effects of LT4 on pregnancy outcomes from a meta-analysis of studies in women with 
subclinical hypothyroidism undergoing assisted reproduction. Risk ratios >1 signify higher likeli-
hood of event in the levothyroxine vs. control group; p values are for overall effect. (Drawn from 
data presented in Ref. [24])
K. G. Poppe
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quality of the subsequent embryos [41]. Further studies are needed, to investigate 
whether LT4 could improve the ovarian reserve or in vitro outcomes of an ART 
procedure.
3.5  Effects on Offspring
Cognitive outcomes in children born to mothers with hypothyroidism is also an 
active area of research. Low T4 levels in mothers have been associated signifi-
cantly with delayed cognitive development in their children in some [42, 43] but not 
all [44] studies. A meta-analysis, of three randomised trials conducted in women 
diagnosed with SCH during pregnancy, found no effect of LT4 treatment on chil-
dren’s neuropsychological outcomes [45]. Treatment of hypothyroid mothers in the 
second trimester did not improve neurocognitive outcomes in the offspring [46]. 
A follow-up study to the Tehran Thyroid and Pregnancy Study will evaluate the 
neurocognitive development of 3-year old children born to mothers with mild hypo-
thyroidism (without TAI) [47].
4  Summary of Current Major Guidelines
4.1  Guidelines Considered Here
Guidelines from Europe (on subclinical hypothyroidism) [48] and the USA (a broad 
guideline considering most aspects of hypothyroidism [14]) will be considered here, 
as examples of major guidelines with international reach. Many other guidelines are 
available for other regions: it is beyond the scope of this chapter to review them all, 
and chapter, “Practical Application of Levothyroxine-Based Therapy” of this book 
lists a number of them.
4.2  Overt Hypothyroidism During Pregnancy and Postpartum
The American Thyroid Association (ATA) published a major guideline on the man-
agement of thyroid disease in 2017 [14]. This comprehensive guidance covered all 
aspects of thyroid dysfunction and stated 109 clinical questions that were answered 
by 111 recommendations. Table 1 provides an overview of these recommendations, 
grouped under convenient subheadings, and a brief description of the main points 
with regard to LT4 therapy follows.
Briefly, diagnosis of maternal hypothyroidism should be conducted using 
trimester- specific reference ranges for TSH, ideally specific to a particular assay 
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used, and defined in local, healthy, euthyroid, pregnant women without TPO-Abs. 
Depending on these factors, serum TSH values defining SCH during the first tri-
mester will be >3.5–4.5 mIU/L. Measurement of TSH is recommended regularly for 
women at risk of thyroid disease (e.g. due to TAI or SCH). General screening for 
elevated TSH is not supported for women at low risk for thyroid disease, with the 
exception of women undergoing ART.
Table 1 Overview of principal recommendations from the American Thyroid Association 
regarding the management of hypothyroidism during pregnancy
Measure TSH •  In women under care for infertility
•  At start of pregnancy, and every 4 weeks through mid-pregnancy and at least 
once near 30 weeks gestation in women with thyroid Abs
•  Measure TSH 2 weeks after controlled ovarian stimulation during ART, as 
this renders test results difficult to interpret (repeat at 2–4 weeks if TSH is 
high)
•  No support for universal screening for abnormal TSH in women without risk 
factors for thyroid disease (except for those planning ART)
Diagnosis •  Maternal hypothyroidism = TSH > upper limit of trimester-specific 
reference range
•  Use assay-specific reference ranges (if possible locally derived from healthy, 
I-replete, TPO-Ab—pregnant women without thyroid illness)
•  Use an upper reference limit of ~4 mIU/L where such reference ranges are 
not available




•  Use median urinary iodine concentrations, not spot or 24 h measurements to 
determine iodine status in an individual
•  Pregnant women need ~250 μg iodine/day, usually via a potassium iodide 
supplement (an annual dose of iodised oil is a temporary solution for some 
I-depleted low-resource areas)
•  No need for iodine supplementation if a woman is taking LT4
•  Avoid excessive iodine exposure during pregnancy (except pre-surgery for 
Graves’ disease) due to concerns about causing hypothyroidism in the foetus
•  Breastfeeding women should take iodine supplementation (similar to above; 
all breastfeeding women should ingest a ~250 μg iodine/day)
Use of LT4 
during 
pregnancy
•  Counsel hypothyroid women of an increased requirement for LT4 during 
pregnancy: if pregnancy occurs, they should increase their LT4 dose by 
about 20–30% and contact/see their physician promptly
•  Use oral LT4 for all women with overt hypothyroidism who are planning 
pregnancy, or during pregnancy; aim for lower half of trimester-specific 
reference range for TSH (or TSH <2.5 mIU/L)
•  There is insufficient evidence for routine use of LT4 for women with 
subclinical hypothyroidism without thyroid autoimmunity who are trying to 
become pregnant—but, LT4 may be considered as it may prevent 
progression to overt hypothyroidism
•  Do not use LT4 + T3 or desiccated thyroid preparations
•  Consider LT4 for TPO-Ab + women with prior recurrent idiopathic 
pregnancy loss
•  Do not routinely treat isolated hypothyroxinaemia (low FT4 with normal 
TSH)




Oral LT4 is the mainstay of treatment of overt hypothyroidism during or lead-
ing up to a pregnancy, as for other populations with hypothyroidism. The guideline 
strongly recommends against the use of LT4 + LT3 combinations, or the use of des-
iccated thyroid preparations for treatment, a practice, which continues in spite of a 
lack of evidence of benefit, an evidence for harm, during pregnancy [49]. In general, 
targeting the lower half of the TSH reference range is supported for women with 
hypothyroidism who are, or who are planning to become pregnant. Women should 
be educated on the likelihood of a steep rise in LT4 requirement during pregnancy 
and should be ready to increase their LT4 dose on discovering a pregnancy before 
seeking prompt advice from their healthcare team. In daily practice, this could be 
implemented by adding two LT4 tablets a week at confirmation of the pregnancy 
[50]. LT4 requirements decrease postpartum, sometimes to zero, especially where 
the maintenance dose during pregnancy was low (<50 μg).
LT4 treatment may be considered also for the management of the hypothyroid 
phase of postpartum thyroiditis (PPT), which classically follows a transient hyper-
thyroid phase and occurs from 3 to 12  months postpartum. Indications to treat 
are women with symptomatic hypothyroidism and/or TSH values >10 mIU/L. In 
10–20% of the cases, the hypothyroidism can be permanent, depending on pre- 
existing thyroid dysfunction (elevation of TSH and TPO-Ab levels). In most 
women, the duration of LT4 therapy, once initiated, is uncertain. It is reasonable to 
start weaning patients off treatment after 6–12 months of treatment, in the absence 
of a new pregnancy or decision to breastfeed [14].
It is important to note that LT4 treatment does not prevent PPT. Finally, oral LT4 
may be considered for hypothyroid women who lack milk production, once other 
possible causes have been excluded. Breastfeeding per se is not a contraindication 
to LT4 treatment.
The ATA guidance considered that there was insufficient evidence to support the 
use of LT4 with the intention of preventing pregnancy loss, for euthyroid women 
with TAI, a position that is likely to be strengthened by the recent results of the 
TABLET study, described above. However, a weak recommendation supports the 
administration of a low dose of LT4 (typically starting at 25–50 μg) to women with 
TAI undergoing ART, given the possibility of benefit vs. minimal risk. One more 
Table 1 (continued)
Postpartum •  Reduce LT4 dose to the preconception level after delivery, check TSH ~6 w 
postpartum (some women do not need LT4 postpartum, especially where the 
dose was <50 μg)
•  Check thyroid status for otherwise unexplained lack of milk production
•  Treat hypothyroidism irrespective of severity in women seeking to 
breastfeed
•  TSH measurement to follow course of postpartum thyroiditis (PPT; 
including annually in women with prior PPT) and consider LT4 for the 
hypothyroid phase (discontinue LT4 by ~12 months in the absence of new 
pregnancy)
•  Do not use LT4 to prevent PPT in euthyroid, Ab+ pregnant women
Selected recommendations relating to the management of overt hypothyroidism are summarised 
here; these have been paraphrased, and in some cases aggregated, for brevity: see the full guide-
line. “Weak” recommendations are shown in italics; others are “Strong”. Compiled from informa-
tion presented in Ref. [14]
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indication (not as yet in the ATA guidance) could be women with recurrent idio-
pathic miscarriage and TAI (see above) [33].
A guideline on the management of SCH from the European Thyroid Association 
(ETA), published in 2014 [48], contains some recommendations on the manage-
ment of overt hypothyroidism. These are in general compatible with the ATA guide-
line. In particular, this guideline agreed with the later ATA guidance on:
• The use of LT4, rather than combination therapy or desiccated thyroid products.
• The principle of managing TSH to the lower half of its trimester-specific refer-
ence range.
• The return to the preconception dose of LT4 postpartum.
The ETA guideline differs from the ATA guideline in providing low-strength 
support for the use of LT4 for managing isolated hypothyroxinaemia in the first 
trimester, on the basis of an association of this condition with neuropsychological 
impairment on the neonate.
Other guidance summarised in Table 1 concerns the maintenance of adequate 
iodine intake. This is included for completeness and will not be discussed further 
here. Similar recommendations are provided in the ETA guideline for SCH (see the 
full guideline for details) [48].
4.3  Subclinical Hypothyroidism During Pregnancy 
and Postpartum
The principal sources of guidance for the management of SCH are from the 2014 
guideline from the ETA [48] and the 2017 ATA guideline, described above for the 
management of overt hypothyroidism [14].
The ETA guideline notes the likely association between SCH and a range of 
adverse pregnancy outcomes (pregnancy loss, gestational diabetes, gestational 
hypertension, pre-eclampsia, and preterm delivery), while acknowledging the con-
flicting results of some of these studies (see above). Accordingly, the ETA guideline 
supports treating women diagnosed with SCH before and during pregnancy with 
oral LT4 (Table 2). Both the ETA and ATA guidelines provide stronger recommen-
dations on the use of oral LT4 treatment for women who are TPO-Ab+ (Table 2). 
The ATA guideline further supports LT4 treatment of women with SCH who are 
receiving ART or are breastfeeding (Table 2).
No recommendation was provided on screening for SCH was made by the ETA, 
due to a lack of evidence, consistent with the views of the ATA, discussed above. 
The authorship was split on this issue, however, with some authors noting that such 
an approach would avoid the danger of pregnancies being exposed to undiagnosed 
overt hypothyroidism. This uncertainty has been reflected in clinical practice, where 
survey evidence identified marked differences within Europe with respect to screen-
ing for hypothyroidism in pregnancy [51]. The ATA guideline noted that prevention 





Overt hypothyroidism must be managed effectively with oral LT4 during pregnancy, 
with increases in the dose made to match the changing requirements for LT4 as the 
pregnancy progresses. The management of subclinical hypothyroidism remains a 
matter for debate and further research. Clear and consistent evidence for improved 
pregnancy outcomes with LT4 in thyroid Ab-negative women is scarce. The pres-
ence of thyroid autoimmunity increases the risk of adverse pregnancy outcomes and 
is strongly associated with some causes of infertility. LT4 therapy may have a role 
in these patients especially those undergoing a hyperstimulation protocol as part of 
ART. Emerging evidence suggests that ICSI may be a particularly suitable mode of 
ART for women receiving LT4 for autoimmune hypothyroidism.
Table 2 Comparison of European and US guideline recommendations on the use of LT4 to 
manage subclinical hypothyroidism in pregnant women, or women planning a pregnancy
Patients ETA recommendations (2014) ATA recommendations (2017)
TPO-Ab+
Recommends use of oral LT4 to 
maintain TSH <2.5 mIU/L in women 
planning pregnancy, especially those 
who are TPO-Ab+ (level 2 
recommendation)
Recommends use of oral LT4 for 
women with newly diagnosed 
subclinical hypothyroidism to control 
TSH to within its trimester-specific 
reference range (no recommendation 
level provided)
Recommends use of oral LT4 where 
TSH is above the trimester-specific 
reference range (strong 
recommendation)
Consider use of oral LT4 where TSH 
is between 2.5 mIU/L and the top of 
the trimester-specific reference range 
(weak recommendation)
TPO-Ab−
Recommends use of oral LT4 to 
maintain TSH <2.5 mIU/L for 
women with subclinical 
hypothyroidism (level 2 
recommendation)
Stop LT4 after pregnancy if TSH <5 
mIU/L (level 2 recommendation)
Recommends use of oral LT4 where 
TSH is >10 mIU/L (strong 
recommendation)
Consider use of oral LT4 where TSH 
is between 2.5 and the 10 mIU/L 
(weak recommendation)
Do not use LT4 where TSH is within 





Recommends use of oral LT4 to 
reduce TSH to below 2.5 mIU/L in 
women with SCH undergoing in vitro 
fertilisation or intracytoplasmic sperm 
injection (strong recommendation)
Breastfeeding –
Treat subclinical hypothyroidism in 
women wishing to breastfeed 
postpartum (weak recommendation)
Recommendations are abbreviated and paraphrased for clarity: see the full guidelines. SCH sub-
clinical hypothyroidism, TSH thyrotropin, TPO-Ab anti-thyroid peroxidise antibody. Compiled 
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Thyroid hormones are essential for the development of the central nervous 
system early in life. Congenital hypothyroidism once caused the devastating 
cognitive and physical deficits of cretinism, but this condition is now detected 
routinely at birth using population- wide neonatal screening in most countries. 
Early and continuous treatment of these children with levothyroxine 
(LT4), according to age-specific reference ranges, ensures near-normal 
neuropsychological development, with preserved IQ, although the possibility of 
subtle residual effects on some indices of neuropsychological functioning remain 
an active area of research. Children who develop overt hypothyroidism also 
require treatment with LT4. Most children diagnosed with subclinical 
hypothyroidism are unlikely to require intervention with LT4, as this condition 
reverses spontaneously over time. These children should be monitored for 
possible deterioration of thyroid function in future, especially where thyroid 
autoimmunity is present.
1  Introduction
This chapter considers the aetiology, clinical course, and management of hypothy-
roidism in children. Thyroid hormones are essential for normal physical and neural 
development in neonates, and many countries include a measurement of thyrotropin 
(thyroid-stimulating hormone; TSH) in their neonatal screening programmes.
The genetic control of thyroid hormone levels appears to function similarly in chil-
dren and adults [1]. Levels of thyroid hormones differ markedly with age, however. 
The average level of thyrotropin is high, and highly variable, compared with usual 
adult measurements [2, 3]. One study showed that the average thyrotropin (thyroid-
stimulating hormone, TSH) level was 6.4 mIU/L at birth, declining to 5.5, 6.6, 3.8, 
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2.9, and 2.1 mIU/L at 1, 2, 3, 4, and 7 days after birth, respectively [2]. Fig. 1 shows 
average levels of thyroid hormones from 1 month to 18 years of age [3].
Determination of reference ranges for thyroid hormones in other populations of 
children have confirmed the different evolution of levels of these hormones in chil-
dren, compared with adults [4, 5]. These data emphasise the importance of using age-
appropriate reference ranges for the diagnosis of thyroid dysfunction [5]. In general, 
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Fig. 1 Median values of (a) thyrotropin (TSH) and (b, c) free and total thyroxine (T4) calculated 
for children of different ages. Data were not presented between day of birth and 1 week of age for 
measurement of free or total T4, and for 18 years for measurement of total T4. (Drawn from data 
presented in Ref. [2])
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2  Overview of Hypothyroidism in Children
2.1  Congenital Hypothyroidism
The recognition of the causative role of severe, untreated hypothyroidism in the 
disastrous neurodevelopmental damage associated with cretinism was an impor-
tant milestone in the historical development of the field of thyroidology (see chap-
ter, “Therapeutic Use of Levothyroxine: A Historical Perspective” of this book). 
However, hypothyroidism may be transient in newborns identified via neonatal 
screening, especially when the initial TSH level is mildly elevated at diagnosis, or 
when relatively low LT4 doses are required for the first 2 years of life [6]. Children 
with congenital hypothyroidism appear to be at increased genetic risk of other 
adverse outcomes, including other congenital defects [7], non-alcoholic fatty liver 
disease [8], or urinary tract disorders [9], compared with the general population.
The optimal TSH cut-off level to diagnose congenital hypothyroidism is still 
a matter of debate. A study from the USA showed that TSH levels only slightly 
outside the reference range (e.g. ~5 mIU/L) were a poor predictor of future thyroid 
dysfunction, and such children need not be referred for specialist care and possible 
treatment [10]. However, another research group calculated that a TSH cut-off value 
of 6 mIU/L was optimal for identifying congenital hypothyroidism (transient or 
permanent) that may have required treatment [11].
2.2  Subclinical Hypothyroidism
2.2.1  Prevalence and Clinical Course
The prevalence of subclinical hypothyroidism in paediatric subjects is reported as 
being <2%, generally lower than the prevalence of this condition in adults [12, 13]. 
A large database analysis, conducted using records of more than 1 million paediat-
ric outpatients, found that TSH was 5.5–10 mIU/L in 2.9%, and >10 mIU/L in 0.4% 
[14]. A recent study of more than 3 million children in Italy using administrative 
health databases for the years 2001–2014 found an annual prevalence of subclinical 
hypothyroidism (based on receipt of a low dose of LT4) of 1 case per 5000 chil-
dren [15]. The annual prevalence remained relatively stable over time and tended to 
increase at age >10 years.
Many children with subclinical hypothyroidism revert to normal thyroid func-
tion or, at least, do not deteriorate to overt hypothyroidism [14, 16]. The analysis 
of >1 million children revealed that TSH reverted to within the normal range in 
76% of children with initial 5.5–10 mIU/L, and in 40% of those with initial TSH 
>10 mIU/L [14]. The presence of thyroid autoimmunity, or higher levels of TSH at 
baseline, predicts a more severe clinical course, however [16–20]. In one study, the 
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presence of Hashimoto’s thyroiditis with high titres of anti-thyroglobulin antibodies 
was associated with a 28-fold higher risk of needing LT4 treatment vs. Hashimoto’s 
thyroiditis patients without the presence of these antibodies [17]. Elsewhere, 63% of 
a population of girls with Hashimoto’s thyroiditis and subclinical hypothyroidism 
required LT4 treatment during 5 years of follow-up, compared with 24% of girls 
without autoimmunity; the proportions with overt hypothyroidism at 5 years were 
31% (with thyroid autoimmunity) and 12% (without thyroid autoimmunity) [21]. 
Children with Hashimoto’s thyroiditis may still recover normal thyroid function, 
as shown by a study which involved withdrawal of LT4 therapy from 148 children 
or adolescents with this condition. One third of the population did not need re-
initiation of LT4 after 2 years off-treatment [22].
2.2.2  Outcomes in Children with Subclinical Hypothyroidism
Subclinical hypothyroidism is associated with obesity in paediatric subjects [23, 
24]. A retrospective study identified subclinical hypothyroidism (normal FT4, TSH 
5–10 mIU/L) in 36% of a population of 215 obese children and adolescents [25]. 
Subjects with vs. without subclinical hypothyroidism were more insulin resistant 
and showed signs of atherogenic dyslipidaemia (low HDL-C, high triglycerides), 
but BMI was similar. Waist, BMI, LDL-C, serum triglycerides, and a measure of 
insulin resistance were higher, and HDL-C was lower, in 27 children (mean age 11 
years) with subclinical hypothyroidism, compared with a control group [26]. Other 
studies have associated subclinical hypothyroidism with high blood pressure and/
or other components of the metabolic syndrome in children or adolescents [23, 24, 
27–29]. The TSH level correlates with insulin resistance or triglycerides in euthy-
roid children, also [30].
A study in 32 children with autoimmune thyroiditis and subclinical hypothyroid-
ism (mean age 14 years) revealed increased atherogenic index, a greater thickness 
of epicardial fat (an emerging risk factor for metabolic dysfunction), and reduced 
endothelial vascular function, compared with 32 healthy matched control children 
[31]. A further study in 64 children also associated subclinical hypothyroidism with 
dyslipidaemia and increased cIMT vs. controls, although upper diagnostic limit for 
TSH was 20 mIU/L, and may have included children with overt hypothyroidism 
[32]. However, another observational study, in 110 obese children, found no cor-
relation between TSH level and dyslipidaemia or carotid intima-media thickness, a 
measure of the overall burden of atherosclerosis [33].
Relatively mild neuropsychological deficits have been observed in children with 
subclinical hypothyroidism, relating mainly to indices of attention [12, 34, 35], or 
verbal memory/verbal recall [36]. Measures of intelligence of cognition were gener-
ally unaffected in these studies.
Finally, no impairment of growth or bone maturation was observed in a popula-
tion of 36 children with persistent, untreated subclinical hypothyroidism followed 
for an average of 3.3 years [37].
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2.3  Other Causes of Hypothyroidism in Children
Several other factors can produce a hypothyroid-like state in children, including 
consumptive hypothyroidism due to infantile hepatic hemangioma [38], older anti-
epileptic drugs [39], chronic liver disease [40], or gastrointestinal disorders [41]. 
Other autoimmune diseases, such as type 1 diabetes or celiac disease tend to clus-
ter with hypothyroidism in children [42–44]. Hyperprolactinaemia is also strongly 
associated with thyroid status: a cross-sectional study of 602 children found this 
disorder on 32% of children with subclinical hypothyroidism and 52% of children 
with overt hypothyroidism [45]. Finally, the prevalence of hypothyroidism may be 
higher in children with Down syndrome or Turner Syndrome, compared with the 
general population [46–51].
Hypothyroidism can also follow partial thyroid resection. A retrospective review 
of 14 aged <18 years children who had undergone hemithyroidectomy for benign 
thyroid nodules showed that only one patient in six needed LT4 replacement [52]. 
The authors suggested that these patients should be followed for sufficient time to 
allow natural recovery of thyroid function, before administration of LT4.
3  Effects of Levothyroxine in Children with Hypothyroidism
3.1  Congenital or Overt Hypothyroidism
Children with any form of overt hypothyroidism must be treated promptly with 
LT4 [53]. Treatment for congenital hypothyroidism should start within the first 2 
weeks of life, and even before a confirmatory thyroid function test in more severe 
cases [54, 55]. A recommended starting dose is 10–15 mg/kg/day given orally, with 
the precise dose depending on the severity of the condition. Early and continuous 
treatment with LT4 effectively prevents the onset of the gross adverse effects of 
hypothyroidism in the brain [54]. For example, Fig. 2 shows the similar scores for 
measures of intelligence quotient (IQ) for children with early- and continuously 
treated congenital hypothyroidism, compared with euthyroid children in one study 
[56], and according to initial doses of LT4 in another study [57]. No behavioural 
abnormalities were observed between groups in the first study [56]. Optimisation 
of LT4 treatment is important in preserving neuropsychological outcomes in this 
population, as over- or under-treatment with LT4 early in life has been associated 
with neuropsychological or behavioural problems later on [56, 58, 59].
Severe hypothyroidism may be associated with subtle and long-lasting neuro-
cognitive deficits, even when children are identified via new born screening and 
treated promptly with LT4. This was shown in a recent study in 30 such children 
aged at least 6 years, who demonstrated multiple brain white matter lesions, which 
correlated with deficits in language development [60]. A study from Turkey showed 
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mild-to-moderate developmental delay at age 2–3 years in early-diagnosed and 
treated children with congenital hypothyroidism [61]. Ten-year old children with 
congenital hypothyroidism who were diagnosed via neonatal screening have been 
shown to be at risk of reduced health-related quality of life (HRQoL), and adverse 
perception of self-worth, compared with their euthyroid peers [62]. These deficits in 
QoL were independent of cognitive or neuropsychological functioning.
3.2  Subclinical Hypothyroidism
Individual studies have demonstrated that LT4 treatment reduced hypothyroid-
like symptoms in children with subclinical hypothyroidism [63], or the mean anti- 





































Fig. 2 Neuropsychological outcomes in children with congenital hypothyroidism (CH) treated 
early and continuously with levothyroxine (LT4). (a) Study 1: global intelligence quotient mea-
sured at 5.75 years of age in children with CH of varying severity, and in euthyroid control chil-
dren. Children with CH received LT4 at a median dose of 12 μg/kg from a median age of 14 days. 
Bars show range of measurements. Differences between groups were described as being not statis-
tically significant (the source did not provide p values). (Drawn from data presented in Ref. [56]). 
(b) Study 2: IQ measurements at 5.9 years of age in children with CH according to whether they 
had received a low or high dose of LT4. LT4 treatment started between 13 and 60 days after birth 
(mean 27 days). Low-dose LT4 = 6–<10 μg/kg/day; high-dose LT4 = 10–16 μg/kg/day). Bars are 
SD. There were no significant differences between low- and high-dose groups for any measure of 
IQ (p = 0.16–0.78). (Drawn from data presented in Ref. [57])
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children with mild, subclinical hypothyroidism with LT4 was not disease modify-
ing, in that it did not decrease the likelihood of an increase in TSH after treatment 
withdrawal [65]. There is little evidence to support improved neuropsychological 
outcomes with LT4 treatment in this population, however [34]. One prospective 
study found significantly reduced scores for verbal memory and verbal recall in 20 
children with TSH 5–10 μIU/L, compared with a control group [36]. Treatment for 
6 months with LT4 restored the test performance in the children with subclinical 
hypothyroidism to the level of controls.
Obesity is associated with hypothyroidism (especially the subclinical form) in 
children, as described above. A 6-month, randomised trial in 51 obese children 
with TSH 4–10 mIU/L (with or without abnormalities of other thyroid hormones) 
showed that administration of LT4 vs. no additional treatment, alongside weight 
loss interventions, had no significant effect on BMI or lipid abnormalities [66]. A 
similar study, where LT4 was or was not added to a behavioural intervention for 
obesity, reported similar results [67]. These data suggest there is no place for LT4 in 
the general management of obesity in children with TSH levels consistent with 
subclinical hypothyroidism. Correlations of higher TSH levels with higher BMI in 
hypothyroid children controlled on LT4 have been observed [68], but this associa-
tion is probably not independently causative for obesity [1, 69].
Administration of LT4 to 30 children with subclinical hypothyroidism (mean age 
7 years, mean TSH 8.7 mIU/L) for 6 months increased measures of left ventricular 
systolic performance (myocardial performance index, fraction shortening, and ejec-
tion fraction), but did not affect diastolic function (E/E′ ratio) [70]. This study was 
uncontrolled, and these parameters were not overtly decreased before treatment, 
so that the clinical relevance of these findings is difficult to assess. Migraine may 
be a symptom of subclinical hypothyroidism, which responds to treatment with 
LT4 [71].
Box 1 summarises guideline recommendations for the management of subclini-
cal hypothyroidism in children [43, 53, 69]. The majority of this population will 
not need active treatment, as long as thyroid hormones are within range and thyroid 
function is not deteriorating. The European guidance differs from the guidelines 
from Latin America and from the USA since it was specifically addressed for hypo-
thyroidism in children, and it identifies the first 3 years of life as the crucial period 
for optimising thyroid function with LT4 (this is the time when thyroid hormones 
have their greatest influence on development of the brain). Monotherapy with LT4 is 
used exclusively: there is no role for the therapeutic use of T3 currently, as in other 
populations. A recent expert opinion recommends reserving LT4-based manage-
ment of subclinical hypothyroidism to children with autoimmune (Hashimoto) dis-
ease, children whose thyroid function is deteriorating over time, or for children with 
goitre, other congenital abnormalities associated with thyroid dysfunction (Turner 
Syndrome or Down Syndrome) [72].
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3.3  Biochemically Euthyroid Children
A randomised trial in 59 biochemically euthyroid children with Hashimoto’s thy-
roiditis showed that treatment with LT4 (mean dose 1.6 μg/kg/day, based individ-
ually on body weight) vs. no treatment reduced thyroid volume transiently, and 
did not affect either thyroid function or the level of thyroid autoantibodies [73]. 
Observational data from 330 children with autoimmune thyroiditis and type 1 dia-
betes showed a reduction in antibodies in the treated cohort, suggesting a possible 
role for LT4 therapy in this population [74].
4  Conclusions
Thyroid hormones are essential for the development of the central nervous system 
early in life. Early and continuous treatment with LT4 of children with overt hypo-
thyroidism preserves near-normal neuropsychological development. Subclinical 
Box 1: Summary of Guidance Relating to the Use of Levothyroxine 
(LT4) in Children with Subclinical Hypothyroidism [46, 53, 69]
• Discuss decisions to treat or not to treat with LT4 carefully with parents/
guardians
• Most children with TSH <10 mIU/L and FT4 or TT4 within normal range 
will not need treatment with LT4
• Initiating LT4 is a reasonable strategy for patients with TSH >10 mIU/L, 
including children
 – Especially beyond 1 month of age and who have signs and symptoms of 
hypothyroidism and/or risk factors for progression of thyroid dysfunction
• Use LT4 only, there is no current role for treatment with LT3
• Consider a trial of withdrawal of LT4 at age 3 years, as development of the 
CNS is no longer dependent on thyroid function
• Monitor the TSH level and for thyroid autoimmunity periodically beyond 
age 3 years (more frequent monitoring is recommended if thyroid autoim-
munity is present already)
Guidance has been adapted and combined from Latin American [46], the 
USA [53], and European [69] guidelines and has been paraphrased for brev-
ity. See the full guidelines for more details
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hypothyroidism often resolves spontaneously and most children will not need LT4 
treatment. However, close observation is key since some children with this condi-
tion may require LT4 to manage symptoms, or they may develop overt hypothyroid-
ism in the future.
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Levels of the pituitary hormone thyrotropin (thyroid-stimulating hormone, 
TSH) tend to run higher in older individuals than in younger adults. As TSH is 
used to guide replacement with levothyroxine (LT4), older patients may be at 
risk of over treatment if TSH levels towards the lower part of the standard 
adult reference range are aimed for. Recent randomised clinical trials have not 
demonstrated clinical benefit from the use of LT4  in older patients with 
subclinical hypothyroidism (diagnosed and treated according to standard, 
adult TSH reference ranges). The results of the recent Study of Optimal 
Replacement of Thyroxine in the Elderly (SORTED 1) feasibility trial suggest 
that older hypothyroid patients can be treated using a higher than usual target 
range for TSH with no apparent adverse effects, at least over the short term.
1  Thyroid Homeostasis in Older Individuals
1.1  Thyroid Homeostasis
Hypothyroidism is diagnosed when serum thyrotropin (thyroid-stimulating hormone 
or TSH) is elevated and thyroid hormones are low. The incidence of hypothyroidism 
increases with age. The reference range limits for serum TSH and thyroid hormones 
are calculated from measurements obtained from all age groups. However, both 
the median and 97.5th centile values for TSH increase with age (Fig. 1) [1]. Several 
studies from various parts of the world have confirmed the increase in serum TSH 
concentrations with ageing [2–6].
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A study of ambulatory older individuals found that 1  in 40 people had low 
levels of circulating free thyroxine (FT4) index although thyrotropin levels were 
normal [7]. A comparison of six of these subjects (mean age 69 years) with six 
age- and gender-matched subjects with normal FT4 index (also with a normal thy-
rotropin level) showed that pituitary or hypothalamic dysfunction, pituitary thyro-
tropin reserve, thyroid reserve, and the biological actions of secreted thyrotropin, 
did not differ between these groups [7]. Accordingly, the authors concluded that 
this functional hypothyroidism in some older patients was due to a resetting of 
the hypothalamic- pituitary-thyroid feedback axis. The mechanisms underlying the 
increase in TSH with age remain to be elucidated. It does appear, however, that TSH 
secretion in older people is increased without any change in its bioactivity [8].
1.2  Thyroid Hormone Levels and Clinical Outcomes
Lower TSH or higher FT4 levels, including variations of these hormones within 
the normal range, have been associated with increased risk of mortality [9–12], 
major adverse cardiovascular events (including myocardial infarction) [13], heart 
failure [14], frailty [15], and dementia [16, 17] in older populations. Conversely, 
low- normal FT4 was associated with better mobility and less fatigue, compared 
with higher levels of FT4, in a study of 602 older euthyroid individuals [18].
Not all studies have associated higher FT4 levels within the normal range with 
adverse outcomes in older patients, however. Higher thyrotropin and lower FT4 in 
hospitalised older patients was associated with an increased risk of a composite 





















Fig. 1 Medians and 2.5th–97.5th percentile reference ranges for thyrotropin (TSH) according to 
age in healthy subjects from a large (n = 13,344) population-based study in the USA. Subjects with 
risk factors for thyroid dysfunction such as pregnancy, oestrogens, androgens, lithium, antithyroid 
antibodies, and treated thyroid disease were excluded. (Drawn from data presented in Ref. [1])
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hospital stay >18 days) in a retrospective study [19]. Another study found a higher 
rate of cognitive decline over time in older women with low-normal vs. high-nor-
mal, FT4 [20]. A population-based study demonstrated no association between FT4 
levels and cognitive decline in a cohort born in 1912–1914 [10].
Some of these studies suggested little or no significant effect of modest increases 
in TSH (consistent with subclinical hypothyroidism) on outcomes in this popula-
tion, even where higher FT4 was associated with an adverse prognosis [12, 14, 17]. 
Higher TSH in 85 year-old individuals was associated with reduced mortality in the 
Leiden 85+ study though the authors emphasised the need for further data to cor-
roborate this finding [10]. Another study of a larger number of 85-year-old individu-
als followed up for a longer period of time than the Leiden study did not confirm 
the protective association of high TSH with mortality in this age group but never-
theless confirmed that a slightly raised serum TSH was not associated with adverse 
outcomes [4]. Elsewhere, the risk of heart failure was only increased if TSH was 
unequivocally abnormal (<0.1 or >10 mIU/L) [14]. A meta-analysis concluded that 
the excess risk of adverse cardiovascular outcomes in older patients with subclinical 
hypothyroidism was small, with minimal increased risk in studies of higher quality 
(relative risks 1.2–1.8 vs. euthyroid individuals) [21]. A second meta- analysis found 
no association between subclinical hypothyroidism and adverse cardiovascular out-
comes in older patients [22].
2  Therapeutic Use of Levothyroxine in Older Patients 
with Hypothyroidism
2.1  Analyses from Randomised, Placebo-Controlled Trials
The Thyroid Hormone Replacement for Untreated Older Adults with Subclinical 
Hypothyroidism Trial (TRUST) randomised 737 adults aged ≥65 years with thyro-
tropin 4.6–<20 mIU/L and normal FT4 to double-blind treatment with levothyrox-
ine (LT4) or placebo for 1 year [23, 24]. As expected, mean thyrotropin was lower 
in the LT4 group (3.6 mIU/L) compared with the placebo group (5.5 mIU/L) at 
study end. However, there was no effect on the co-primary endpoints in this study 
(change from baseline in two validated questionnaires specific to thyroid dysfunc-
tion: Hypothyroid Symptoms and Tiredness, and the Thyroid-Related Quality-of- 
Life Patient-Reported Outcome Questionnaire), or on other secondary outcomes. 
The TRUST trial has been criticised for recruiting participants with mostly low 
symptom burden [25]. Therefore, it is interesting that a post hoc analysis in subjects 
with more pronounced symptoms of hypothyroidism at baseline produced a similar 
lack of clinical benefit of LT4 treatment [26]. Additional sub-analysis from TRUST 
found no effect of LT4 treatment on cardiac function [27] or bone metabolism [28] 
in this population.
Pooling the data from two randomised trials, including a subgroup from TRUST, 
involving a total of 251 patients with subclinical hypothyroidism aged ≥80 years 
also found no significant effect of LT4 on thyroid symptoms or fatigue, relative to 
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placebo [29]. Administration of LT4 for 1 year to patients aged ≥65 years in the pri-
mary care setting had no significant effect on cognitive function [30]. A randomised 
trial in outpatients aged 55 years or over reported a nominally significant effect of 
LT4 treatment on a composite memory score though there were no benefits of treat-
ments relating to other endpoints, or to health-related quality of life [31]. A meta-
analysis published in 2018, which included two studies in patients aged >65 years 
with subclinical hypothyroidism also found no evidence of clinical benefit arising 
from intervention with LT4 [32].
Hypothyroidism has been associated with an adverse cardiovascular prognosis in 
some studies (see chapter, “Levothyroxine and the Heart”). Randomisation of 185 
patients with subclinical hypothyroidism in a nested subgroup of participants within 
the TRUST trial aged ≥65 years to LT4 vs. placebo for an average of 18 months had 
no significant effect on carotid intima-media thickness (a measure of the overall 
burden of atherosclerosis), however [33].
2.2  Observational Studies of Levothyroxine in Older Patients 
with Hypothyroidism
Observational data in subjects with subclinical hypothyroidism (diagnosed using a 
cut-off for thyrotropin of 8 mIU/L) showed that a similar overall improvement from 
baseline in health-related quality of life occurred following LT4 treatment in younger 
(<40 years) and older (>60 years) patients [34]. Both age groups benefitted from 
improvements in “Emotional Susceptibility” and “Impaired Daily Life” domains; 
older patients additionally improved their score for “Tiredness” and younger patients 
improved their score for “Cognitive Complaints”. A recent study that included 24 
patients with hypothyroidism who were aged ≥65 years and already receiving stable 
doses of LT4 involved increasing the dose of LT4 by 12.5 mg/day (irrespective of 
the previous dose) in a single-blind manner for 3 months [35]. This change was suf-
ficient to reduce mean thyrotropin from 1.95 to 0.47 mIU/L. The period of admin-
istration of the higher LT4 dose was accompanied by a significant improvement in 
the Geriatric Depression Scale score, including in patients with a score consistent 
with clinical depression at baseline, without inducing symptoms of hyperthyroid-
ism. However, the impact of higher doses of LT4  in this age group on long-term 
outcomes, particularly the risk of atrial fibrillation and osteoporosis, is unknown.
Any severity of hyperthyroidism increases the risk of bone fractures [36], which 
is a particular concern for the elderly who may be already at risk of age-related 
osteoporosis [37]. Treatment of women aged ≥65 years with LT4 at a daily dose 
>150 μg/day was associated with increased fracture risk in an observational study, 
with the highest risk in women already receiving treatment for osteoporosis [38]. A 
case-control study in subjects aged ≥70 years also found a dose-related increase in 
the risk of fractures associated with LT4 treatment [39]. One potential mechanism for 
the observed adverse events may be due to the risk of inadvertent over-treatment with 
LT4. In a community-based cohort study, iatrogenic thyrotoxicosis accounted for 
approximately half of low TSH events, with the highest rates among older women, 
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who are vulnerable to atrial fibrillation and osteoporosis [40]. No evidence of any 
differences in long-term health outcomes are observed when thyrotropin concentra-
tions are maintained within the reference range [41]. Chapter “Levothyroxine and 
Bone” provides a fuller account of the effects of LT4 on bone health.
2.3  Managing Elderly Patients with Hypothyroidism: 
Implications of the SORTED 1 Trial
The studies reviewed above suggest that the clinical sequelae of hypothyroidism, par-
ticularly the subclinical form, appear to be less severe in older vs. younger patients. 
The randomised evaluations of LT4 have not provided unequivocal evidence for 
benefit of intervention with LT4 in older patients, especially those with subclinical 
hypothyroidism [23, 24, 26–29]. It is important to remember that the diagnosis of 
hypothyroidism and the titration of the LT4 dose were guided in these studies by 
standard reference ranges for thyrotropin in adults. Given the shift towards higher 
levels of thyrotropin in elderly populations, the population of TRUST and similar 
studies probably included individuals who had high TSH relative to the standard 
adult reference range, who would have been classified as euthyroid using a more 
age-appropriate reference range [32].
The Study of Optimal Replacement of Thyroxine in the Elderly (SORTED1) 
study evaluated the clinical consequences of using LT4 to control the level 
of thyrotropin within a higher range than the usual reference range used to 
guide LT4 therapy in adults [42–44]. This trial was conducted in 48 elderly 
(≥80 years) patients with pre-existing hypothyroidism whose thyrotropin was 
well controlled as per the usual local adult reference range (0.4–4.0 mIU/L). 
The patients were randomised in a single-blind manner to continuing treatment 
guided by the standard reference range, or by a higher range (4.1–8.0 mIU/L) 
for 6 months.
As expected, the mean thyrotropin level (±SD) was higher at 6 months in the 
higher range group (6.6 ± 2.9 mIU/L) than in the standard range group (1.4 ± 1.0 
mIU/L); corresponding mean values of other hormones were 16.0  ±  2.5 and 
19.4  ±  3.5  pmol/L, respectively, for FT4 and 3.5  ±  0.5 and 3.9  ±  0.4  pmol/L, 
respectively, for FT3. The mean FT3/FT4 ratio was similar in the higher range 
(0.23 ± 0.04) and standard range (0.21 ± 0.05) groups.
There were no clinically significant differences between groups for mean val-
ues of lipid parameters, blood pressures, weight, pulse rate, and a bone resorption 
marker at study end (Fig.  2). In addition, small and similar changes in group 
occurred in scores on questionnaires that measured generic and thyroid dysfunc-
tion-specific quality of life (EQ-5D and ThyDQoL), or on the risk of falling (falls 
risk assessment test) or mobility (timed up and go test). The most common all-
cause adverse events (AE) in the standard and higher range groups were “Feeling 
more tired” (38% and 50%, respectively) and “Problems with balance or mobil-





Thyrotropin levels shift towards higher concentrations in older individuals but cur-
rent reference ranges are applied uniformly across all age groups. Hence, a sig-
nificant number of people, particularly in the older age group, are diagnosed with 
subclinical hypothyroidism and a proportion of these are treated with LT4. The 
long-term health outcomes and cost-effectiveness of treatment in this particular 
group of patients is unknown. Furthermore, it also remains unclear whether a higher 
thyrotropin reference range should be aimed for in older patients on LT4 therapy.
The SORTED 1 trial demonstrated that titrating LT4 therapy to a higher than 
usual reference range in elderly patients may not adversely affect symptoms of 
hypothyroidism, or impair quality of life. Moreover, this trial has shown that a suit-
ably powered long-term study is feasible, in order to verify these findings.
Current guidelines for the management of hypothyroidism in adults date back 
to 2014, or earlier [45, 46]. These guidelines acknowledge the shift towards higher 
levels of thyrotropin as people age (Box 1), as well as the possibility of accept-
ing a higher target value for thyrotropin. There is no unequivocal recommenda-
tion to use age-specific reference ranges for thyrotropin in elderly patients with 
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Fig. 2 Effects of randomisation of elderly subjects with subclinical hypothyroidism to a higher or 
lower target range for thyrotropin on cardiovascular risk factors and a marker of bone resorption in 
the SORTED 1 Trial. Formal statistical testing was not carried out in this trial, but differences may 
be considered to be not statistically significant as 95%CI for mean differences between groups 
overlap zero for every parameter. HDL high density lipoprotein. See text for definitions of higher 
and lower range groups. (Drawn from data presented in Ref. [44])
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hypothyroidism, however. There is growing recognition, though, that the TSH ref-
erence range does need to appropriately reflect the age of the individual [47]. The 
results of recent randomised trials, including SORTED 1 and TRUST, will inform 
future guidance on the management of the elderly patient with hypothyroidism, 
probably leading to a less intensive application of LT4 and acceptance of a higher 
range of thyrotropin levels in elderly patients.
References
 1. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies 
in the United States population (1988 to 1994): National Health and Nutrition Examination 
Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489–99.
 2. Ceresini G, Lauretani F, Maggio M, et  al. Thyroid function abnormalities and cognitive 
impairment in elderly people: results of the Invecchiare in Chianti study. J Am Geriatr Soc. 
2009;57:89–93.
 3. Yeap BB. Hormones and health outcomes in aging men. Exp Gerontol. 2013;48:677–81.
 4. Pearce SH, Razvi S, Yadegarfar ME, et al. Serum thyroid function, mortality and disability in 
advanced old age: the Newcastle 85+ study. J Clin Endocrinol Metab. 2016;101:4385–94.
 5. Wang D, Li D, Guo X, et  al. Effects of sex, age, sampling time, and season on thyroid- 
stimulating hormone concentrations: a retrospective study. Biochem Biophys Res Commun. 
2018;506:450–4.
Box 1: Key Recommendations from the USA [45] and European [46] 
Guidelines on the General Approach for the Management of 
Hypothyroidism in Elderly Patients
• Thyrotropin levels tend to be higher in elderly vs. younger people with 
hypothyroidism, and a higher than usual target level of thyrotropin may be 
acceptable for an elderly patient [45, 46].
• The dose of LT4 to control the thyrotropin level is lower, on average, in 
older vs. younger subjects, due in part to a lower muscle mass in this popu-
lation [45].
• Extra vigilance for interference of other medications with the effects of 
LT4 is necessary for the elderly population, who may be receiving multiple 
other treatments for comorbid conditions [45].
• Avoidance of iatrogenic thyrotoxicosis due to over treatment with LT4 is a 
clinical priority in elderly patients with hypothyroidism, especially given 
the association of higher FT4 levels with adverse outcomes, described 
above [45].
• Consider monitoring, rather than intervening with LT4, for very elderly 
(>80 years) patients with subclinical hypothyroidism [46].




 6. Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid anti-
bodies in the US population: implications for the prevalence of subclinical hypothyroidism. J 
Clin Endocrinol Metab. 2007;92:4575–82.
 7. Lewis GF, Alessi CA, Imperial JG, Refetoff S. Low serum free thyroxine index in ambulat-
ing elderly is due to a resetting of the threshold of thyrotropin feedback suppression. J Clin 
Endocrinol Metab. 1991;73:843–9.
 8. Jansen SW, Akintola AA, Roelfsema F, et al. Human longevity is characterised by high thyroid 
stimulating hormone secretion without altered energy metabolism. Sci Rep. 2015;5:11525.
 9. Ceresini G, Marina M, Lauretani F, et al. Relationship between circulating thyroid-stimulating 
hormone, free thyroxine, and free triiodothyronine concentrations and 9-year mortality in 
euthyroid elderly adults. J Am Geriatr Soc. 2016;64:553–60.
 10. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frölich M, Westendorp RG. Thyroid 
status, disability and cognitive function, and survival in old age. JAMA. 2004;292:2591–9.
 11. Yeap BB, Alfonso H, Hankey GJ, et al. Higher free thyroxine levels are associated with all-cause 
mortality in euthyroid older men: the health in men study. Eur J Endocrinol. 2013;169:401–8.
 12. Waring AC, Arnold AM, Newman AB, Bùzková P, Hirsch C, Cappola AR.  Longitudinal 
changes in thyroid function in the oldest old and survival: the cardiovascular health study all- 
stars study. J Clin Endocrinol Metab. 2012;97:3944–50.
 13. Golledge J, Hankey GJ, Almeida OP, Flicker L, Norman PE, Yeap BB. Plasma free thyroxine 
in the upper quartile is associated with an increased incidence of major cardiovascular events 
in older men that do not have thyroid dysfunction according to conventional criteria. Int J 
Cardiol. 2018;254:316–21.
 14. Nanchen D, Gussekloo J, Westendorp RG, et  al. Subclinical thyroid dysfunction and the 
risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab. 
2012;97:852–61.
 15. Yeap BB, Alfonso H, Chubb SA, et al. Higher free thyroxine levels are associated with frailty 
in older men: the health in men study. Clin Endocrinol (Oxf). 2012;76:741–8.
 16. Yeap BB, Alfonso H, Chubb SA, et al. Higher free thyroxine levels predict increased incidence 
of dementia in older men: the health in men study. J Clin Endocrinol Metab. 2012;97:E2230–7.
 17. Eskelinen SI, Vahlberg TJ, Isoaho RE, Löppönen MK, Kivelä SL, Irjala KM. Associations of 
thyroid-stimulating hormone and free thyroxine concentrations with health and life satisfac-
tion in elderly adults. Endocr Pract. 2007;13:451–7.
 18. Simonsick EM, Chia CW, Mammen JS, Egan JM, Ferrucci L. Free thyroxine and functional 
mobility, fitness, and fatigue in euthyroid older men and women in the Baltimore Longitudinal 
Study of Aging. J Gerontol A Biol Sci Med Sci. 2016;71:961–7.
 19. Mingote E, Meroño T, Rujelman R, et al. High TSH and low T4 as prognostic markers in older 
patients. Hormones (Athens). 2012;11:350–5.
 20. Volpato S, Guralnik JM, Fried LP, Remaley AT, Cappola AR, Launer LJ. Serum thyroxine 
level and cognitive decline in euthyroid older women. Neurology. 2002;58:1055–61.
 21. Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical thyroid dysfunction and the risk 
for coronary heart disease and mortality. Ann Intern Med. 2008;148:832–45.
 22. Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH.  The influence of age on the 
relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. J 
Clin Endocrinol Metab. 2008;93:2998–3007.
 23. Stott DJ, Gussekloo J, Kearney PM, et al. Study protocol; thyroid hormone replacement for 
untreated older adults with subclinical hypothyroidism—a randomised placebo controlled trial 
(TRUST). BMC Endocr Disord. 2017;17:6.
 24. Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with sub-
clinical hypothyroidism. N Engl J Med. 2017;376:2534–44.




 26. de Montmollin M, Feller M, Beglinger S, et al. L-thyroxine therapy for older adults with sub-
clinical hypothyroidism and hypothyroid symptoms: secondary analysis of a randomized trial. 
Ann Intern Med. 2020;172:709–16.
 27. Gencer B, Moutzouri E, Blum MR, et al. The impact of levothyroxine on cardiac function 
in older adults with mild subclinical hypothyroidism: a randomized clinical trial. Am J Med. 
2020;133:848–856.e5.
 28. Gonzalez Rodriguez E, Stuber M, Del Giovane C, et al. Skeletal effects of levothyroxine for 
subclinical hypothyroidism in older adults: a TRUST randomized trial nested study. J Clin 
Endocrinol Metab. 2020;105:dgz058.
 29. Mooijaart SP, Du Puy RS, Stott DJ, et al. Association between levothyroxine treatment and 
thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroid-
ism. JAMA. 2019;322:1–11.
 30. Parle J, Roberts L, Wilson S, et  al. A randomized controlled trial of the effect of thyrox-
ine replacement on cognitive function in community-living elderly subjects with sub-
clinical hypothyroidism: the Birmingham Elderly Thyroid study. J Clin Endocrinol Metab. 
2010;95:3623–32.
 31. Jaeschke R, Guyatt G, Gerstein H, et  al. Does treatment with L-thyroxine influence health 
status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med. 
1996;11:744–9.
 32. Feller M, Snel M, Moutzouri E, et al. Association of thyroid hormone therapy with quality of 
life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic 
review and meta-analysis. JAMA. 2018;320:1349–59.
 33. Blum MR, Gencer B, Adam L, et al. Impact of thyroid hormone therapy on atherosclerosis 
in the elderly with subclinical hypothyroidism: a randomized trial. J Clin Endocrinol Metab. 
2018;103:2988–97.
 34. Recker S, Voigtländer R, Viehmann A, et  al. Thyroid related quality of life in elderly with 
subclinical hypothyroidism and improvement on levothyroxine is distinct from that in young 
patients (TSAGE). Horm Metab Res. 2019;51:568–74.
 35. Moon JH, Han JW, Oh TJ, et al. Effect of increased levothyroxine dose on depressive mood 
in older adults undergoing thyroid hormone replacement therapy. Clin Endocrinol (Oxf). 
2020;93:196–203.
 36. Blum MR, Bauer DC, Collet TH, et al. Subclinical thyroid dysfunction and fracture risk: a 
meta-analysis. JAMA. 2015;313:2055–65.
 37. Swedish Council on Health Technology Assessment. Osteoporosis—prevention, diagnosis and 
treatment: a systematic review [Internet]. Stockholm: Swedish Council on Health Technology 
Assessment (SBU); Oct 2003. SBU Yellow Report No. 165/1+2. Available at https://www.
ncbi.nlm.nih.gov/books/NBK447989/. Accessed Jul 2020.
 38. Ko YJ, Kim JY, Lee J, et al. Levothyroxine dose and fracture risk according to the osteoporosis 
status in elderly women. J Prev Med Public Health. 2014;47:36–46.
 39. Turner MR, Camacho X, Fischer HD, et al. Levothyroxine dose and risk of fractures in older 
adults: nested case-control study. BMJ. 2011;342:d2238.
 40. Mammen JS, McGready J, Oxman R, Chia CW, Ladenson PW, Simonsick EM. Thyroid hor-
mone therapy and risk of thyrotoxicosis in community-resident older adults: findings from the 
Baltimore Longitudinal Study of Aging. Thyroid. 2015;25:979–86.
 41. Thayakaran R, Adderley NJ, Sainsbury C, et al. Thyroid replacement therapy, thyroid stimulat-
ing hormone concentrations, and long term health outcomes in patients with hypothyroidism: 
longitudinal study. BMJ. 2019;366:l4892.
 42. Wilkes S, Pearce S, Ryan V, Rapley T, Ingoe L, Razvi S. Study of Optimal Replacement of 
Thyroxine in the ElDerly (SORTED): protocol for a mixed methods feasibility study to assess 
the clinical utility of lower dose thyroxine in elderly hypothyroid patients: study protocol for a 
randomized controlled trial. Trials. 2013;14:83.
Levothyroxine in the Older Patient
84
 43. Razvi S, Ingoe L, Ryan V, Pearce SH, Wilkes S. Study of Optimal Replacement of Thyroxine 
in the Elderly (SORTED)—results from the feasibility randomised controlled trial. Thyroid 
Res. 2016;9:5.
 44. Razvi S, Ryan V, Ingoe L, Pearce SH, Wilkes S. Age-related serum thyroid-stimulating hor-
mone reference range in older patients treated with levothyroxine: a randomized controlled 
feasibility trial (SORTED 1). Eur Thyroid J. 2020;9:40–8.
 45. Jonklaas J, Bianco AC, Bauer AJ, et  al. Guidelines for the treatment of hypothyroidism: 
prepared by the American Thyroid Association task force on thyroid hormone replacement. 
Thyroid. 2014;24:1670–751.
 46. Pearce SH, Brabant G, Duntas LH, et  al. 2013 ETA guideline: management of subclinical 
hypothyroidism. Eur Thyroid J. 2013;2:215–28.
 47. Cappola AR. The thyrotropin reference range should be changed in older patients. JAMA. 2020 
(advance publication online, https://doi.org/10.1001/jama.2019.14728).
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative Commons license and 
indicate if changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative 
Commons license, unless indicated otherwise in a credit line to the material. If material is not 
included in the chapter’s Creative Commons license and your intended use is not permitted by 
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder.
S. Razvi
85© The Author(s) 2021




Thyroid hormone deficiency has been associated with multiple changes in 
cardiovascular structure and function in recent studies. A strong relationship has 
been reported between overt and subclinical hypothyroidism with serum 
TSH ≥10 mIU/L and adverse cardiovascular outcomes, suggesting the necessity 
of replacement doses of Levothyroxine. The potential benefits of replacement 
therapy remain an active area of research in euthyroid patients with heart failure.
1  Introduction
Hypothyroidism is a common condition of thyroid hormone deficiency which can 
lead to increased cardiovascular mortality when untreated. Overt hypothyroid-
ism is defined by thyroxine concentrations below the reference range and a serum 
thyrotropin (thyroid-stimulating hormone, TSH) measurement that is outside an 
appropriate reference range (typically between 0.4 and 4.0–4.5 mIU/L, defined in a 
population of subjects without thyroid disease) [1, 2]. Subclinical hypothyroidism 
occurs where there is elevation of TSH despite the level of free thyroxine (FT4) 
being within the normal reference range. Patients with a serum TSH ≥10 mIU/L 
have a severe form of subclinical hypothyroidism, whereas patients with subclinical 
hypothyroidism and TSH <10 mIU/L are described as having a “mild” form of this 
condition, according to European guidance [1]. This chapter considers the effects 
of hypothyroidism and levothyroxine (LT4) replacement therapy on the heart and 
cardiovascular system.
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2  Overview of the Adverse Effects of Thyroid Dysfunction 
on the Heart
Many observational studies have evaluated cardiovascular function in people with 
hypothyroidism and Table 1 summarises the results of some large, recent studies 
[3–19]. The findings of these studies were variable, probably because of differ-
ences between populations in terms of the severity of hypothyroidism, the age of the 
patients, and the presence of comorbidities. Nevertheless, expert opinions reported 
a significant association between hypothyroidism with serum TSH ≥10 mIU/L and 
adverse cardiovascular outcomes [20, 21]. A systematic review demonstrated mul-
tiple effects of subclinical hypothyroidism on the heart that were consistent with 
reduced diastolic or systolic cardiac left ventricular performance, and some of its 
key findings are summarised in Table 2 [21, 22]. In contrast, a meta-analysis found 
that the presence or absence of anti-thyroid peroxidase antibodies neither increases 
nor reduces the risk of adverse cardiovascular outcomes in people with subclinical 
hypothyroidism [23].
Table 1 Overview of observational studies of the associations between thyroid status and 
cardiovascular health that recruited at least 1000 subjects
Refs. Cardiovascular outcome in patients with hypothyroidism
Population based (without known thyroid dysfunction and with/without CHD at baseline)
[3–5] No association between SCH or overt hypothyroidism and MACE
[6] SCH and overt hypothyroidism associated with higher all-cause mortality and increased 
risk of MACE (but mortality was lower for TSH 5–10 mIU/L)
[7] SCH increased risk of mortality in acute CHD
[8] SCH associated with increased prevalence of CHD, and higher than expected rate of 
MACE
[9] SCH increased the risk of all-cause and CV mortality
[10] SCH increased risk of stroke in adults
[11] SCH increased total and CHD mortality
[12] Increased 10-year CVD risk score in people with SCH vs. euthyroid
Patients with or at risk of heart failure (HF)
[13] Higher TSH associated with more severe CHF presentation
[13, 
14]
Higher TSH associated with adverse clinical outcomes in patients with HF
[15] Hypothyroidism predicted adverse clinical outcomes, but the association was not 
independent and disappeared after adjustment for other covariates
[16] Low FT3 associated with higher risk of developing HF after myocardial infarction
[17] Hypothyroidism increased the 5-year risk of death in patients with LVEF <35%
[18] TSH ≥10 mIU/L increased the risk of new-onset HF, increased LV mass, and decreased 
diastolic function in patients free of HF at baseline
[19] SCH increased the risk of HF in older subjects at elevated CV risk
B. Biondi
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Results of studies that evaluated the relationships between thyroid status and 
the lipid profile have also been variable although there is some evidence that more 
severe increases in TSH are associated with a more adverse change in the lipid 
profile [22]. Effects of the hypothyroid state on “non-traditional” cardiovascular 
risk factors (e.g. markers of haemostasis or systemic inflammation) were variable 
although there was some support for a possible action of hypothyroidism in exacer-
bating atherosclerosis [22].
The association of hypothyroidism with adverse cardiovascular outcomes 
appears to be stronger and most consistent for people with heart failure [24–26]. 
A recent (2019) meta-analysis of 14 studies (21,221 patients) found a significant 
association between hypothyroidism (including the subclinical form) and major 
prognostic outcomes associated with heart failure, such as cardiac death and/or 
hospitalisation [27]. A pooled analysis of prospective cohort studies showed that 
the risk of heart failure events (any physician-diagnosed acute heart failure event, 
or hospitalization or death related to heart failure) increased as the level of TSH 
increased above a euthyroid range defined as a TSH level of 0.45–4.49 mIU/L 
[28]. The hazard ratio (HR) for heart failure events for TSH 7–9.9 mIU/L vs. the 
euthyroid state was 1.65 (95%CI 0.84–3.23). TSH levels associated with hyperthy-
roidism also increased the risk of heart failure events in this analysis. Elsewhere, 12 
years of prospective follow-up of 3,044 elderly (age ≥65 years) subjects with sub-
clinical hypothyroidism showed that a TSH level >10 mIU/L was associated with 
an almost doubled risk of developing new heart failure HR 1.88; 95%CI 10.5–3.34) 
[18]. On the other hand, cardiovascular diseases such as heart failure may them-
selves lead to an altered thyroid function [29]. Low circulating T3 levels are a 
common finding in patients with heart failure and contribute to adverse outcomes 
in this condition [25].
Table 2 Overview of the effects of subclinical hypothyroidism and levothyroxine replacement 





















↑ ↓ or 
↔
↑ ↑a ↑a ↑ or ↔ ↑ or ↔ ↑ or ↔
Effect of LT4 
replacement
↓ ↑ ↑ – ↓ ↓ or ↔ ↓ or ↔ ↔↑
Changes in parameters reflect those seen in most (not necessarily all) studies: ↑ = increased; ↓ = 
decreased; ↔ = variable effects
E/A early-to-late transmitral peak flow velocity ratio, ET ejection time, IRT isovolumic relaxation 
time, LV left ventricular, PEP pre-ejection period. Compiled from information presented in 
Refs. [21, 22]




3  Effects of Levothyroxine Replacement Therapy 
on the Cardiovascular System
3.1  Effects on ECG Parameters
Hypothyroid patients have abnormal heart rate variability compared with euthy-
roid controls, which can be corrected by an adequate LT4 replacement therapy 
[30]. Ambulatory ECG recording showed that long-term LT4 replacement appears 
to avoid the bradyarrhythmias commonly associated with hypothyroidism [31]. 
Moreover, LT4 treatment may reduce QT interval dispersion in patients with sub-
clinical hypothyroidism, reducing the risk of malignant cardiac arrhythmias [32].
3.2  Effects of l-Thyroxine on Cardiovascular Structure 
and Function
Subclinical hypothyroidism appears to represent a mild form of thyroid failure that 
displays early signs of the cardiovascular dysfunction associated with hypothyroid-
ism [33, 34]. The impairment in systolic and/or diastolic performance observed in 
patients with subclinical hypothyroidism, compared with healthy controls, has been 
shown to reverse during treatment with LT4 for periods of up to 1 year (Table 2) 
[21]. Such effects have been observed in young adults but not in elderly subjects in 
some randomized trials [35–37].
An overview of these and other studies in populations with subclinical hypo-
thyroidism are summarised in Table 3 [32, 35–51]. Markers of atherosclerosis or 
arterial stiffness improved in some studies [39, 52]. A further cross-sectional analy-
sis demonstrated an improvement in atrial volume [53]. Another randomised trial 
showed that treatment with LT4 improved cholesterol levels in people with sub-
clinical hypothyroidism [39]. In addition, patients with mild subclinical hypothy-
roidism without associated cardiovascular risk factors have a coronary endothelial 
dysfunction that appears in response to a physiological stimulus [54]. A meta-
analysis found an improved lipid profile and reduced carotid intima-media thick-
ness (a marker of the overall burden of atherosclerosis) in patients with subclinical 
hypothyroidism [38]. Finally, treatment with LT4 may reduce cardiovascular risk in 
patients with diabetes: increased prevalence of thyroid dysfunction in patients with 
diabetes (and vice versa) suggests that there may be pathogenetic links between 
these conditions [55].
Thus, clinical evidence has associated overt and severe subclinical hypothy-
roidism with indices of increased cardiovascular risk, including dyslipidaemia, 
impaired cardiac function (especially during diastole) and impaired vascular func-
tion [56]. Evidence of potentially beneficial cardiovascular effects of LT4 replace-
ment therapy on these parameters has led some experts to propose intervention with 
LT4 in patients with mild subclinical hypothyroidism and elevated cardiovascular 
risk factors. However, until more reliable evidence is available from randomised, 
B. Biondi
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Table 3 Clinical evaluations of the cardiovascular effects of levothyroxine substitution in people 
with subclinical hypothyroidism
Ref. Design/dur. of LT4 N Précis of main findings
(a) Effects of LT4 replacement therapy on lipid profiles and markers of atherosclerosis
[38] MA up to 1 year 543 LT4 replacement improved total and LDL-C and reduced 
markers of vascular disease (carotid atherosclerosis and 
arterial stiffness
[39] RCT 6 months 49 Patients with SCH had higher cholesterol, LDL-C and 
ApoB vs. 33 euthyroid controls (LDL-C was proportional 
to the TSH level). Randomisation to LT4 resulted in 
reduced cholesterol and LDL-C, with no change in Lp(a); 
there were no significant changes on placebo.
[40] O, 7 months 30 Blood pressure and augmentation index (measure of 
arterial stiffness) decreased on LT4 therapy; reduced 
augmentation index was associated with reduced LDL-C
[41] O, 6 months 33 In patients with CHD, LT4 treatment improved the lipid 
profile in patients with shorter duration of CHD, lower 
BMI and higher cholesterol at baseline.
(b) Effects of LT4 replacement therapy on cardiac function
[37] RCT, 18 months 185 No significant difference for LT4 vs. placebo for changes 
in LV ejection fraction, E/E’ ratio or other parameters 
relating to diastolic functional; no significant interactions 
relating to gender, baseline TSH, pre-existing HF, and 
treatment duration
[35] RCT, 6 months 42 Increased early diastolic velocity and ratio of early/late 
diastolic velocities and reduced isovolumetric relaxation 
time was observed after 6 months of LT4; no change was 
seen in untreated patients
[36] RCT, 1 year 20 LT4 associated with reversal of impairments (vs. 
euthyroid controls) in pre-ejection/ejection time ratio, 
peak A, isovolumic relaxation time, cyclic variation index 
(myocardial viability); no significant changes on placebo.
[42] O, 6 months 30 Significant increase in indices of LV contractility 
(ejection fraction, fractional shortening, myocardial 
performance index) and end diastolic LV diameter in 
children; no change in LV end systolic volume or 
diastolic function (E/E′ ratio).
[43] O, 6 monthsa 31 Adverse changes in parameters of systolic and diastolic 
function in SCH (compared with 32 euthyroid control 
children) were partially reversed on LT4 replacement 
therapy.
[44] O, 5 monthsa 54 Parameters relating to systolic and diastolic function were 
within normal range in newly diagnosed SCH patients but 
were significantly adverse compared with 30 euthyroid 
controls; LT4 replacement partially reversed these 
changes.
[45] O, 12 months 26 Impairments (vs. 13 healthy controls) in systolic and 
diastolic cardiac function parameters (LV ejection 
fraction, diastolic relaxation, compliance to ventricular 




controlled trials, intervention with LT4 should be considered on an individual, case-
by- case basis, balancing the patient’s potential for progressive thyroid failure with 
the need to protect the cardiovascular system [56].
An increase in left ventricular mass with a consequent diastolic dysfunction can 
be observed during long-term therapy with TSH-suppressive doses of LT4 [57, 
58]. The addition of a β-blocker can ameliorate the potentially adverse effects of 
Table 3 (continued)
Ref. Design/dur. of LT4 N Précis of main findings
[46] O, 6 monthsa 53 Multiple indices of systolic/diastolic right ventricular 
function were impaired vs. 25 euthyroid controls; LT4 
associated with improved isovolumic acceleration (no 
change in systolic wave velocity, early/late velocity or 
myocardial precontraction times.
[32] O, 16 weeks 16 Treatment with LT4 reduced the QT interval of the ECG, 
and its temporal dispersion (QT interval dispersion was 
proportional to the TSH level).
(c) Effects of LT4 replacement therapy on clinical outcomes
[47] RT, mean 38 
months
257 LT4 replacement for ≥180 days (vs. <180 days) predicted 
significantly lower risk of acute coronary syndromes or 
stroke, but no effect on peripheral vascular disease in 
patients with diabetic neuropathy (average follow-up 
38 months).
[48] RT, median 6 years 162,369 Increased risk (HR [95%CI]) at TSH >10 vs. 2–2.5 
mIU/L of IHD (1.18 [1.02–1.38], p = 0.03), HF (1.42 
[1.21–1.67], p < 0.001), or mortality (2.21 [2.07–2.36] 
p < 0.001) in an LT4-treated cohort (97% received LT4 
during follow-up)
[49] RCT, mean 5.6 
years
1192 No significant difference for LT4 vs. no LT4 treatment 
(adjusted IRR [95%CI]) for risk of all-cause death (1.17 
[0.90–1.52), MACE (1.08 [0.80–1.45]), or hospital 
admission (0.94 [0.71–1.24]) in patients with CHD.
[50] RCT, mean 5.0 
years
12,212 No significant effect of LT4 vs. no LT4 on IRR [95%CI] 
for MI (1.08 [0.81–1.44]), CV death (1.02 [0.83–1.25]), 
all-cause death (1.03 [0.90–1.19]); suggestion of benefit 
for all-cause death in patients aged <65 years (0.63 
[0.40–0.99]).
[51] RCT, mean 7.6 
years
4735 Fewer IHD events (HR [95%CI]) with LT4 treatment in 
younger (40–70 years) patients (0.61 [0.39–0.95]) but not 
in older (≥70 years) patients (HR 0.99 [0.59–1.33]) in the 
primary care setting.
Diagnoses of subclinical hypothyroidism are as described in source publications according to 
clinical guidance at the time and have not been reviewed against current guidance
Abbreviations for study designs: DB double blind, MA meta-analysis (individual studies included 
in this analysis are omitted here for conciseness), O observational/cohort study, R randomised, RT 
retrospective. Other abbreviations: BMI body mass index, CHD coronary heart disease, HF heart 
failure, IHD ischaemic heart disease, IRR incidence rate ratio, LV left ventricular, MACE major 
adverse cardiac events, ACH subclinical hypothyroidism, TSH thyroid-stimulating hormone (thy-
rotropin)
aMonths with euthyroid function established on LT4 replacement therapy
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prolonged TSH suppression and be useful in patients with high-risk differentiated 
thyroid cancer [58]. The role of LT4 in the management of thyroid cancer is dis-
cussed in chapter, “Levothyroxine and Cancer” of this book.
3.3  Effects of LT4 on Major Adverse Cardiovascular Events
So far, only retrospective studies have evaluated the effects of LT4 treatment on car-
diac endpoints in patients with subclinical hypothyroidism (Table 3c). The results 
of these studies, however, are variable. Two studies showed no significant effects 
of LT4 replacement on the risk of myocardial infarction, or on cardiovascular and 
all cause death [49, 50]. Intriguingly, there was a suggestion of a greater potential 
for cardiovascular benefit of LT4 therapy in younger than in older patients [51, 52]. 
A smaller study suggested some cardiovascular benefit for a longer rather than a 
shorter duration of LT4 treatment [47].
A large database analysis in a population with hypothyroidism, of whom 97% 
received LT4 during a median follow-up of 6  years, showed that treatment with 
LT4 per se was insufficient to protect the cardiovascular system if TSH was not 
normalised [48]. Specifically, under-treatment with LT4 (TSH >10 mIU/L) in 
this study was associated with increased risk of ischaemic heart disease (HR 1.18 
[1.02–1.38], p  =  0.03), heart failure (HR 1.42 [1.21–1.67], p  <  0.001), or death 
(HR 2.21 [2.07–2.36], p < 0.001), compared with euthyroid subjects (TSH 2–2.5 
mIU/L). A further, register-based study showed that every 6  months of elevated 
TSH was associated with increased risk of mortality in LT4-treated individuals, 
with identical risks (HR 1.05 [1.03–1.08], p < 0.0001) for TSH >4 IU/L or TSH 
>10 IU/L, compared with euthyroid controls (this study is not shown in Table 3, as 
it did not report cardiovascular outcomes) [59].
Treatment with LT4 for more than 1 year reduced the risk of developing CHD, 
compared with no LT4 treatment, in a large retrospective analysis from Taiwan [60]. 
The effect of LT4 therapy on clinical outcomes was also measured in a retrospective 
study on 12,283 patients with atrial fibrillation [61]. The adjusted risk of mortality 
was lower in women treated with LT4 (hazard ratio [HR] 0.78 [95%CI 0.68–0.91]), 
but not men (HR 0.87 [95%CI 0.69–1.10]) compared to those untreated. There was 
no significant effect of LT4 treatment on rates of myocardial infarction, stroke, or 
heart failure in this study. A large (N = 87,902) retrospective study saw no differ-
ence in cardiovascular outcomes between patients receiving a branded or generic 
preparation of LT4 [62].
3.4  Effects of LT4 in Patients with Heart Failure
A retrospective analysis of a large database of patients with heart failure from 
Denmark (N  =  224,670) compared outcomes in non-users of LT4 and in 6,560 
patients using LT4 at the start of the analysis, and in 9007 who subsequently 
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received LT4 therapy [63]. Both groups of LT4 users were at increased risk of all-
cause death, cardiovascular death, or MACE, compared with non-users. However, 
the risk of myocardial infarction was increased in patients already taking LT4 at 
baseline but reduced in patients who started LT4 during the follow-up period. 
Large, randomized clinical trials of LT4 replacement therapy powered for deter-
mination of effects on clinical outcomes are lacking in populations of euthyroid 
subjects with heart failure and hypothyroidism. A placebo-controlled evaluation 
of LT4 treatment in 20 subjects with cardiac insufficiency secondary to idiopathic 
dilated cardiomyopathy demonstrated improvements in multiple measures of car-
diac function, including LV ejection fraction, cardiac output, LV diastolic dimen-
sions, systemic vascular resistance, and functional capacity [64, 65]. Another small 
(N = 28) study involved randomization of patients with severe symptoms of heart 
failure (New York Heart Association class III–IV) to LT4 supplementation or to 
no treatment for 1 month [66]. Significant improvements were seen in LV ejection 
fraction and isovolumic relaxation time in the LT4 group. An uncontrolled evalu-
ation of LT4  in 10 patients with severe LV systolic dysfunction and cardiogenic 
shock demonstrated significant improvements in cardiac index, pulmonary capillary 
wedge pressure, and mean arterial blood pressure at times up to 36 h after treatment 
[67]. LT4 treatment also contributed to stabilization of the condition of 9/10 of 
these patients, allowing for surgical intervention (heart transplant or insertion of a 
mechanical device to assist the heart).
Administration of T3 in patients with heart failure has also been demonstrated 
to improve cardiac performance in patients with severe heart failure, in some [68, 
69] but not all [70] studies. Although current guidance for the management of 
thyroid dysfunction (see chapter, “Pharmacodynamic and Therapeutic Actions of 
Levothyroxine”) does not support the therapeutic use of preparations of T3, these 
findings are consistent with a role for thyroid dysfunction within the pathophysiol-
ogy of heart failure, and with the importance of the low T3 syndrome in this setting 
[25]. The therapeutic use of T3  in patients with heart failure remains within the 
research domain, for now, and further clinical studies are needed in this area.
4  Conclusions
Hypothyroidism, including the severe form of subclinical hypothyroidism in which 
TSH is ≥10 mIU/L, has been associated with multiple negative changes in the struc-
ture and function of cardiovascular tissues and adverse cardiovascular outcomes. 
Some studies have shown that intervention with LT4 to correct hypothyroidism can 
result in a reduced risk of MACE although the results of studies are conflicting. 
Randomized clinical trials are needed and yet problematic in patients with overt 
hypothyroidism because management guidelines clearly state that all patients with 
this condition must be treated with LT4.
A potential role for LT4 therapy remains an active area of research in patients with 
subclinical hypothyroidism. It is particularly important to correct hypothyroidism 
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and the more severe form of subclinical hypothyroidism in these patients [20, 21, 
25]. Elderly patients with hypothyroidism may be especially challenging to man-
age, as they are more likely than younger patients to present with one or more 
cardiovascular comorbidities. For all patients, careful tailoring of the LT4 dose in 
hypothyroid patients should be performed to ovoid over-treatment and possible 
adverse effects on the cardiovascular system.
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Thyroid hormones play an important role in the development of the skeleton in 
children, and in maintaining bone mineral content in adults. Hyperthyroidism is 
associated with loss of bone mineral content, with increased risk of fractures. 
This has raised concerns that treatment (especially over treatment) with 
levothyroxine (LT4) might mimic these adverse effects on the skeleton. Clinical 
data on the effects of LT4 administration on bone are conflicting. In general, the 
use of LT4 to maintain euthyroid levels of thyroid hormones in patients with 
hypothyroidism, or even the use of thyrotropin-suppressive therapy following 
removal of thyroid tumours, does not appear to carry a substantial risk of 
osteoporosis or fractures. Nevertheless, a cautious approach to avoid over 
treatment is recommended, especially in patients with or at risk of developing 
osteoporosis.
1  Overview of the Effects of Thyroid Hormones 
on the Skeleton
Thyroid hormones (principally triiodothyronine, derived from naturally produced 
thyroxine or exogenously administered levothyroxine [LT4]) are essential for the 
normal development of the skeleton [1, 2]. Untreated congenital hypothyroidism, 
where there is a profound lack of thyroid function from birth, is associated with 
delayed development of the skeleton, impaired development of epiphyseal growth 
plates, short stature (dwarfism), reduced mineralisation of bones, scoliosis and con-
genital hip displacement, among other complications [1, 2]. Reduced bone turnover 
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in adults with hypothyroidism may result in increased bone mineralisation and 
mass, but such changes are slow to develop and this phenomenon has not been well 
studied clinically [2]. Hypothyroidism is not strongly associated with fractures [3, 
4] although one meta-analysis described such a relationship that was apparently 
independently of changes in bone mineral density (BMD).
Hyperthyroidism increases the rate of turnover of bone, with a net loss of bone 
mineralisation; accordingly, suboptimally managed hyperthyroidism can be a cause 
of osteoporosis and increased fracture risk [1, 2]. Restoration of euthyroid status 
reverses the loss of bone mineral content and also ameliorates the excess fracture risk 
in patients with hyperthyroidism [5]. Meta-analyses of cohort studies have revealed an 
excess risk of fractures in people with subclinical hyperthyroidism [3, 4, 6], and even 
in populations with high-normal free thyroxine (FT4) and low- normal thyrotropin 
(thyroid-stimulating hormone, TSH), according to current reference ranges [7].
The association of even mild severities of hyperthyroidism with bone loss and 
increased fracture risk raises a question over the possibility of an adverse effect 
on the skeleton of either over treatment with LT4, or during receipt of the TSH- 
suppressive doses of LT4 administered following the surgical removal of thyroid 
tumours. This chapter reviews clinical studies of bone health in people receiving 
treatment with LT4 in these settings.
2  Bone Health in Patients Receiving Treatment 
with Levothyroxine
2.1  Patients with Congenital Hypothyroidism
Early and continuous treatment with LT4 has been shown to promote normal growth 
[8, 9] and BMD or other indices of bone health [10–12] in children with congeni-
tal hypothyroidism, relative to their euthyroid peers (Fig. 1), and normal BMD in 
adults [13]. Maintenance of a healthy weight and calcium intake appears to be an 
important determinant of bone health in these children, as in other populations [11].
2.2  Adult Patients with Hypothyroidism
2.2.1  Subclinical Hypothyroidism
Administration of LT4 to women with subclinical hypothyroidism increased the 
rate of bone turnover although whether this effect of LT4 per se, or a reversal of 
a previous hypothyroid-induced reduction in bone turnover was unclear [14]. A 
meta- analysis of studies in populations with subclinical hypothyroidism found no 
clinically significant reduction in bone loss during LT4 treatment in pre-meno-
pausal women (2.7% after 8.5 years of treatment), but there was more significant 
bone loss in post-menopausal women (9.0% after 9.9  years of treatment) [15]. 












































































































































































































































































































vs. no treatment on BMD in 17 women with subclinical hypothyroidism [16]. 
Observational data over 3 years showed that the bone-preserving effect of hormone 
replacement therapy for post-menopausal women was blunted during administra-
tion of LT4 for subclinical hypothyroidism [17]. Finally, BMD in adolescent girls 
treated with LT4 for subclinical hypothyroidism for 2–5 years had similar BMD to 
a control group [18].
2.2.2  Overt Hypothyroidism
LT4 dosage >150 mg/day, vs. lower doses, was associated with increased risk of 
fractures in women aged ≥65  years with hypothyroidism and a prior history of 
osteoporosis (Fig. 2) [19]. There was no significant effect in women without prior 
osteoporosis in this study. Another cross-sectional, observational study in post- 
menopausal women found reduced BMD associated with a longer duration of LT4 
treatment, with no significant relationship between LT4 dosage and BMD in these 
women [20]. Another observational study in post-menopausal women found no 
association between LT4 treatment and bone loss, irrespective of the degree of sup-
pression of TSH [21].
Adjustede hazard ratios for fractures (95% CI)












Fig. 2 Risk of fractures associated with different daily doses of levothyroxine in a large database 
population stratified by osteoporosis status at baseline. aNo prior diagnosis of osteoporosis and no 
prescriptions for bisphosphonates; bprior diagnosis of osteoporosis regardless of treatment; cprior 
diagnosis of osteoporosis without prescription of bisphosphonate or raloxifene; dprior diagnosis of 
osteoporosis with prescription of bisphosphonate or raloxifene; efor age, comorbidities, co- 




Large database studies have also evaluated the effect of LT4 treatment on bone in 
general populations of patients with hypothyroidism. In one study, patients receiv-
ing LT4 therapy were at increased risk of fractures if they had either a high TSH 
level (>4 mIU/L) or a suppressed TSH level (≤0.03 mIU/L), compared with patients 
with TSH within the reference range (Fig. 3) [22]. Patients with TSH 0.4–4.0 mIU/L 
were not at increased risk of fractures in this study. Another large database study of 
162,369 people with hypothyroidism, of whom 97% received LT4 during follow-
up, found increased fracture risk among those with TSH >10 mIU/L, compared with 
those well controlled to within the euthyroid range (HR 1.15 (95%CI 1.01–1.31, 
p = 0.03) [23]. These studies demonstrated the importance of optimisation of LT4 
treatment, rather than LT4 treatment per se, for maintaining bone health.
A case-control study from Denmark, where all 124,655 patients with a fracture 
served as cases and 373,962 randomly selected age- and gender-matched people 
without fractures served as controls, found no association between LT4 treatment 
and risk of fracture [24]. An analysis of 23,183 LT4 users from the UK General 
Practice Research Database (i.e. managed in the primary care setting) also found 
no significant association between LT4 use and fracture risk overall although there 
was an apparent increased risk in males [25]. Other observational data also did not 
identify a significant effect of LT4 treatment on bone health [26].
The recent SORTED 1 trial found no difference in effects on bone health 
measured using circulating levels of C-terminal telopeptide (CTx) levels in very 
elderly patients (≥80 years) with hypothyroidism randomised to control of TSH 
in the standard reference range (0.4–4.0 mIU/L), or to a higher target range 
(4.1–8.0 mIU/L) [27]; see chapter, “Levothyroxine in the Older Patient” for a 
fuller account of this trial. CTx correlates inversely with TSH, including during 
treatment with LT4, and may provide a useful marker for following effects of LT4 
on bone metabolism [28].












Hazard ratios for osteoporetic fracture or death (95% CI)
Fig. 3 Risk of a composite outcome of osteoporotic fractures or death, according to the prevailing 
level of thyrotropin (TSH), in a population-based database study of individuals receiving treatment 
with levothyroxine from the UK. aAdjusted for age, gender, history of hyperthyroidism, history of 
osteoporotic fracture, presence or absence of diabetes. (Drawn from data presented in Ref. [22])
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2.3  Effects of Thyrotropin-Suppressive Doses of Levothyroxine
Long-term treatment with high doses of LT4 may be administered to suppress 
the activity of residual thyroid tumour cells after total thyroidectomy for well- 
differentiated thyroid carcinoma (see chapter, “Levothyroxine and Cancer”). 
This setting has been likened to a state of “subclinical hyperthyroidism” by some 
authors [29].
The application of TSH-suppressive doses of LT4 has raised concern over its 
effects on bone health, given the known association between hyperthyroidism, 
osteoporosis and increased risk of fractures, as described above. Indeed, many clini-
cal studies have applied various measures of bone mineral density or other markers 
of skeletal function to post-surgical, athyroid patients receiving TSH-suppressive 
therapy. Conflicting results of the effects of TSH suppression were reported in pre- 
menopausal women (adverse effect [30–41], or no clear adverse effect [42–47]), 
or post-menopausal women (adverse effect [40, 48, 49] or no clear adverse effect 
[31, 45, 47, 50–53]). Clear adverse safety signals for osteoporosis during TSH sup-
pression did not emerge from several studies in populations that included female 
populations of mixed pre-/post-menopausal status [54–60], men [31, 45, 61–63] or 
a mixture of either gender [37, 64–67] (one small study in a mixed population dem-
onstrated increased bone loss with TSH suppression in patients with thyroid cancer 
[68]). Trabecular bone score may be a more sensitive measure than bone mineral 
density of the effects of treatment with LT4 on bone structure this parameter has 
been used in patients who have [31, 32], or have not [69], received thyroidectomy 
and TSH suppression for thyroid cancer, although changes in this measure did not 
correlate with changes in BMD in LT4-treated patients in another study [70]. An 
absence of marked effects on bone health was also observed in studies in which 
pre- menopausal women [71–74], post-menopausal women [71, 74, 75] or mixed 
populations [76, 77] received less intensive TSH-suppressive therapy for benign 
thyroid nodules, or for goitre.
Several studies evaluated fracture risk. One study found that the 10-year fracture 
risk (assessed using FRAX, an online risk assessment tool) in women (mean age 
52 years) did not correlate significantly with LT4 dose, the duration of LT4 therapy 
or FT4 [42]. Others found no marked increase in the risk of fractures associated 
with TSH-suppressive therapy [65, 78, 79]. One study found associations between 
the intensity of TSH suppression and fracture risk: the incidence of vertebral frac-
tures was 45% for patients with TSH <0.5 mIU/L, compared with 24% for TSH 
0.5–1.0 mIU/L and 4% for TSH >1.0 mIU/L [80]. Similarly, the risk of osteoporosis 
was increased in patients receiving a cumulative LT4 dose over time of >395 mg, 
but not in patients receiving a lower dose, among 9398 patients with new-onset 
thyroid cancer followed for an average of 6.6 years [81].
Determinants of bone health in patients receiving TSH-suppressive therapy 
appear to be complex and multifactorial. A family history of osteoporosis and oes-
trogen deficiency have been identified as risk factors for adverse effects on bone in 
this population [57, 58, 82]. TSH-suppressive therapy itself was shown not to affect 
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levels of sex hormone-binding globulin [83]. More data on the relationship of TSH- 
suppressive therapy and bone health are required, relating to older subjects, and 
men, in particular, however [84].
3  Clinical Perspectives
Clinical data on the effects of LT4 administration on bone are conflicting. The many 
studies reviewed above differed importantly in design, their populations, their dura-
tions and the indices of bone health measured, especially with regard to important 
clinical outcomes, such as fractures. In general, the use of LT4 to maintain euthy-
roid levels of thyroid hormones in patients with hypothyroidism, or even the use of 
TSH-suppressive therapy following removal of thyroid tumours, does not appear to 
carry a substantial risk of osteoporosis or fractures. Nevertheless, the associations 
between LT4 administration and loss of bone mineralisation of increased fracture 
risk in some studies suggests the use of a cautious approach to avoid over treat-
ment, especially in patients with or at risk of developing osteoporosis, such as post- 
menopausal women, or the elderly.
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Treatment with LT4 is used to suppress thyrotropin levels after the management 
of differentiated thyroid cancers after surgery, with doses and targets for 
thyrotropin (thyroid- stimulating hormone, TSH) determined by the risk of 
cancer recurrence determined in the individual patient. Moreover, the role of 
thyroid hormones and their receptors in the initiation—and, potentially, 
cure—of a range of cancer types is an active area of research.
1  Introduction
1.1  Overview of the Management of Differentiated 
Thyroid Cancer
In general, the treatment of differentiated thyroid cancers (DTC) consists of surgery, 
post-operative/adjuvant radioactive iodine (RAI, 131I) treatment and hormonal ther-
apy with levothyroxine (LT4) [1, 2]. Surgery is the standard intervention for the man-
agement of DTC (although the management of microcancers of the thyroid remains a 
matter of debate) [1, 2]. Where the patient receives a total thyroidectomy, the result-
ing athyroid state induces a severe hypothyroidism that causes thyrotropin (TSH) to 
rise to high levels, typically at least 30 IU/mL after several weeks (compared with the 
usual upper limit of the normal reference range of about 4 mIU/L) [3].
For papillary or follicular thyroid tumours, the high TSH level stimulates any 
remaining unresectable thyroid tissue or metastatic tumour cells that retain some 
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endocrine activity to take up iodine from the circulation [3]. Treatment with RAI is 
then administered periodically over a period of years and the RAI is taken up avidly 
by these cells resulting in their irradiation and ablation: in this way, the majority 
of these cancers can be eradicated successfully [1, 3]. Injections of recombinant 
human TSH may also be used to increase RAI uptake of residual thyroid cancer 
cells [3, 4].
Patients may require lifelong substitution of LT4 after thyroid surgery for DTC, 
depending on the amount of thyroid tissue removed [3, 5]. Moreover, high-risk 
patients may receive TSH-suppressive therapy with LT4. The decision on whether 
to aim for full suppression of TSH (TSH < 0.1 mIU/L), or partial TSH suppression 
(TSH 0.1–0.4 mIU/L) should be personalised [2, 3].
1.2  Scope of This Chapter
This chapter reviews the benefits and risks associated with LT4-suppressive therapy 
in patients who have undergone surgery and RAI for DTC. The diagnosis of thyroid 
cancer, tumour staging, allocation of patients to different modalities of surgery and 
their outcomes, and the application, effectiveness of and development of refractori-
ness to RAI per se are beyond its scope and will not be discussed further here (we 
refer the reader to current guidelines in these areas [1, 3, 5, 6]). In addition, the 
consequences of long-term suppressive LT4 administration for bone homeostasis 
and health in these patients are considered in chapter “Levothyroxine and Bone” 
of this book, and are also not discussed in detail here. Chapter “Levothyroxine and 
the Heart” of this book reviews the effects of TSH-suppressive doses of LT4 on the 
heart. Finally, medullary thyroid tumours arise from calcitonin-secreting parafol-
licular cells (C-cells) that do not secrete thyroxine: these patients are not treated 
with RAI and LT4 and their management is also not addressed here [7].
2  Application of Thyrotropin-Suppressive Doses 
of Levothyroxine After Surgery and Radioactive Iodine 
for Well-Differentiated Thyroid Tumours
2.1  Need for Suppression of Thyrotropin in Thyroid 
Cancer Survivors
TSH promotes the growth of thyroid tumours, and levels of this hormone are sup-
pressed in the initial period following surgery for many DTC. A meta-analysis sup-
ports the effectiveness of this approach in improving long-term clinical outcomes 
post-thyroidectomy, compared with patients who did not receive TSH-suppressive 
therapy [8]. However, it has become clear in recent years that stringent suppression 
of TSH does not improve long-term clinical outcomes in patients with other than 
high-risk presentations of well-differentiated thyroid cancer [9–13]. Accordingly, 
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patients with thyroid cancer assessed as being at lower risk of disease recurrence do 
not require complete suppression of TSH. This approach is designed to optimise the 
balance between suppression of disease recurrence (benefit) and the potential for 
adverse effects on bone [9].
For adults, the level of thyroglobulin has been found to be strongly predictive 
of the risk of recurrent disease (see Fig.  1a) [14], and thus different targets for 
TSH suppression are provided in guidelines for low-risk patients according to their 
post- surgery thyroglobulin levels [1, 3]. A recent meta-analysis has confirmed the 
diagnostic and prognostic power of thyroglobulin measurement during post-thy-
roidectomy TSH suppression using LT4, with negative predictive value for ruling 
out evidence of structural thyroid carcinoma in excess of 99% [15]. The relationship 
between thyroglobulin and post-surgical outcome is less well understood in chil-
dren, for whom targets for TSH suppression are accordingly not stratified formally 
according to the thyroglobulin level [3].















Fig. 1 Thyroid hormones homeostasis and the risk of thyroid cancer. (a) Case-control study from 
the EPIC cohort. A population of 357 individuals with differentiated thyroid cancer were matched 
with 2 (women) or 3 (men) cancer-free control subjects. Significance values shown are p for trend. 
Total thyroxine (T3) and total triiodothyronine (T3) did not significantly influence cancer risk and 
have been omitted for clarity. Adjusted for study site, age, gender, time/data of blood draw. (Drawn 
from data presented in Ref. [14]). (b) Risk factors for malignancy within the thyroid nodules in a 
multivariable logistic regression analysis that included variation of thyrotropin (TSH) levels within 
the normal range. Adjusted for gender, age, nodule size, preoperative TSH in patients not on levo-
thyroxine. (Drawn from data presented in Ref. [26])
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2.2  Long-Term Consequences of Thyroidectomy 
and Thyrotropin Suppression
TSH-suppressive LT4 therapy induces a thyroid hormone status that is broadly 
equivalent to subclinical hyperthyroidism [13]. Overt hyperthyroidism during LT4- 
suppressive therapy should be avoided. Accordingly, care must be taken to achieve a 
balance between the achievement of adequate suppression of TSH levels to optimise 
cancer-free survival, with the potential adverse effects associated with subclinical 
hyperthyroidism [16]. Clinical studies in patients who have received LT4-based 
TSH-suppressive therapy have revealed several areas of concern or benefit, which 
are described briefly below.
2.2.1  Bone
Untreated longstanding hyperthyroidism is associated with loss of bone miner-
alisation, osteoporosis and increased risk of fractures. Studies in TSH-suppressed 
populations have been conflicting, but some studies have demonstrated increased 
osteoporosis and fracture risk associated with LT4 treatment (reviewed in chapter 
“Levothyroxine and Bone” of this book).
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2.2.2  The Cardiovascular System
A retrospective study from the Korean National Health Insurance database, which cov-
ers 97% of people in that country, evaluated the risk of coronary heart disease (CHD) 
and ischemic stroke over a follow-up period of 4.3 years in 182,419 patients following 
thyroidectomy for differentiated thyroid cancer [17]. Higher hazard ratios for CHD and 
stroke were found for the thyroidectomised population, relative to propensity score-
matched controls. The signal for adverse cardiovascular outcomes became stronger at 
doses of LT4 that were higher than 115–144 μg/day. Although atrial fibrillation was 
more common in patients receiving higher doses of LT4, this was associated with only 
4% of strokes. As expected, cardiovascular risk factors increased the risk of CHD or 
stroke. Another chart review in thyroid cancer survivors found no association between 
up to 9 years of over-suppression of TSH with LT4 (according to guideline recom-
mendations based on risk of thyroid cancer recurrence) and adverse cardiovascular 
outcomes, but this study only contained 14 subjects [18]. Chapter “Levothyroxine and 
the Heart” of this book reviews the effects of LT4 on the heart.
2.2.3  Patient-Reported Outcomes
Fatigue is often reported as a long-term complication of thyroidectomy and sub-
sequent TSH suppression [19]. One study showed that the persistence of residual 
symptoms reminiscent of hypothyroidism on TSH-suppressive therapy were cor-
related with a low level of FT3 [20]. Altering the dose of TSH, or switching to a 
combination of LT4 and T3 administration did not induce a clear improvement of 
fatigue, however [21, 22]. Current guidelines for the management of hypothyroid-
ism recommend that LT4 remains the first-line treatment. Exercise appears to be an 
effective way of combating fatigue and improving the quality of life in this setting 
[21, 23]. A similar benefit was observed in LT4-treated breast cancer patients under-
going chemotherapy [24]. More clinical studies of this relatively common, and 
potentially disabling, complication of thyroid cancer management are needed [21].
3  Thyroid Hormones and Cancer Risk
Variations in thyroid hormones have been associated with changes in the risk of a 
wide range of cancer types [25]. Examples of effects of thyroid hormones on the 
risk of various tumour types in epidemiological studies are shown below. However, 
the results are often conflicting and have to be judged cautiously since association 
does not prove causation.
 Thyroid: Observational data have associated an increased circulating level of 
TSH with an increased risk of developing differentiated thyroid cancer [26, 27] and/
or a more advanced stage of this tumour at presentation [26]. Other studies found 
that low TSH increased the risk of thyroid cancer [14], that high TSH in men, but 
low TSH in women, was associated with thyroid cancer [28], or that the influence of 
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abnormal TSH on cancer risk was amplified in non-diabetic subjects with higher 
levels of fasting serum glucose [29]. Fig. 1 shows the risk of cancer associated with 
thyroid nodules at different levels of TSH and other markers of thyroid homeostasis 
from two of these observational studies. Higher TSH levels were associated with a 
lower risk of incident differentiated thyroid cancer in one study (Fig. 1a) [14], while 
increases in TSH levels within the normal reference range increased thyroid cancer 
risk in the other study, in patients with thyroid nodules (Fig. 1b) [26].
 Breast: Hyperthyroidism (high TT4 or FT4 and/or low TSH) has been associated 
with increased risk of breast cancer in some observational studies [30–32]. This asso-
ciation was shown to extend into the euthyroid range [33], and to be present pre- and 
post-menopause [34]. There was no effect of variation of TSH in other studies [31, 
35], and the impact of anti-thyroid antibodies on breast cancer risk was variable [30–
32]. A meta-analysis of 8 cross-sectional studies found a positive association between 
elevated T4, T3, anti-thyroid peroxidise antibodies and anti-thyroglobulin antibodies 
and the prevalence of breast cancer [36]. Likewise, autoimmune thyroiditis has been 
found to be more common in women with vs. without breast cancer [37].
A population-based case-control study from Taiwan (65,491 breast cancers, 
261,964 controls) found that LT4 administration vs. no LT4 use was associated with 
a modestly higher risk of breast cancer, with a greater effect in older (≥65 years) 
patients (odds ratio [OR] 1.45 [95%CI 1.23–1.71], p < 0.01) compared with younger 
patients (OR 1.19 [95%CI 1.09–1.29], p < 0.01) [38]. However, the ORs were simi-
lar for patients who received LT4 for ≤1 year (1.22) and >1 year (1.26), and further 
study is required to confirm this association.
 Prostate: Low TSH/high T4 increased the risk of prostate cancer in a population-
based observational study [30]. Conversely, and consistent with this study, high 
TSH was protective against prostate cancer in the population of a clinical trial con-
ducted to answer a clinical question that was unrelated to thyroid function [39].
 Gastrointestinal: A population-based study found no effect of TSH or FT4 levels 
on colorectal cancer risk [30]. However, high FT4, but not a diagnosis of hypothy-
roidism or hyperthyroidism, predicted shorter survival in a cohort of 258 patients 
with advanced gastro- oesophageal cancer [40]. Low FT3 was associated with pro-
longed survival in this study, which is difficult to reconcile with the adverse effect 
of high FT4 [40].
A large population-based case-control study from a UK general practice data-
base (The Health Improvement Network, 20,990 colorectal cancer cases and 82,054 
controls) found that both hyperthyroidism and untreated hypothyroidism predicted 
an increased risk of having colorectal cancer [41]. Long-term treatment with LT4 
was associated with a reduced risk of colorectal cancer, with a lower risk for a lon-
ger treatment duration [41].
 Liver: Higher TSH was associated with larger tumours in a cohort of 838 patients 
with advanced hepatocellular carcinoma, and higher FT4 (≥16.6 ng/L) predicted 
poorer survival vs. lower levels of FT4 [42].
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 Pancreas: A retrospective study found that survival with pancreatic cancer did not 
vary according to hypothyroid or euthyroid status overall, but that hypothyroid 
patients taking LT4 demonstrated higher tumour stage, and more localised and dis-
tant tumour spread than euthyroid patients [43]. However, this study is difficult to 
interpret, as there were only 71 hypothyroid patients included, and there was no 
information presented on how many were taking LT4 [43].
Table 1 summarises briefly some potential mechanisms that have been demon-
strated in clinical or experimental studies to explain an association between thyroid 
hormone status and tumorigenesis [44–67]. Thyroid hormones mediate their effects 
Table 1 Potential mechanisms linking thyroid hormone actions to tumourigenesis or tumour 
suppression
Ref. Potential mechanisms
Promotion of invasion and metastasis
[44–47] Promotion of proliferation of tumour cells or metastasis by altered intracellular 
downstream signalling pathways following interaction of T3 or T4 with a binding site 
on integrin αvβ3 in the extracellular matrix (breast, ovary)
[48, 49] Promotion of metastasis and/or angiogenesis by enhanced epithelial-mesenchymal 
transition in tumour cells, also involving the integrin αvβ3–thyroid hormone axis
[50, 51] Inhibition of apoptosis mediated via downstream signalling from thyroid hormone and 
other ligand binding sites on integrin αvβ3 (ovary)
[43] Increased proliferation, migration, and invasion of pancreatic cancer cell lines in vitro 
after exposure to T3
[52] Crosstalk between thyroid oestrogen receptors increased the growth of cancer cells, 
and this relationship was modulated by integrin αvβ3 (lung)
Modulation of tumour cells
[53–55, 
64]
Enhanced differentiation or renewal of cancer stem cells (colorectal, hepatocellular)
[65] Release of inhibition of epigenetic regulation of gene expression reduced cancer cell 
growth (liver)
[56] T3 may induce senescence in prostate cancer cells, which would oppose tumour 
growth
Altered expression of thyroid hormone receptors α and β (TRα and TRβ)
[57, 58] Expression of TRα drove tumour growth and worsened prognosis (breast)
[57, 59] Higher expression of THRα2 receptor improved prognosis (breast)
[57, 59, 
60, 63]
Expression of TRβ opposed tumour growth (breast)
[61, 62] Suppression of the oncogenic RUNX2 transcription factor by increased expression of 
TRβ (breast, thyroid)
[63] Cytoplasmic TRβ1 predicted improved survival, but nuclear TRβ1 predicted reduced 
survival (breast)




Reversal of epigenetic silencing of tumour suppressor genes via activation of thyroid 
receptors by T3 (thyroid, hepatocellular, kidney)
[67] Reduced tumour growth by activation of the RhoB signalling pathway (thyroid)
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on the cancer cell through several non-genomic pathways including activation of 
integrin avβ3 promoting metastasis and angiogenesis within tumours. Furthermore, 
cancer development and progression are affected by dysregulation of local bio-
availability of thyroid hormones and thyroid hormone receptor changes [25, 45, 
49, 68–70].
Tetraiodothyroacetic acid may oppose these actions [69]. The thyroid receptor, 
TRβ is downregulated in many tumours, and activation of this receptor has been 
proposed as a strategy for increasing the sensitivity of triple-negative breast cancer 
cells to chemotherapy [71].
Ovarian cancer is a highly metastatic tumour, and several thyroid hormone ana-
logues exerted cytotoxic effects in ovarian cancer cell lines, probably by antago-
nising the effects of thyroid hormones on the integrin αvβ3 axis [72] A similar 
phenomenon has been observed in thyroid and lung cancer cells, among others [49, 
51, 52, 69]. Tetraiodothyroacetic acid, a metabolite of T4, may reduce the resistance 
of cancer cells to radiotherapy [73]. Deiodinases modulate the local bioavailability 
of thyroid hormones, by controlling T4 conversion to T3 and other thyroid hormone 
derivatives and this expression of these enzymes differs in a range of tumour types, 
compared with non-neoplastic tissues [74, 75]. These observations provide promis-
ing avenues for future research on the development of novel anticancer agents.
4  Conclusions
Observational data have implicated variations in the levels of thyroid hormones 
with variations in the risk of a range of cancer types, including of the thyroid itself. 
This association extends to within the currently accepted “normal” range for thyroid 
hormones. In addition, the discovery of novel interactions between thyroid hor-
mones and receptors both inside cells and in the extracellular space have opened 
up new avenues for anticancer research. Treatment with suppressive doses of LT4 
is one of the key components of the management of differentiated thyroid cancers 
after surgery, where careful evaluation of the risk of cancer recurrence in the indi-
vidual patient aids a balancing of the need to suppress TSH sufficiently with the 
need to avoid over treatment.
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Practical Application  
of Levothyroxine- Based Therapy
Takashi Akamizu
Levothyroxine (LT4) is a natural, endogenous hormone. Adverse events 
associated with this treatment are mostly symptoms of over-treatment (a state 
of functional thyrotoxicosis), which can be avoided by careful titration of the 
LT4 dosage to keep thyrotropin within an appropriate reference range that is 
relevant to the needs of the individual patient.
1  Introduction
The intention of this chapter is to complete this book on the role of levothyroxine (LT4) 
in the management of thyroid dysfunction, with a summary of the practical application 
of this treatment. The focus of the chapter will be on the management of hypothyroid-
ism; for information relating to the implications of TSH- suppressive doses of LT4, the 
reader should consult chapter “Levothyroxine and Bone” and chapter “Levothyroxine 
and Cancer”. I will consider how to dose LT4, how patients should take it and the 
tolerability and safety implications long-term LT4- based therapy. This approach will 
involve reviewing important information from prescribing documentation for prepara-
tions of LT4 from Europe [1] and the USA [2], as these impact on clinical practice 
across a large area of the world beyond the borders of those regions. For example, phy-
sicians in Middle-Eastern countries are influenced by, but not bound by, labelling from 
both of these regions. Physicians should always consult their local labelling, where 
available, before prescribing LT4, however. Finally, the chapter will provide a resource 
of guidelines for the management of hypothyroidism around the world.
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2  Safety and Tolerability of Levothyroxine
2.1  Avoiding Symptoms of Thyroid Dysfunction
The prescribing documentation for levothyroxine (LT4) products for use in patients 
with hypothyroidism notes that the adverse events associated with this treatment 
generally refer to over-treatment with LT4, which induces a state of thyrotoxicosis. 
Alternatively, inadequate correction of TSH leaves the hypothyroid patient at risk 
of a range of adverse outcomes, including major adverse cardiovascular events and 
premature death (see chapter “Levothyroxine and the Heart” for more details) [3, 4]. 
Accordingly, both over-treatment and under-treatment with LT4 leave the patient 
with hypothyroidism at increased risk of adverse long-term clinical outcomes, as 
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Muscle aches and weakness
Muscle cramps
Dry/scaly skin
Brittle hair and nails
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Abnormal liver function testsb
Decreased bone mineral densityb
Symptoms similar to hypothyroidism
(LT4 dosage too low)
Symptoms of thyrotoxicosis
(LT4 dosage too high)
Fig. 1 Overview of symptoms arising from suboptimal dosing of levothyroxine in patients with 
hypothyroidism. Symptoms of hyperthyroidism/thyrotoxicosis were from athe European Summary of 
Product Characteristics [1] and bUS Prescribing Information [2] for levothyroxine (LT4) products. 
Symptoms of hypothyroidism were as listed by the United Kingdom National Health Service [3]
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The goal of LT4 management is thus to optimise the LT4 dosage [1–5]. It is impor-
tant to note that symptoms of thyroid dysfunction are often non-specific in nature, 
and in some cases similar symptoms are identified for both under- and over-treatment 
with LT4.
Increased actions of catecholamines are a feature of thyrotoxicosis, including 
following an overdose of LT4 [6]. Accordingly, a number of adverse consequences 
of thyrotoxicosis following over-treatment with LT4 are mediated via over-stimu-
lation of β-adrenoceptors, such as tachycardia, anxiety, agitation and hyperkine-
sia. Treatment with a β-blocker may be helpful here. The European prescribing 
documentation also warns that over dosage of LT4 may increase the risk of acute 
psychosis (especially in patients at risk of this condition), and that long-term abuse 
of LT4 has been associated with cardiovascular death. Seizures are another rare 
complication of LT4 therapy [2].
The possibility of increased risk of cardiovascular events (see chap-
ter “Levothyroxine and the Heart”), or of osteoporotic fractures (see chapter 
“Levothyroxine and Bone”), are among the more serious long-term consequences 
of thyrotoxicosis. This is a particular concern where TSH-suppressive doses of LT4 
are administered. Long-term treatment with high doses of LT4 may be adminis-
tered after total thyroidectomy for well-differentiated thyroid carcinoma in order to 
suppress secretion of TSH from the pituitary (e.g. see chapter “Levothyroxine and 
Cancer”), which induces a thyrotoxic status similar to a chronic form of subclinical 
hyperthyroidism [7–9]. These patients are likely to be at elevated risk of long-term 
adverse effects, such as those in the cardiovascular system (possible increased risk 
of adverse cardiovascular events, see chapter “Levothyroxine and the Heart”) or the 
skeleton (possible increased risk of osteoporosis and fractures, especially in those 
at increased risk, such as postmenopausal women—see chapter “Levothyroxine 
and Bone”).
2.2  Adverse Reactions to the LT4 Tablet Itself
Additionally, as with any medicinal product, hypersensitivity reactions in the 
skin or respiratory system may occur rarely in response to components of the 
LT4 tablet, possibly including LT4 itself [1, 2]. Such reactions tend to manifest 
with symptoms, such as urticaria, eczema-like rashes, fever and disturbances of 
liver function tests, and may persist when different LT4 products are prescribed 
[10–13]. Excipients vary somewhat between LT4 preparations, and so changes 
the brand of LT4 may help to resolve the issue; however, hypersensitivity to LT4 
itself may effectively prevent the effective management of hypothyroidism [14]. 
Procedures for oral desensitisation have been described, where administration of 
successively increasing LT4 dosages (e.g. at 30-min intervals, from an initial dose 
as low as 0.01 μg) enable subsequent chronic therapy with doses of LT4 that are 
clinically effective [10–13].
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3  How to Prescribe and Take Levothyroxine
Hypothyroidism usually requires patients to take LT4 for life. Accordingly, patients 
must be educated on how to take their LT4 tablets correctly, to have any chance 
of achieving stable, euthyroid-like thyroid hormone function over the long term 
(Table 1). Food has a markedly inhibitory effect on the absorption and bioavailabil-
ity of LT4 (see chapter “Administration and Pharmacokinetics of Levothyroxine”). 
Accordingly, it is important that LT4 is taken on an empty stomach, and that no 
Table 1 How to take levothyroxine (LT4): examples from products available in Europe and 
in the USA
Europe USA
Dosing frequency for the 
management of hypothyroidism
One tablet, once-daily One tablet, once-daily
When to take LT4 30 min before breakfast on 
an empty stomach
30–60 min before breakfast 
on an empty stomach
Typical starting doses
  Adults with hypothyroidism 25–50 μga 100–125 μg (70 kg adult)e
  Elderly 12.5 μga 12–25 μg
  Adults with 
hypothyroidism + CHD
12.5 μg 12–25 μg
  Infants/neonates with CHb 10–15 μg/kg 10–15 μg/kgb,f
  Children 12.5–50 μg Variesf
Typical dose adjustments Every 2–4 weeks (elderly: 
12.5 mg every 2 weeks)
12.5–25 μg every 4–6 
weeks (6–8 weeks for 
elderly)
Typical maintenance doses
  Adults with hypothyroidism 100–200 μg/day About 1.6 μg/kg
  Adults with 
hypothyroidism + CHD
As above, possibly lowerc May be <1 μg/kg (elderly + 
CHD)
  Children 100–150 μg/m2 Variesf
  Elderly As for adults, possibly lower May be <1 μg/kg
TSH suppression post-surgery for 
well-differentiated thyroid cancer
150–300 μg Usually >2 μg/kg
Contraindications to LT4 •  Hypersensitivity to LT4 or 
excipients
•  Untreated:
   –  Adrenal insufficiency
   –  Pituitary insufficiency
   –  Thyrotoxicosis
•  Acute MI
•  Acute myocarditis
•  Acute pancreatitis
•  Use with anti-thyroid agent 
during pregnancy




food, coffee, etc. is consumed for at least 30 min (according to European guidance, 
and up to 1 h, according to guidance from the USA) after taking the LT4 tablet 
(half a glass of water or so is permitted to allow the tablet to be taken). The usual 
recommendation is to take LT4 first thing in the morning, so that the 30 min before 
needing to eat is occupied by the usual morning rituals of bathing, etc. In principle, 
LT4 can be taken at bedtime although the need to wait for 3 h after the evening meal 
before taking the tablet [15, 16] may be difficult to maintain consistently, with a 
consequent reduction in the stability of LT4’s biological actions.
The administration of LT4 in the management of hypothyroidism is tailored to 
the individual needs of the patient, according to an individually determined target 
for thyrotropin (thyroid-stimulating hormone, TSH) [17, 18]. Starting and mainte-
nance doses (Table 1) vary according to a number of factors, including the therapeu-
tic indication for LT4, age and comorbidity (especially where there is concomitant 
cardiovascular disease). Starting doses of LT4 for the management of hypothy-
roidism, and perhaps long-term targets for the TSH level, are likely to be lower in 
patients with certain comorbidities. US labelling for LT4 permits initiating treat-
ment at the estimated full LT4 dose for T4 replacement in a patient with recent onset 
hypothyroidism uncomplicated by comorbidities, however. The speed at which the 
LT4 dose is titrated to achieve control of TSH also varies with the characteristics of 
the individual patient.
Contraindications and warnings associated with LT4 usually relate to use in 
patients with comorbidities where the potential harm of accidental over-treatment 
with LT4 is highest. These relate especially to comorbidities in the cardiovascular 
and adrenal systems and the risk of osteoporosis (Table 1).
Table 1 (continued)
Europe USA
Special warnings and precautions •  Exclude/treat diseases of:
   –  CV systemd
   –  Pituitary
   –  Adrenals
•  TSH autonomy
•  Psychosis
•  Risk of osteoporosis
•  Patients with CHD 
(especially elderly)
•  Myxoedema coma
•  Acute adrenal crisis 
(patients with adrenal 
insufficiency)
•  Worsened glycaemic 
control
•  Risk of osteoporosis
Compiled from information presented in Refs. [1, 2]
aThe exact starting dose depends on other factors, such as thyrotropin (TSH) level and body weight
bFor the first 3 months of life
cStart low, go slow in adults with hypothyroidism and CHD, and consider the possibility of a lower 
maintenance dose than in an adult without CHD
dAngina, arteriosclerosis, hypertension
eHealthy, non-elderly patients with recent onset hypothyroidism
fGuidance on doses for children of different ages is provided
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4  Overview of Guidelines on the Management 
of Hypothyroidism
This book has drawn on major guidelines from Europe and the USA to summarise 
the current role of LT4 in the management of hypothyroidism, as described in its 
individual chapters. Many other sources of guidance are available; however, we 
have listed some of these in Table 2, alongside those from Europe and the USA, 
as a resource our readers in these areas [17–32]. For clarity and brevity, we have 
restricted this slit to guidelines that impact on the management of hypothyroidism: 
please consult chapter “Levothyroxine and Cancer” for detailed information on the 
use of LT4 in the management of differentiated thyroid cancer.
Table 2 Selection of guidelines for the management of hypothyroidism
Ref. Country/region Sponsor Year Scope
[20] International Expert 
panel
2019 •  Thyroid hormone treatment for subclinical 
hypothyroidism
[21] International ES 2012 •  Management of thyroid dysfunction in pregnancy 
and post-partum
[22] Europe ETA 2014 •  Subclinical hypothyroidism in pregnancy and in 
children
[17] Europe ETA 2013 •  Subclinical hypothyroidism, in younger (<65 years) 
and elderly patients
[18] USA ATA 2017 •  Thyroid disease in pregnancy and post-partum
•  Includes content on iodine deficiency, and 
management of overt and subclinical 
hypothyroidism
[19] USA ATA 2014 •  Broad in scope: Includes hypothyroidism associated 
with iodine deficiency, and management of 
congenital, overt and subclinical hypothyroidism
•  Includes special populations (paediatric subjects, 




2012 •  Broad scope covering multiple aspects of 
hypothyroidism
[24] Latin America LATS 2013 •  Includes hypothyroidism associated with iodine 
deficiency, and management of overt and 
subclinical hypothyroidism
•  Includes special populations (elderly, pregnancy)
[25] Japan JTA NA •  Diagnosis of hypothyroidism (and other aspects of 
thyroid dysfunction)
[26] UK NICE 2019 •  Thyroid dysfunction, including primary 
hypothyroidism, subclinical hypothyroidism, 
hyperthyroidism, thyroid enlargement
[27] UK BTA 2016 •  Management of primary and overt hypothyroidism
[28] UK BTA 2007 •  Use of thyroid extract and LT4 + LT3 combinations
[29] UK ACB, 
BTA, 
BTF
2006 •  Use of thyroid function tests
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Guidelines from the American Thyroid Association tend to be comprehensive 
and cover multiple aspects of thyroid dysfunction, while those from the European 
Thyroid Association tend to focus on specific aspects, such as subclinical hypo-
thyroidism in special patient populations. Hypothyroidism is especially difficult to 
manage in the setting of pregnancy and breastfeeding, and guidelines from these 
expert societies address this need. Regional guidelines are available from Latin 
America, also, as well as individual countries including the UK and Japan.
5  Conclusions
The LT4 molecule is identical chemically with the endogenous thyroid hormone, T4. 
Accordingly, other than rare hypersensitivity reactions to excipients or other phar-
maceutical components of the LT4 tablet, symptoms reported by people with hypo-
thyroidism receiving LT4 treatment will relate to the dosage of LT4 they receive, 
and the severity of their thyroid dysfunction. Novel, re-engineered formulations of 
LT4 have the potential to increase the reproducibility and constancy of exposure to 
LT4 during long-term management, which may help to achieve optimal dose titra-
tion of LT4 (see chapter “Administration and Pharmacokinetics of Levothyroxine” 
for an example). Some patients are given supra-physiologic doses of LT4 as a delib-
erate part of their management, such as those undergoing LT4- based suppression of 
TSH levels to reduce the risk of disease recurrence after thyroidectomy for thyroid 
cancer, or to reduce the growth and potential for malignancy of thyroid nodules. 
Research is continuing to determine the most appropriate LT4- based management 
algorithms for these patients, to optimise their long-term clinical outcomes.
We, the authors, hope that you have enjoyed reading this book, and that you have 
found it useful in your clinical practice.
Ref. Country/region Sponsor Year Scope
[30] Canada 
(Alberta)
TOP 2014 •  Concise, at-a-glance summary of management 
options for primary hypothyroidism
[31] Australia DoH 2019 •  Management of hypothyroidism during pregnancy
[32] Australia, New 
Zealand
RCGPA 2019 •  Thyroid function testing in adults
Guidelines published in or after 2010 are considered here. AACE American Association of Clinical 
Endocrinologists, ACB Association for Clinical Biochemistry, ATA American Thyroid Association, 
BTA British Thyroid Association, BTF British Thyroid Foundation, DoH Department of Health, ES 
Endocrine Society, ETA European Thyroid Association, JTA Japan Thyroid Association, LATS 
Latin American Thyroid Association, NA not available from source, RCPA Royal College of 
Pathologists of Australia, TOP towards optimised practice, LT4 levothyroxine
Table 2 (continued)
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